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AcuTe MyocArdIAl InfArcTIon
Coronary artery disease remains the leading cause of mortality in the western world. Accord-
ing to a recent statistics report, in the US alone an estimated 610,000 people will suffer a 
new myocardial infarction (MI) every year, while 325,000 people will have a recurrent MI.1 
However, there is ample cause for optimism. Following a peak in the mid 1960s, there has 
been a steady decline in coronary heart disease (CHD) mortality in the United States and 
in Western Europe.2-4 In the past 20 years the risk of dying from CHD in the Netherlands 
was successfully reduced by almost 33%.5 Treatment and prevention of classic risk factors 
(hypertension, lipid disorders, and smoking), acute myocardial infarction (AMI) care, and 
secondary prevention are factors accountable for this pattern.6-13 In the 1970s, risk factor 
control and the introduction of specialized coronary care units appeared largely responsible 
for the declining AMI mortality, but in recent years, short- and long-term care for CHD pre-
dominates modeling exercises.8;14;15 Studies showed that approximately half the decline in 
U.S. deaths from coronary heart disease from 1980 through 2000 may be attributable to the 
reduction in major risk factors and approximately half to the introduction of evidence-based 
medical therapies.8
Interestingly over time, the patterns of MI presentation have changed as there is an 
increasing incidence of myocardial infarction without ST-segment elevation (NSTEMI), with a 
concurrent decrease in the incidence of ST-segment elevation myocardial infarction (STEMI). 
In the cardiac catheterization lab, patients with an acute coronary syndrome (ACS) account 
for almost half of the percutaneous coronary interventions (PCIs) performed annually in the 
United States, and 40% of ACSs are STEMIs.16 Both STEMI and NSTEMI are however still 
associated with higher mortality rates than stable angina on presentation.
It is clear that we are making progress in both the reduction of AMI related mortality 
and morbidity in the 21st century. However, as mentioned the numbers are still astonishing 
and force us to focus on the development and implementation of preventive strategies. 
The organization of care around patients with AMI should be re-structured and focus 
on rapid intervention in the acute phase and optimization of care during follow-up. The 
declining mortality and morbidity rates need follow-up to ensure that the reported trends 
continue. Declining mortality and morbidity figures should also play a role in the planning 
of healthcare resources allocation. In other words, the “baby-boom” generation may not 
require additional cardiovascular services which may have an impact on for example the 
number of coronary care units. On the other hand, as the mainstay of AMI treatment will 
be rapid intervention it may be necessary to increase the number of interventional facilities 
in the next decades? Furthermore, as long-term MI care will be provided more and more 
in an out-patient setting, family physicians play an increasingly important role in initiating 
and maintaining risk factor modification using evidence-based standards for secondary 
prevention. Data such as that provided by the work of Chen and colleagues4, the MISSION 
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database at the Leiden University Medical Center and other surveillance systems are impor-
tant to provide guidance to take the correct actions.
GuIdelInes And IMPleMenTATIon
The number of chronic heart disease patients in North America and Western Europe 
is increasing rapidly because of better survival after acute myocardial infarction (AMI), 
improved treatment, and the presence of an aging population. Despite this being a positive 
development, it also imposes a significant socioeconomic burden on society.17 To optimize 
care and outcome of patients with AMI, many organizations, for example, the American 
College of Cardiology/American Heart Association and the European Society of Cardiology, 
have published guidelines for treatment of patients with AMI.18;19 These guidelines advocate 
early and aggressive reperfusion strategies and recommend the use of a combination of 
evidence-based medicine (EBM) and support programs to stimulate a healthier lifestyle. 
Because most of these guidelines are based on large-scale clinical trials, clinical benefit has 
already been established. Nevertheless, the proven benefit and the endorsement of these 
guidelines by the scientific society do not seem sufficient to alter well-established daily clini-
cal practice. Consequently, a large gap between EBM and daily practice still exists. Not so 
long ago, registries showed that only 56% to 76% of the eligible patients actually received 
reperfusion therapy although reperfusion therapy in the acute phase is known to improve 
survival of patients with AMI.20-22 In addition, the National Registry of Myocardial Infarction 
reported that only 4.2% of patients with AMI transferred for primary percutaneous coronary 
intervention (PCI) were treated within 90 minutes, which is the benchmark recommended 
by the international guidelines.23 After the acute phase modifiable risk factors are often not 
controlled and prescription medication is often suboptimal.21;24 Consequently, a significant 
number of patients with AMI is treated less than optimal.
Schiele et al demonstrated that the degree of guideline compliance is independently cor-
related with the 1-year mortality after AMI.25 Various guideline implementation programs, 
such as Guidelines Applied in Practice, Get With the Guidelines and Crusade, have been 
successful in improving the quality of care.26-28 Implementation of this kind of programs 
resulted not only in better adherence to key indicators, but also in a lower 1-year mortality 
in patients with AMI.26;29 Therefore, guideline implementation programs are of paramount 
importance to optimize AMI care. In order to improve AMI care, investigators of the depart-
ment of Cardiology at the Leiden University Medical Center in close collaboration with other 
care providers developed and implemented a pre-hospital, in-hospital and outpatient treat-
ment program in order to standardize evidence-based AMI care in the region “Hollands-
Midden,” The Netherlands: The MISSION!AMI protocol.30
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Pre-hosPITAl cAre
In the acute phase AMI patients require rapid diagnosis and early reperfusion to minimize 
infarct size and to prevent complications. Measures such as pre-hospital triage by 12-lead 
electrocardiography (ECG) in the field, thereby allowing early AMI diagnosis and rapid access 
to an intervention or community center, can reduce the treatment delay significantly.31 
Multiple factors determine treatment delay with its major contributors being patient-delay, 
physician-delay and in-hospital delay. In order to minimize treatment delay an intensive 
collaboration is therefore needed between primary care physicians, regional ambulance 
services, community hospitals (without percutaneous coronary intervention (PCI) facilities), 
and PCI centers. This has proven to be a complex task not easily achieved, particularly in 
countries such as the US with large distances between patients’ homes and the regional 
PCI center. Nevertheless, physical distance from the PCI center should not be of influence 
on in-hospital delays (door-to balloon time). While guidelines recommend having at least 
75% of patients treated within 90 minutes of presentation at the hospital, a study using 
the United States National Registry of Myocardial Infarction led investigators to conclude 
that this benchmark is rarely achieved for patients undergoing primary PCI in the United 
States. Only 4.2% of 4278 patients transferred for primary PCI at 419 hospitals were treated 
within 90 minutes and median door-to-balloon time was 180 minutes.23 More recently, the 
reported percentage of patients with door-to-balloon times of <90 minutes in a community-
wide surveillance study of patients hospitalized with AMI (in a large central New England 
community in the United States) was less than 10%.32 In a Dutch study conducted by Broer 
et al, investigators reported less dramatic hospital delays of 60-72 min.33 A major focus of 
the design of the MISSION! AMI program has been the reduction of such treatment delays 
in the region Hollands-Midden, regardless of area of residence. The pre-hospital emergency 
care part of the protocol requires trained ambulance personnel to obtain a 12-lead ECG at 
patients’ home. Suspect ECG’s are electronically transmitted to the PCI center. Trained coro-
nary care unit (CCU) nurses determine patient’s eligibility for primary PCI and patients found 
eligible for primary PCI are then transferred directly to the PCI center’s coronary care unit. 
The catheterization room is operational within 20 minutes, 24 hours a day, 7 days a week. 
In the absence of contraindications, aspirin, clopidogrel and abciximab (a glycoprotein IIb/
IIIa inhibitor) are already administered to the patient in the ambulance on the way to the PCI 
center. The early administration of abciximab in the ambulance has proven to significantly 
improve early reperfusion in STEMI patients treated with primary PCI.34 Moreover it was 
found to be associated with smaller infarct size, improved LV function, a lower risk of heart 
failure and decreased 1-year mortality on clinical follow-up.35;36
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In-hosPITAl cAre
Primary percutaneous coronary intervention
The principal cause of acute ST segment elevation myocardial infarction (STEMI) is intra-
coronary plaque rupture with associated occlusive thrombus. Primary percutaneous coronary 
intervention (PCI) is now established as the optimum treatment for STEMI and for the major-
ity of patients treated in this fashion coronary flow in the infarct-related vessel is restored 
and myocardial damage limited. Unlike PCI in the setting of stable angina, which reduces 
anginal symptoms but does not extend life expectancy, PCI in the setting of ACS has proven 
mortality benefits compared to medical therapy alone.37-39 In the setting of STEMI, several 
randomized controlled trials have demonstrated that coronary stenting reduces mortality 
compared to thrombolysis. In NSTEMI, a meta-analysis of randomized clinical trials (RCTs) has 
shown a reduction in mortality as well. As a result, PCI has become the preferred treatment 
for eligible patients with ACS.40-43
drug-eluting stents
Although coronary stents have proven successful, patients treated with bare metal stents 
(BMS) remain susceptible to restenosis requiring repeat revascularization, which can occur in 
14% of patients.44 Drug-eluting stents (DES) were introduced in the United States in 2003 
and have been widely adopted on the basis of profound reductions in restenosis compared 
with BMS. Randomized trials showed that both sirolimus- and paclitaxel-eluting stents (SES 
and PES, respectively) reduce in-stent restenosis.45-50 Over five-year follow-up, these results 
appear to be durable.51-53 These trials included patients with unstable angina, but they 
excluded patients with acute MI (AMI), which remains an “off-label” indication for DES use. 
Similar results have been published on newer DES, such as everolimus- and zotarolimus-
eluting stents.54-56 AMI, particularly STEMI, has been associated with higher rates of late 
stent thrombosis (ST).57-60 Whereas the one-year rate of ST observed in DES or BMS placed 
for stable angina is 0.6%–0.7%, it has been as high as 3.5% in AMI.61;62 Whether these 
rates differ according to stent selection has been a matter of clinical controversy.63
The initial report of the Swedish Coronary Angiography and Angioplasty Registry 
(SCAAR) on BMS- and DES-associated outcomes, published in 2007, reported a signifi-
cant increase in mortality with DES.64 Even though a second report extending follow-up 
and sample size showed no difference in mortality,65 the findings of the initial study had 
a substantial impact on clinical practice. First reported in 2007, the GRACE registry, an 
international study of 5093 patients with STEMI, raised concerns regarding DES safety in 
AMI in particular. After excluding events of the first six months, the two-year mortality was 
higher in DES- than in BMS-treated patients (from six months to two years, HR 4.90, p = 
0.001).66 As acknowledged by the authors, the GRACE analysis only adjusted for a limited 
number of characteristics, and two-year follow-up, based on telephone surveys, was only 
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completed in 55% of BMS-treated patients and 60% of DES-treated patients. These fac-
tors, including the elimination of early events more common in the BMS group, may have 
introduced bias in this study. Nonetheless, these observations led to a heightened sense of 
concern regarding the use of DES in AMI.67 Over longer periods of follow-up, other recently 
published international registries have not reproduced the results of the GRACE registry. The 
T-SEARCH and RESEARCH registries have published four-year follow-up data, the longest 
follow-up in an AMI population. 68
Among the 1738 consecutive patients with STEMI, despite a higher incidence of late 
ST (2.7% SES, 0.9% PES, 0 BMS, p-value not reported), there was a nonsignificant trend 
toward improved survival with SES versus BMS (mortality 11.4% SES, 16.4% BMS, adjusted 
HR 0.63, 95% CI 0.33–1.18).
Through 2008, there have been 14 randomized controlled trials (RCT) of DES in AMI, with 
>7700 patients, evaluating DES versus BMS in the setting of AMI.50;62;69-78 These confirm a 
higher risk of ST in AMI compared to patients with stable angina in similar RCTs. However, 
in published RCTs to date, rates of ST for BMS and DES in AMI were similar up to one year 
- approximately 1% when confirmed angiographically, and nearly 2.5%-3.5% in studies 
using clinical definitions. Most randomized studies, including the MISSION! intervention 
trial, reported DES to be superior to BMS at 12 months follow-up when comparing DES with 
BMS treatment for primary PCI in STEMI patients.50;62;73-76;78;79 In these studies DES mainly 
reduced the need for repeat revascularization procedures, but with no significant reduction 
of 12 month rates of death or myocardial infarction.
While randomization is the strongest method to control bias, many of these randomized 
studies had limitations of lack of follow-up beyond one year or relatively small sample sizes 
insufficient to detect small differences in ST or mortality. Although the MISSION intervention 
study found SES implantation in STEMI patients to be associated with a favorable midterm 
clinical and angiographic outcome compared with BMS treatment, van der Hoeven et al 
also raised concern about the long-term safety of SES in STEMI patients due to late stent 
malapposition that was seen more often after SES implantation than after implantation 
of BMS.50 The largest RCT comparing DES and BMS in AMI (>3000 patients) showed no 
difference between BMS and DES rates of death, MI, or ST at one year and longer-term 
follow-up is in progress.75
One of few studies with 5-year follow-up, reported by Goy et al80, showed durable 
longer-term results of SES. The authors followed up 344 consecutive patients treated with 
SES in 2002 (20% of patients were treated for acute coronary syndrome). Over the course 
of 5-year follow-up, SES appeared to provide durable benefit, particularly with regard to 
reducing target lesion revascularization (TLR) and the need for repeat procedures. Another 
5-year comparison, is the long-term follow-up of the RAVEL study, which randomized 238 
patients with stable angina pectoris to either SES or BMS.52 In the SES group in RAVEL, the 
5-year rates of death, MI, and TLR were 12.1%, 8.9%, and 10.3%, respectively (vs 7.1%, 
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6.9%, and 26.0%, respectively, for BMS). Four-year pooled analysis of 4 major random-
ized trials of SES (all four studies excluded patients with AMI) reported similar rates.81 The 
authors also raised the issue of a late “catch-up” phenomenon of SES. It has been shown 
that most target lesion-related events in BMS occur within the first year, whereas the risk 
of TLR among SES appears low but persistent over time.82 However, although the risk of 
TLR persists, the low overall risk of TLR at 5 years seemed to argue against a catch-up 
phenomenon. In addition, 4-year follow-up of the SIRIUS and TAXUS patients notes a per-
sistent reduction in TLR, confirming that a catch-up phenomenon is unlikely within available 
follow-up to date.83 Fortunately for those millions of patients treated with DES, these initial 
5-year data are reasonably encouraging with regards to DES safety and efficacy in the real 
world. Nevertheless, more long-term follow-up results on patients treated with DES for AMI 
is still being eagerly awaited.
Adjunctive medical therapy
The benefit of dual-antiplatelet therapy for 12 months after PCI for ACS has been well estab-
lished.84;85 On this basis, the current guidelines of the American College of Cardiology and 
American Heart Association recommend 12 months of dual-antiplatelet therapy following 
PCI for ACS with either BMS or DES.86;87 However, compliance with dual-antiplatelet therapy 
continues to be a significant challenge. After PCI for STEMI, the rate of noncompliance at 30 
days was nearly 14% in one study.88 Many studies have shown that premature discontinua-
tion of antiplatelet therapy in patients receiving DES is the most important predictor of late 
ST, particularly in ACS.88-90 In AMI, patients who stopped thienopyridines within 30 days 
were more likely to die within the subsequent 11 months (7.5% versus 0.7%, p < 0.0001; 
adjusted HR 9.0; 95% CI 1.3–60.6).88 Although both DES and BMS require compliance with 
dual-antiplatelet therapy, and in the setting of ACS for either stent 12 months of treatment is 
recommended based on large randomized trials, the window of vulnerability to ST resulting 
from delayed endothelialization is thought to be longer for DES than for BMS, and the 
ill effects of noncompliance, therefore, greater. Some observational studies indicate that 
patients with DES may uniquely benefit from dual-antiplatelet therapy beyond 12 months.91 
RCTs that include subjects with and without AMI are under way to determine whether 
continuation of dual-antiplatelet therapy beyond one year after stent placement will further 
reduce adverse cardiovascular events or ST.92
oPTIMAl TreATMenT AfTer AMI
secondary prevention
In the outpatient phase the MISSION! AMI program concentrates on active lifestyle improve-
ment and structured medical therapy. 30
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Lifestyle- Regular physical activity is an important component of secondary prevention 
of CAD; it increases exercise capacity, treats comorbid risk factors, and improves quality 
of life.93-95 Exercise-based cardiac rehabilitation has been shown to reduce all-cause and 
cardiac mortality compared with usual care.93;94;96-98 The goal for all patients is 30 to 60 
minutes of moderate-intensity physical activity (e.g., brisk walking, biking) on most, if not 
all, days of the week.93;94;99;100 Consistent physical activity improves cardiovascular risk 
factors - especially total cholesterol and triglyceride levels - and systolic blood pressure.99
Exercise-based cardiac rehabilitation programs may be initiated shortly after an acute 
coronary syndrome or revascularization procedure.94;100 The MISSION! AMI protocol offers a 
standard cardiovascular exercise-based rehabilitation program to each patient, commencing 
approximately three months after hospital discharge.30
Obesity is associated with increased CAD mortality and adversely affects cardiac function 
and comorbid CAD risk factors.101 Obesity is classified using the body mass index (BMI). 
Weight loss is indicated for patients who are classified as overweight or obese according 
to their BMI. The American Heart Association (AHA) recommends measuring BMI at each 
office visit, then providing objective feedback and consistent counseling on weight loss 
strategies.93;99-101 Improvements in cardiac risk factors are commonly observed with even 
modest weight loss (i.e., 10 percent of baseline weight).99;101 Insufficient evidence exists to 
determine whether weight reduction decreases cardiovascular mortality in persons who are 
obese.101
Smoking cessation has been shown to reduce all-cause mortality in patients with estab-
lished CAD.102;103 In a recent Cochrane review, investigators concluded that persons who 
quit smoking after a myocardial infarction (MI) or cardiac surgery reduce their risk of death 
by at least one third, and that discontinuing smoking is at least as beneficial as modifying 
other risk factors.102;103 In the MISSION AMI protocol physicians are encouraged to ask 
about tobacco use at each outpatient visit, and to extend a clear recommendation to quit 
to every patient who smokes. If a patient is willing to try to quit, family physicians can assist 
with cessation through counseling and pharmacotherapy, which are most effective when 
combined.104;105
Medication- A marked survival advantage in patients with acute coronary syndromes can be 
achieved, when a combination of evidence-based drugs is prescribed.106
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure (JNC 7) and the AHA recommend treating hyperten-
sion (i.e., blood pressure greater than 140/90 mmHg, or greater than 130/80 mmHg for 
persons with diabetes mellitus or chronic kidney disease) for the secondary prevention of 
CAD.107;108 Lifestyle modifications involve weight management, regular physical activity, 
prudent alcohol consumption, and a low-sodium diet. The JNC 7 and the AHA recommend 
initial treatment of hypertension after an MI with beta blockers or angiotensin-converting 
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enzyme (ACE) inhibitors, with additional medications added in a stepwise fashion to achieve 
goal blood pressure.107;108
Antiplatelet agents are recommended in all patients for the secondary prevention of 
CAD. In a large meta-analysis, antiplatelet therapy reduced recurrent vascular events by one 
fourth in patients with a previous vascular event.109 Aspirin treatment should begin imme-
diately after diagnosis of CAD and continued indefinitely unless contraindicated.93;100;109 
Clopidogrel (Plavix) is an effective alternative in patients who cannot take aspirin, and the 
AHA recommends using clopidogrel in combination with aspirin for up to 12 months after an 
acute cardiac event or percutaneous coronary intervention (PCI) with stent placement.109;110 
The MISSION! AMI protocol includes standard dual antiplatelet treatment during the initial 
12 months and lifelong use of Aspirin thereafter.30
Recent clinical trials have demonstrated that reducing cholesterol levels decreases the 
risk of recurrent coronary events, and evidence-based cholesterol-lowering guidelines have 
been established by the National Cholesterol Education Program Adult Treatment Panel 
III (ATP III).111-113 The AHA and ATP III recommend that all patients with CAD initiate lipid 
management through therapeutic lifestyle changes.93;100;111 For the secondary prevention 
of CAD, ATP III recommends LDL levels of less than 100 mg per dL (2.59 mmol per L), with 
an optional goal of less than 70 mg per dL (1.81 mmol per L); if the LDL level is greater 
than 130 mg per dL (3.37 mmol per L), cholesterol-lowering medications are indicated in 
addition to lifestyle changes.111
Statins should be the initial medication choice; however, additional agents may be con-
sidered if the LDL goal is not reached through statin therapy alone.100;111;112 Recent studies 
have shown intensive statin therapy reduces all-cause mortality in patients after acute coro-
nary syndromes compared with standard therapy; consequently, some have encouraged 
statin use in all patients who have CAD.114;115 For every sustained 2 mg per dL reduction in 
LDL cholesterol, statin therapy has been shown to reduce major coronary events, coronary 
revascularization, and stroke by 1 percent.115
Prevention of sudden cardiac death (scd)
AMI survivors are at increased risk for sudden death from cardiac causes, in most patients due 
to a ventricular arrhythmia.116;117 The Multicenter Automatic Defibrillator Implantation Trial 
(MADIT) II and Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) prospectively tested 
the hypothesis that implantable cardioverter-defibrillators (ICDs) could reduce mortality in 
patients at increased risk for sudden death from ventricular tachycardia (VT) or ventricular 
fibrillation (VF).118;119 These trials, which demonstrated 5% to 7% absolute mortality reduc-
tions over 2 to 4 years, established ICDs as a standard of care for primary prevention of 
sudden cardiac death. Selection of patients for ICD therapy as primary prevention of sudden 
cardiac death after AMI depends mainly on the left ventricular ejection fraction (EF). It is now 
widely accepted that patients who have had an AMI more than 6 weeks previously and have 
General introduction 17
an EF of 30–35% or less satisfy evidence-based criteria for ICD implantation, without need 
for further investigation.120 Most risk stratification efforts to identify candidates for primary 
prevention ICDs have been based on the hypothesis that patients are likely to benefit if their 
risk of sudden death is high enough. Various electric measures of arrhythmic risk, such as 
T-wave alternans, signal-averaged ECG, and electrophysiological study, have not demon-
strated adequate or consistent discriminatory power.121;122 Mortality reduction benefit of 
primary prevention ICDs was established only when risk stratification was based on measures 
of left ventricular dysfunction and functional class (left ventricular ejection fraction <30% 
after myocardial infarction in MADIT II or left ventricular ejection fraction <35% with New 
York Heart Association class II to III in SCD-HeFT) rather than direct measures of arrhythmic 
risk.
On the basis of a proportional hazards regression analysis in MADIT II, Goldenberg et al 
reported a U-shaped curve for efficacy of primary prevention ICDs, in which patients with 
the lowest and highest risk scores were less likely to benefit.123 Much attention has been 
focused on the lowest-risk patients comprising the left arm of this U-shaped curve. It has 
been motivated by observations that only approximately 20% of patients receive ICD shocks 
for VT/VF at 3 to 5 years and that this rate of shocks is approximately twice the mortality 
rate in control groups.118;124 Thus, only 10% of primary prevention ICD patients receive 
life-saving therapy, exposing the remaining 90% to all of the risks of ICD implantation and 
therapy without benefit.125 However, examination of the mode of death in the low-risk 
group does not support the concept of patients “too healthy” to benefit from ICD therapy: 
ICDs reduced the risk of sudden death in this group, but there was a counterbalancing 
increase in nonarrhythmic death, similar to the findings in the Defibrillator in Acute Myocar-
dial Infarction Trial (DINAMIT) of primary prevention ICDs in patients early after myocardial 
infarction.123;126 Several cohort analyses have evaluated the right limb of the U-shaped 
curve of Goldenberg et al, comprising the sickest patients. Investigators have reported that 
patients with advanced age and chronic renal failure do not benefit from primary prevention 
ICDs because of imminent, competing causes of death.127-129
In summary, both the risk-benefit and cost-benefit ratios of primary prevention ICD 
therapy would be improved by strategies to exclude presently indicated patients who are 
unlikely to benefit, if they could be identified accurately. Clinicians fear that the population, 
eligible for primary prevention ICD treatment, is of such magnitude that provision of ICD 
therapy will strain financial resources and the pool of trained personnel.130 As LV func-
tion has proven to be a strong indicator for an increased risk of SCD,131-133 prevention of 
severe LV dysfunction post-MI should be a priority of AMI care. The MISSION! AMI program 
attempted to address this problem by focusing on minimal treatment delays, aggressive 
reperfusion therapy and the use of early and consistent optimal pharmacological therapy.
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objecTIves And ouTlIne of ThIs ThesIs
The aim of the main part of this thesis was to evaluate the implementation of the MISSION! 
AMI protocol in clinical practice at various stages of the program (from pre-hospital care to 
secondary prevention), to evaluate efficacy and safety of sirolimus-eluting stents at 3-year 
follow-up, and to study differences in stent edge characteristics in a subgroup of patients by 
the use of virtual histology-intravascular ultrasound imaging.
In chapter 2 the pre-hospital part of the MISSION! AMI program is addressed, with time 
to treatment delays as particular point of interest. Data collected in a dedicated database 
show the efficacy of the pre-hospital protocol in achieving predefined targets in all 4 areas of 
residence in the region “Hollands-Midden”.
chapter 3 describes 3-year clinical outcome of the prospective randomized MISSION! 
Intervention study. The study compared efficacy and safety of sirolimus-eluting stents with 
bare-metal stents in eligible patients in the MISSION! AMI program with ST-segment elevation.
In chapter 4 the impact of the sirolimus-eluting stent is assessed on plaque composition 
and morphology at stent edges at 9-month follow-up using Virtual Histology intravascular 
ultrasound imaging in a subgroup of the MISSION! AMI population. Sirolimus is a potent 
anti-inflammatory, immunosuppressive and antiproliferative drug effective in inhibiting in-
stent neointimal hyperplasia.134 It was hypothesized that effects of the drug may potentially 
affect plaque composition at the distal stent edge as part of a downstream effect.
chapter 5 studies potential advantages of the use of intracoronary aspiration thrombec-
tomy during primary PCI in STEMI patients from the MISSION! AMI program, when used 
as adjunctive therapy to early abciximab administration. chapter 6 briefly describes the 
frequency and distribution of culprit lesions in patients presenting with ST-segment eleva-
tion acute myocardial infarction. In addition, the location of the culprit lesion was related to 
residual left ventricular function.
Despite the greater incidence and risk of acute myocardial infarction (AMI) among older 
patients135;136, there is still a considerable lack of data regarding success of aggressive AMI 
treatment in this subgroup and factors contributing to clinical outcome. chapter 7 aims 
to provide more insight into the clinical profile, presentation delays, medication compliance 
and outcome of treatment in the elderly AMI population up to one year post myocardial 
infarction (MI).
chapter 8 investigates the clinical relevance of baseline resting heart rate as potential 
risk factor for adverse outcome in AMI patients with preserved left ventricular function. 
chapter 9 offers suggestions on how to maintain ICD implantation rates within manage-
able proportions. As it remains difficult to identify patients who will receive ICD therapy in 
their lifetime, chapter 10 offers the right ventricular pacing threshold as a simple parameter 
to better facilitate evaluation of the prognosis post-implant.
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others:
chapters 11 and 12 focus on different patient populations and cardiac pathology than the 
previous Chapters. Catheter ablation has evolved as a possible curative treatment modality 
for atrial tachyarrhythmias (AT) in patients with congenital heart defects (CHD). However, 
long-term data on outcome is scarce. chapter 11 examines characteristics of recurrent AT 
after ablation of post-operative AT during long-term follow-up in CHD patients. In chapter 
12 the long-term success of cavotricuspid isthmus ablation is studied particularly in terms of 
atrial fibrillation (AF) occurrence in a population of “real-practice” patients with electrocar-
diographically documented isthmus dependent atrial flutter with and without preablation AF.
Finally, a general summary and conclusions are described.
C
ha
pt
er
 1
20
references
 1. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics--2010 update: a 
report from the American Heart Association. Circulation 2010; 121: e46-e215.
 2. Luepker RV, Berger AK. Is acute myocardial infarction disappearing? Circulation 2010; 121: 1280-
1282.
 3. National Heart Lung and Blood Institute. Morbidity and Mortality: 2009 Chart Book on Cardiovas-
cular, Lung, and Blood Diseases. Bethesda, Md: National Institutes of Health; 2009.
 4. Chen J, Normand SL, Wang Y, Drye EE, Schreiner GC, Krumholz HM. Recent declines in hospital-
izations for acute myocardial infarction for Medicare fee-for-service beneficiaries: progress and 
continuing challenges. Circulation 2010; 121: 1322-1328.
 5. van der Meulen A. Sterfte aan hart- en vaatziekten sinds 1970 gehalveerd; bron: Statistics Neth-
erlands 2005.
 6. Arnett DK, Jacobs DR, Jr., Luepker RV, Blackburn H, Armstrong C, Claas SA. Twenty-year trends 
in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart 
Survey, 1980-1982 to 2000-2002. Circulation 2005; 112: 3884-3891.
 7. Dobson R. US cigarette consumption falls to lowest point since 1951. BMJ 2006; 332: 687.
 8. Ford ES, Ajani UA, Croft JB et al. Explaining the decrease in U.S. deaths from coronary disease, 
1980-2000. N Engl J Med 2007; 356: 2388-2398.
 9. Goldberg RJ, Yarzebski J, Lessard D, Gore JM. A two-decades (1975 to 1995) long experience 
in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarction: a 
community-wide perspective. J Am Coll Cardiol 1999; 33: 1533-1539.
 10. Luepker RV, Arnett DK, Jacobs DR, Jr. et al. Trends in blood pressure, hypertension control, and 
stroke mortality: the Minnesota Heart Survey. Am J Med 2006; 119: 42-49.
 11. McGovern PG, Pankow JS, Shahar E et al. Recent trends in acute coronary heart disease--mortality, 
morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. N Engl J Med 
1996; 334: 884-890.
 12. Roger VL, Jacobsen SJ, Weston SA et al. Trends in the incidence and survival of patients with 
hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. Ann Intern Med 
2002; 136: 341-348.
 13. Rosamond WD, Chambless LE, Folsom AR et al. Trends in the incidence of myocardial infarction 
and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998; 339: 861-867.
 14. Goldman L, Cook F, Hashimotso B, Stone P, Muller J, Loscalzo A. Evidence that hospital care for 
acute myocardial infarction has not contributed to the decline in coronary mortality between 
1973-1974 and 1978-1979. Circulation 1982; 65: 936-942.
 15. McGovern PG, Jacobs DR, Jr., Shahar E et al. Trends in acute coronary heart disease mortality, 
morbidity, and medical care from 1985 through 1997: the Minnesota heart survey. Circulation 
2001; 104: 19-24.
 16. Mauri L, Silbaugh TS, Garg P et al. Drug-eluting or bare-metal stents for acute myocardial infarc-
tion. N Engl J Med 2008; 359: 1330-1342.
 17. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task 
Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics 
in Europe. Eur Heart J 1997; 18: 1231-1248.
 18. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of 
patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 
General introduction 21
Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 
110: e82-292.
 19. Van de Werf F, Ardissino D, Betriu A et al. Management of acute myocardial infarction in patients 
presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial 
Infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28-66.
 20. Barron HV, Bowlby LJ, Breen T et al. Use of reperfusion therapy for acute myocardial infarction in 
the United States: data from the National Registry of Myocardial Infarction 2. Circulation 1998; 
97: 1150-1156.
 21. Burwen DR, Galusha DH, Lewis JM et al. National and state trends in quality of care for acute 
myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality 
improvement program. Arch Intern Med 2003; 163: 1430-1439.
 22. Hasdai D, Behar S, Wallentin L et al. A prospective survey of the characteristics, treatments and 
outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the 
Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 23: 
1190-1201.
 23. Nallamothu BK, Bates ER, Herrin J, Wang Y, Bradley EH, Krumholz HM. Times to treatment in 
transfer patients undergoing primary percutaneous coronary intervention in the United States: 
National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 2005; 111: 761-767.
 24. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine 
countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention 
to Reduce Events. Lancet 2001; 357: 995-1001.
 25. Schiele F, Meneveau N, Seronde MF et al. Compliance with guidelines and 1-year mortality in 
patients with acute myocardial infarction: a prospective study. Eur Heart J 2005; 26: 873-880.
 26. Eagle KA, Montoye CK, Riba AL et al. Guideline-based standardized care is associated with 
substantially lower mortality in medicare patients with acute myocardial infarction: the American 
College of Cardiology’s Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll 
Cardiol 2005; 46: 1242-1248.
 27. LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular 
secondary prevention: pilot results. Arch Intern Med 2004; 164: 203-209.
 28. Ohman EM, Roe MT, Smith SC, Jr. et al. Care of non-ST-segment elevation patients: insights from 
the CRUSADE national quality improvement initiative. Am Heart J 2004; 148: S34-S39.
 29. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease 
by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). 
Am J Cardiol 2001; 87: 819-822.
 30. Liem SS, van der Hoeven BL, Oemrawsingh PV et al. MISSION!: optimization of acute and chronic 
care for patients with acute myocardial infarction. Am Heart J 2007; 153: 14-11.
 31. Canto JG, Rogers WJ, Bowlby LJ, French WJ, Pearce DJ, Weaver WD. The prehospital electrocar-
diogram in acute myocardial infarction: is its full potential being realized? National Registry of 
Myocardial Infarction 2 Investigators. J Am Coll Cardiol 1997; 29: 498-505.
 32. Saczynski JS, Yarzebski J, Lessard D et al. Trends in prehospital delay in patients with acute myo-
cardial infarction (from the Worcester Heart Attack Study). Am J Cardiol 2008; 102: 1589-1594.
 33. Broer J, Bleeker JK, Bouma J, de Jongste MJ, Erdman RA, Meyboom-de JB. [Regional differences 
in prehospital time delay for patients with acute myocardial infarction; Rotterdam and Groningen, 
1990-1995]. Ned Tijdschr Geneeskd 2000; 144: 78-83.
 34. Hassan AK, Liem SS, van der Kley F et al. In-ambulance abciximab administration in STEMI 
patients prior to primary PCI is associated with smaller infarct size, improved LV function and 
C
ha
pt
er
 1
22
lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction 
treatment optimization program. Catheter Cardiovasc Interv 2009; 74: 335-343.
 35. Rakowski T, Zalewski J, Legutko J et al. Early abciximab administration before primary percutane-
ous coronary intervention improves infarct-related artery patency and left ventricular function in 
high-risk patients with anterior wall myocardial infarction: a randomized study. Am Heart J 2007; 
153: 360-365.
 36. Rakowski T, Siudak Z, Dziewierz A et al. Early abciximab administration before transfer for primary 
percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortal-
ity in patients with high-risk profile. Results from EUROTRANSFER registry. Am Heart J 2009; 158: 
569-575.
 37. Boden WE, O’Rourke RA, Teo KK et al. Optimal medical therapy with or without PCI for stable 
coronary disease. N Engl J Med 2007; 356: 1503-1516.
 38. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy 
for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 
13-20.
 39. Mehta SR, Cannon CP, Fox KA et al. Routine vs selective invasive strategies in patients with 
acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005; 293: 
2908-2917.
 40. Antoniucci D, Santoro GM, Bolognese L, Valenti R, Trapani M, Fazzini PF. A clinical trial com-
paring primary stenting of the infarct-related artery with optimal primary angioplasty for acute 
myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary 
Occlusions (FRESCO) trial. J Am Coll Cardiol 1998; 31: 1234-1239.
 41. Rodriguez A, Bernardi V, Fernandez M et al. In-hospital and late results of coronary stents versus 
conventional balloon angioplasty in acute myocardial infarction (GRAMI trial). Gianturco-Roubin 
in Acute Myocardial Infarction. Am J Cardiol 1998; 81: 1286-1291.
 42. Saito S, Hosokawa G, Tanaka S, Nakamura S. Primary stent implantation is superior to balloon 
angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent 
implantation in acute myocardial infarction (PASTA) trial. PASTA Trial Investigators. Catheter 
Cardiovasc Interv 1999; 48: 262-268.
 43. Suryapranata H, Ottervanger JP, Nibbering E et al. Long term outcome and cost-effectiveness of 
stenting versus balloon angioplasty for acute myocardial infarction. Heart 2001; 85: 667-671.
 44. Williams DO, Holubkov R, Yeh W et al. Percutaneous coronary intervention in the current era 
compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation 
2000; 102: 2945-2951.
 45. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent 
with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
 46. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients 
with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
 47. Schampaert E, Cohen EA, Schluter M et al. The Canadian study of the sirolimus-eluting stent in 
the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J 
Am Coll Cardiol 2004; 43: 1110-1115.
 48. Schofer J, Schluter M, Gershlick AH et al. Sirolimus-eluting stents for treatment of patients with 
long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial 
(E-SIRIUS). Lancet 2003; 362: 1093-1099.
 49. Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with 
coronary artery disease. N Engl J Med 2004; 350: 221-231.
General introduction 23
 50. van der Hoeven BL, Liem SS, Jukema JW et al. Sirolimus-eluting stents versus bare-metal stents 
in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravas-
cular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention 
Study. J Am Coll Cardiol 2008; 51: 618-626.
 51. Caixeta A, Leon MB, Lansky AJ et al. 5-year clinical outcomes after sirolimus-eluting stent implan-
tation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-
eluting stents with bare-metal stents. J Am Coll Cardiol 2009; 54: 894-902.
 52. Morice MC, Serruys PW, Barragan P et al. Long-term clinical outcomes with sirolimus-eluting 
coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 2007; 50: 1299-1304.
 53. Weisz G, Leon MB, Holmes DR, Jr. et al. Five-year follow-up after sirolimus-eluting stent implanta-
tion results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am 
Coll Cardiol 2009; 53: 1488-1497.
 54. Fajadet J, Wijns W, Laarman GJ et al. Randomized, double-blind, multicenter study of the Endeavor 
zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery 
lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114: 798-806.
 55. Serruys PW, Ong AT, Piek JJ et al. A randomized comparison of a durable polymer Everolimus-
eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention 2005; 1: 
58-65.
 56. Tsuchiya Y, Lansky AJ, Costa RA et al. Effect of everolimus-eluting stents in different vessel sizes 
(from the pooled FUTURE I and II trials). Am J Cardiol 2006; 98: 464-469.
 57. Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-
eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional 
cohort study. Lancet 2007; 369: 667-678.
 58. de la Torre-Hernandez JM, Alfonso F, Hernandez F et al. Drug-eluting stent thrombosis: results 
from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents 
FArmacoactivos). J Am Coll Cardiol 2008; 51: 986-990.
 59. Jensen LO, Maeng M, Kaltoft A et al. Stent thrombosis, myocardial infarction, and death after 
drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 2007; 50: 463-470.
 60. Park DW, Park SW, Park KH et al. Frequency of and risk factors for stent thrombosis after drug-
eluting stent implantation during long-term follow-up. Am J Cardiol 2006; 98: 352-356.
 61. Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE. Stent thrombosis in randomized 
clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029.
 62. Spaulding C, Henry P, Teiger E et al. Sirolimus-eluting versus uncoated stents in acute myocardial 
infarction. N Engl J Med 2006; 355: 1093-1104.
 63. Sakhuja R, Mauri L. Controversies in the use of drug-eluting stents for acute myocardial infarc-
tion: a critical appraisal of the data. Annu Rev Med 2010; 61: 215-231.
 64. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes 
with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009-1019.
 65. James SK, Stenestrand U, Lindback J et al. Long-term safety and efficacy of drug-eluting versus 
bare-metal stents in Sweden. N Engl J Med 2009; 360: 1933-1945.
 66. Steg PG, Fox KA, Eagle KA et al. Mortality following placement of drug-eluting and bare-metal 
stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coro-
nary Events. Eur Heart J 2009; 30: 321-329.
 67. Austin D, Pell JP, Oldroyd KG. The rise and fall of drug-eluting stents: time trend analysis in 13,647 
consecutive patients undergoing percutaneous coronary intervention. Am Heart J 2007; 154: e37.
C
ha
pt
er
 1
24
 68. Kukreja N, Onuma Y, Garcia-Garcia H, Daemen J, van DR, Serruys PW. Primary percutaneous 
coronary intervention for acute myocardial infarction: long-term outcome after bare metal and 
drug-eluting stent implantation. Circ Cardiovasc Interv 2008; 1: 103-110.
 69. Chechi T, Vittori G, Biondi Zoccai GG et al. Single-center randomized evaluation of paclitaxel-
eluting versus conventional stent in acute myocardial infarction (SELECTION). J Interv Cardiol 
2007; 20: 282-291.
 70. Diaz de la Llera LS, Ballesteros S, Nevado J et al. Sirolimus-eluting stents compared with standard 
stents in the treatment of patients with primary angioplasty. Am Heart J 2007; 154: 164-166.
 71. Karjalainen PP, Ylitalo A, Niemela M et al. Titanium-nitride-oxide coated stents versus paclitaxel-
eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX AMI 
trial. EuroIntervention 2008; 4: 234-241.
 72. Kelbaek H, Thuesen L, Helqvist S et al. Drug-eluting versus bare metal stents in patients with 
st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal 
Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 2008; 118: 1155-1162.
 73. Laarman GJ, Suttorp MJ, Dirksen MT et al. Paclitaxel-eluting versus uncoated stents in primary 
percutaneous coronary intervention. N Engl J Med 2006; 355: 1105-1113.
 74. Menichelli M, Parma A, Pucci E et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-
Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 2007; 49: 1924-1930.
 75. Stone GW, Lansky AJ, Pocock SJ et al. Paclitaxel-eluting stents versus bare-metal stents in acute 
myocardial infarction. N Engl J Med 2009; 360: 1946-1959.
 76. Valgimigli M, Percoco G, Malagutti P et al. Tirofiban and sirolimus-eluting stent vs abciximab and 
bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005; 293: 2109-2117.
 77. Valgimigli M, Campo G, Percoco G et al. Comparison of angioplasty with infusion of tirofiban 
or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial 
infarction: the MULTISTRATEGY randomized trial. JAMA 2008; 299: 1788-1799.
 78. Di LE, De LG, Sauro R et al. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal 
Stent in Primary Angioplasty) Randomized Trial. JACC Cardiovasc Interv 2009; 2: 515-523.
 79. Kastrati A, Dibra A, Spaulding C et al. Meta-analysis of randomized trials on drug-eluting stents vs. 
bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007; 28: 2706-2713.
 80. Goy JJ, Urban P, Kaufmann U, Seydoux C, De BE, Berger A. Incidence of stent thrombosis and 
adverse cardiac events 5 years after sirolimus stent implantation in clinical practice. Am Heart J 
2009; 157: 883-888.
 81. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing 
sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 989-997.
 82. Cutlip DE, Chhabra AG, Baim DS et al. Beyond restenosis: five-year clinical outcomes from 
second-generation coronary stent trials. Circulation 2004; 110: 1226-1230.
 83. Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coro-
nary stents. N Engl J Med 2007; 356: 998-1008.
 84. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed 
by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE 
study. Lancet 2001; 358: 527-533.
 85. Steinhubl SR, Berger PB, Mann JT, III et al. Early and sustained dual oral antiplatelet therapy 
following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 
2411-2420.
 86. Grines CL, Bonow RO, Casey DE, Jr. et al. Prevention of premature discontinuation of dual anti-
platelet therapy in patients with coronary artery stents: a science advisory from the American 
General introduction 25
Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and 
Interventions, American College of Surgeons, and American Dental Association, with representa-
tion from the American College of Physicians. J Am Coll Cardiol 2007; 49: 734-739.
 87. Smith SC, Jr., Feldman TE, Hirshfeld JW, Jr. et al. ACC/AHA/SCAI 2005 Guideline Update for 
Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Car-
diology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing 
Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll 
Cardiol 2006; 47: 216-235.
 88. Spertus JA, Kettelkamp R, Vance C et al. Prevalence, predictors, and outcomes of premature 
discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the 
PREMIER registry. Circulation 2006; 113: 2803-2809.
 89. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after 
successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-2130.
 90. Pfisterer M, Brunner-La Rocca HP, Buser PT et al. Late clinical events after clopidogrel discontinu-
ation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus 
bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-2591.
 91. Eisenstein EL, Anstrom KJ, Kong DF et al. Clopidogrel use and long-term clinical outcomes after 
drug-eluting stent implantation. JAMA 2007; 297: 159-168.
 92. Mauri L. Dual antiplatelet therapy trial design. Abstract presented at Transcatheter Therapeutics, 
Washington, DC, Oct 15, 2008.
 93. Leon AS, Franklin BA, Costa F et al. Cardiac rehabilitation and secondary prevention of coronary 
heart disease: an American Heart Association scientific statement from the Council on Clinical 
Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council 
on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collabora-
tion with the American association of Cardiovascular and Pulmonary Rehabilitation. Circulation 
2005; 111: 369-376.
 94. Thompson PD, Buchner D, Pina IL et al. Exercise and physical activity in the prevention and 
treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical 
Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutri-
tion, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003; 107: 
3109-3116.
 95. Hall SL, Lorenc T. Secondary prevention of coronary artery disease. Am Fam Physician 2010; 81: 
289-296.
 96. Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation 
for coronary heart disease. Cochrane Database Syst Rev 2001; CD001800.
 97. McGrath PD. Review: exercise-based cardiac rehabilitation reduces all-cause and cardiac mortality 
in coronary heart disease. ACP J Club 2004; 141: 62.
 98. Taylor RS, Brown A, Ebrahim S et al. Exercise-based rehabilitation for patients with coronary heart 
disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004; 
116: 682-692.
 99. Balady GJ, Williams MA, Ades PA et al. Core components of cardiac rehabilitation/secondary 
prevention programs: 2007 update: a scientific statement from the American Heart Association 
Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; 
the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical 
Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Reha-
bilitation. Circulation 2007; 115: 2675-2682.
C
ha
pt
er
 1
26
 100. Smith SC, Jr., Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients 
with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National 
Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-2372.
 101. Klein S, Burke LE, Bray GA et al. Clinical implications of obesity with specific focus on cardio-
vascular disease: a statement for professionals from the American Heart Association Council on 
Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology 
Foundation. Circulation 2004; 110: 2952-2967.
 102. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart dis-
ease. Cochrane Database Syst Rev 2003; CD003041.
 103. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients 
with coronary heart disease: a systematic review. JAMA 2003; 290: 86-97.
 104. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public 
Health Service report. Am J Prev Med 2008; 35: 158-176.
 105. Barth J, Critchley J, Bengel J. Psychosocial interventions for smoking cessation in patients with 
coronary heart disease. Cochrane Database Syst Rev 2008; CD006886.
 106. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination 
evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circula-
tion 2004; 109: 745-749.
 107. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 
1206-1252.
 108. Rosendorff C, Black HR, Cannon CP et al. Treatment of hypertension in the prevention and man-
agement of ischemic heart disease: a scientific statement from the American Heart Association 
Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiol-
ogy and Prevention. Circulation 2007; 115: 2761-2788.
 109. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, 
myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
 110. King SB, III, Smith SC, Jr., Hirshfeld JW, Jr. et al. 2007 focused update of the ACC/AHA/SCAI 2005 
guideline update for percutaneous coronary intervention: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 
51: 172-209.
 111. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult 
Treatment Panel III). JAMA 2001; 285: 2486-2497.
 112. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart 
disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am 
Coll Cardiol 2004; 44: 1772-1779.
 113. Pitt B, Waters D, Brown WV et al. Aggressive lipid-lowering therapy compared with angioplasty 
in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N 
Engl J Med 1999; 341: 70-76.
 114. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: 
prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. 
Lancet 2005; 366: 1267-1278.
 115. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-
analysis of randomized trials. CMAJ 2008; 178: 576-584.
General introduction 27
 116. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death. Structure, function, and time-
dependence of risk. Circulation 1992; 85: I2-10.
 117. Myerburg RJ. Implantable cardioverter-defibrillators after myocardial infarction. N Engl J Med 
2008; 359: 2245-2253.
 118. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for 
congestive heart failure. N Engl J Med 2005; 352: 225-237.
 119. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with 
myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
 120. Vardas PE, Auricchio A, Blanc JJ et al. Guidelines for cardiac pacing and cardiac resynchroniza-
tion therapy. The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the 
European Society of Cardiology. Developed in collaboration with the European Heart Rhythm 
Association. Europace 2007; 9: 959-998.
 121. Chow T, Kereiakes DJ, Onufer J et al. Does microvolt T-wave alternans testing predict ventricular 
tachyarrhythmias in patients with ischemic cardiomyopathy and prophylactic defibrillators? The 
MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction 
Patients) trial. J Am Coll Cardiol 2008; 52: 1607-1615.
 122. Daubert JP, Zareba W, Hall WJ et al. Predictive value of ventricular arrhythmia inducibility for 
subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator 
Implantation Trial (MADIT) II patients. J Am Coll Cardiol 2006; 47: 98-107.
 123. Goldenberg I, Vyas AK, Hall WJ et al. Risk stratification for primary implantation of a cardioverter-
defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008; 51: 
288-296.
 124. Germano JJ, Reynolds M, Essebag V, Josephson ME. Frequency and causes of implantable 
cardioverter-defibrillator therapies: is device therapy proarrhythmic? Am J Cardiol 2006; 97: 1255-
1261.
 125. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator 
therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008; 52: 1111-1121.
 126. Hohnloser SH, Kuck KH, Dorian P et al. Prophylactic use of an implantable cardioverter-defibrillator 
after acute myocardial infarction. N Engl J Med 2004; 351: 2481-2488.
 127. Cuculich PS, Sanchez JM, Kerzner R et al. Poor prognosis for patients with chronic kidney disease 
despite ICD therapy for the primary prevention of sudden death. Pacing Clin Electrophysiol 2007; 
30: 207-213.
 128. Lee DS, Tu JV, Austin PC et al. Effect of cardiac and noncardiac conditions on survival after 
defibrillator implantation. J Am Coll Cardiol 2007; 49: 2408-2415.
 129. Pellegrini CN, Lee K, Olgin JE et al. Impact of advanced age on survival in patients with implant-
able cardioverter defibrillators. Europace 2008; 10: 1296-1301.
 130. Hlatky MA, Mark DB. The high cost of implantable defibrillators. Eur Heart J 2007; 28: 388-391.
 131. Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309: 331-336.
 132. Morishima I, Sone T, Tsuboi H et al. Risk stratification of patients with prior myocardial infarction 
and advanced left ventricular dysfunction by gated myocardial perfusion SPECT imaging. J Nucl 
Cardiol 2008; 15: 631-637.
 133. Rouleau JL, Talajic M, Sussex B et al. Myocardial infarction patients in the 1990s--their risk factors, 
stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) 
Study. J Am Coll Cardiol 1996; 27: 1119-1127.
 134. Serruys PW, Degertekin M, Tanabe K et al. Intravascular ultrasound findings in the multicenter, 
randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity 
C
ha
pt
er
 1
28
balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) 
trial. Circulation 2002; 106: 798-803.
 135. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative over-
view of early mortality and major morbidity results from all randomised trials of more than 1000 
patients. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Lancet 1994; 343: 311-322.
 136. Mehta RH, Granger CB, Alexander KP, Bossone E, White HD, Sketch MH, Jr. Reperfusion strategies 
for acute myocardial infarction in the elderly: benefits and risks. J Am Coll Cardiol 2005; 45: 
471-478.
Chapter 2
Standardized pre-hospital care of 
acute myocardial infarction patients: 
MISSION! guidelines applied in practice.
Jael Z. Atary1, Matthijs de Visser2, Rene van den Dijk1, Jan Bosch2, Su San Liem1, 
M. Louisa Antoni1, Marianne Bootsma1, Eric P. Viergever3, Charles J. Kirchhof4, 
Iman Padmos5, Meredith I. Sedney6, Henk J. van Exel7, Harriette F. Verwey1, 
Douwe E. Atsma1, Ernst E. van der Wall1, J. Wouter Jukema1, Martin J. Schalij1
1Department of Cardiology, Leiden University Medical Center, The Netherlands,
2Regional Ambulance Service Hollands-Midden, Leiden, The Netherlands,
3Groene Hart Hospital, Gouda, The Netherlands,
4Rijnland Hospital, Leiderdorp, The Netherlands,
5Diaconessenhuis, Leiden, The Netherlands,
6Bronovo Hospital, The Hague, The Netherlands,
7Rijnlands Rehabilitation Center, Leiden, The Netherlands
Neth Heart J. 2010 Sep;18(9):408-15.
C
ha
pt
er
 2
30
AbsTrAcT
background
To improve acute myocardial infarction (AMI) care in the region “Hollands-Midden” (the 
Netherlands), a standardized guideline based care program was developed (MISSION!). This 
study aimed to evaluate outcome of the pre-hospital part of the MISSION! program and to 
study potential differences in pre-hospital care between four areas of residency.
Methods
Time to treatment delays, AMI risk profile, cardiac enzymes, hospital stay, in-hospital mortal-
ity, and pre-AMI medication was evaluated in consecutive AMI patients (n=863, 61±13years, 
75% male) transferred to the Leiden University Medical Center for primary percutaneous 
coronary intervention (PCI).
results
Median time interval between onset of symptoms and arrival at the catheterization laboratory 
was 150(101-280)minutes. The alert of emergency service to arrival at the hospital time was 
48(40-60)minutes and the door to catheterization laboratory time was 23(13-42)minutes. 
Despite significant regional differences in ambulance transportation times no difference in 
total time from onset of symptoms to arrival at the catheterization room was found. Peak 
troponin T was 3.33(1.23-7.04)µg/L, hospital stay was 2(2-3)days and in-hospital mortality 
was 2.3%.
Twelve percent had 0 known risk factors, 30% had 1 risk factor, 45% 2-3 risk factors 
and 13% had ≥4 risk factors. No significant differences were observed for AMI risk profiles 
and medication pre-AMI.
conclusions
This study shows that a standardized regional AMI treatment protocol achieved optimal and 
uniformly distributed pre-hospital performance in the region “Hollands-Midden”, resulting 
in minimal time delays regardless of area of residence. Hospital stay was short and in-hospital 
mortality low. Eighty-eight percent of patients had ≥1 modifiable risk factor.
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InTroducTIon
Coronary heart disease (CHD) is the leading cause of death in the western world. Current 
guidelines are therefore aimed at optimizing care and outcome of patients with acute myo-
cardial infarction (AMI).1;2 In the past 20 years the risk of dying from CHD in the Netherlands 
was successfully reduced by almost 33%.3 This was in part the result of increased efforts to 
improve acute treatment and secondary prevention strategies.3-5
In the acute phase AMI patients require rapid diagnosis and early reperfusion to minimize 
infarct size and to prevent complications. Several factors determine treatment delay with 
its major contributors being patient-delay, physician-delay and in-hospital delay. In order to 
minimize treatment delay an intensive collaboration is therefore needed between primary 
care physicians, regional ambulance services, community hospitals (without percutaneous 
coronary intervention (PCI) facilities), and PCI centers.
A regional AMI guideline implementation program (MISSION!) was developed to opti-
mize the use of evidence-based medicine in practice.6 MISSION! contains a pre-hospital, 
in-hospital and out-patient clinical framework for decision making and treatment of AMI 
patients. The main goal of this study was to study the outcome of the pre-hospital part of 
MISSION! and to evaluate and identify potential regional differences in multidisciplinary 
performance and related patient factors in the region “Hollands-Midden”.
MeThods
Patients
The geographical region studied (Hollands Midden = “Center of Holland”) spans an area of 
875 km2 with a population of approximately 750.000 inhabitants. Patients included in this 
study were all living in the region and were admitted with the diagnosis of AMI in the years 
2006-2008 at the Leiden University Medical Center for primary PCI. The study population 
was partitioned into four areas of residency within Hollands-Midden, classified as “Duin & 
Bollen” (region 1), “Leiden” (region 2), “Alphen” (region 3) and “Gouda” (region 4) (Fig. 1). 
AMI patients admitted for primary PCI living outside of the region Hollands-Midden were 
excluded.
clinical protocol
To align AMI care, an intensive collaboration was established among primary care physicians, 
the regional ambulance services, three community hospitals without PCI facilities, three 
cardiac rehabilitation centers and the Leiden University Medical Center, serving as primary 
PCI facility. The MISSION! protocol was developed based on the American College of Cardiol-
ogy/American Heart Association and European Society of Cardiology guidelines for AMI.2;7 
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The pre-hospital emergency care required trained ambulance personnel to obtain a 12-lead 
ECG at patients’ home. In the case of suspect characteristics, the ECG was electronically 
transmitted to the PCI center. Trained coronary care unit (CCU) nurses determined patient’s 
eligibility for primary PCI. Patients not eligible for PCI, were transferred to a community 
hospital for further assessment. Patients eligible for primary PCI, were transferred directly to 
the PCI center’s Cardiac Care Unit. In the ambulance aspirin, abciximab and clopidogrel was 
administered to the patient. The catheterization room was operational within 20 minutes, 
24 hours a day, 7 days a week. After discharge, patients were offered a cardiac rehabilitation 
program and benefited from intensive out-patient follow up for the period of 1 year.
The current study focused on the pre-PCI phase of the MISSION! protocol.
data collection
Data was recorded by ambulance personnel and medical staff at the hospital. All the data 
was registered in a departmental electronic patient system (EPD-Vision, LUMC, Leiden, The 
Netherlands).
endpoints
Pre-clinical performance in the four residence areas was measured by the following time 
intervals (minutes): Onset of Symptoms to Alert of Emergency Services (patient delay), Onset 
of Symptoms to Arrival at Catheterization Room (Cath-Lab), Door to Cath-Lab (hospital delay) 
and Interval between the Alert of Emergency Services to Arrival at the Hospital. Additional 
endpoints of interest were peak Troponin T and peak Creatine Phosphokinase (CPK) levels.
Furthermore, risk profile for CHD was compared between the 4 areas of residency 
within Hollands-Midden, including risk factors like smoking, hypertension, hyperlipidemia, 
positive family history, diabetes mellitus and prior myocardial infarction. Lastly, drug treat-
ment before occurrence of AMI was studied. Pre-admission medication use of interest was 
beta-blockers, statins, aspirin, ACE-inhibitors, angiotensine II (AT2)-antagonists, diuretics 
and calcium-antagonists.
statistical Analysis
Sample comparisons were made with a Pearson χ2 test for categorical variables using Yate’s 
correction where appropriate. A Kruskal-Wallis one-way analysis of variance was employed 
for the comparison of not normally distributed continuous variables such as time intervals. 
All tests were two-sided, a p-value of < 0.05 was considered significant (using Bonferroni 
correction where appropriate). All data were analyzed with SPSS 16.0.02.
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resulTs
study population
A total of 1002 consecutive AMI patients were admitted at the PCI center between 2006 
and 2008. Of these patients, 863 (86%) were Hollands-Midden residents and included in the 
final study population. Baseline characteristics are shown in Table 1. The majority of patients 
was male (75%) and the mean age was 61 ± 13 years. The distribution of patients from 
the areas of residence 1, 2, 3 and 4 was 31%, 29%, 21% and 19%, respectively (Fig. 1). 
Table 1. Patient characteristics.
Patient Characteristics (n=863)
Male (%) 646 (74.9)
Age (years) 61 ± 13
BMI (kg/m2) 28.4 (24.9-41.1)
 BMI ≥30 kg/m2 (%) 374 (43.3)
Region of residency (%)
 1 265 (30.7)
 2 253 (29.3)
 3 185 (21.4)
 4 160 (18.5)
Risk factors for coronary diseases (%)
 Smoking 462 (53.5)
 Hypertension 307 (35.6)
 Hyperlipidemia 167 (19.4)
 Family History 358 (41.5)
 Diabetes Mellitus 108 (12.5)
 Prior Myocardial Infarction 90 (10.4)
Median time intervals in minutes (IQR)
 Onset Symptoms - Arrival at Cath-Lab 150 (101-280)
 Door - Arrival at Cath-Lab 23 (13-42)
 Onset Symptoms – Alert of Emergency Services 61 (25-158)
 Alert of Emergency Services – Arrival at Hospital 48 (40-60)
Hospitalization
 Days hospitalized (median [IQR]) 2 (2-3)
 In-hospital mortality (%) 20 (2.3)
Values expressed as n (%), normally distributed data as mean ± standard deviation, otherwise as me-
dian (interquartile range [IQR]: 25th-75th percentile).
BMI = Body Mass Index, Cath-Lab = Catheterization Room.
Hyperlipidemia= Total cholesterol ≥190 mg/dl or previous pharmacological treatment.
Hypertension = Blood pressure ≥140/90 mm Hg or previous pharmacological treatment.
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The four most common risk factors were smoking (54%), a family history of coronary artery 
disease (CAD) which was present in 42% of patients, a Body Mass Index (BMI) ≥30 kg/m2 
(43%) and hypertension in 36% of patients.
Median duration from onset of symptoms to arrival at the Cath-Lab was 150 minutes 
(101-280 min). Median patient delay, measured as time between the onset of symptoms 
and the moment of alerting the emergency service, was 61 minutes (25-158 min), whereas 
the median time between the alert of emergency services and the arrival at the hospital 
was 48 minutes (40-60 min). Median Door to Cath-Lab time was 23 minutes (13-42 min). 
Hospital stay was only 2 (2-3) days and in-hospital mortality was 2.3% (20/863). Total 30 
day mortality was 3.5% (30/863, including in-hospital mortality).
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figure 1. The region of “Hollands-Midden” as divided into four areas of residency.
Schematic map of the region “Hollands-Midden” (The Netherlands) further subdivided into the four 
areas of residency: “Duin & Bollen” (region 1), “Leiden” (region 2), “Alphen” (region 3), “Gouda” 
(region 4). The star within “Leiden” (region 2) represents the location of the PCI center. Maximal travel 
time to each area of residency (minutes) and percentage of patients per area are shown in the bar 
graphs on the right.
AMI = acute myocardial infarction, KM = kilometers, Max. = maximal, PCI = percutaneous coronary 
intervention.
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clinical characteristics per area of residency
Clinical characteristics according to the area of residency are shown in Table 2. In summary, 
comparisons revealed a similar age and gender distribution between the 4 areas and similar 
Table 2. Patients’ medical history per region of residency.
Region 1
n = 265
Region 2
n = 253
Region 3
n = 185
Region 4
n = 160
p-value
Patient Characteristics
 Male (%) 203 (76.6) 190 (75.1) 130 (70.3) 123 (76.9) 0.415
 Age (years) 61 ± 13 61 ± 13 61 ± 13 62 ± 12 0.931
 Body Mass Index (kg/m2) 28.7 (25.5-42.6) 28.4 (25.0-40.4) 27.5 (24.5-39.6) 27.8 (24.7-42.3) 0.466
Risk factors (%)
 Smoking 151 (57.0) 128 (50.8) 105 (57.1) 78 (49.1) 0.239
 Hypertension 102 (38.5) 86 (34.3) 68 (37.0) 51 (32.1) 0.540
 Hyperlipidemia 50 (18.9) 49 (19.4) 35 (19.0) 33 (20.8) 0.969
 Family History 115 (43.4) 99 (39.3) 81 (44.0) 63 (39.6) 0.658
 Diabetes Mellitus 29 (11.0) 36 (14.3) 26 (14.1) 17 (10.7) 0.533
 Prior Myocardial Infarction 24 (9.1) 34 (13.5) 16 (8.7) 16 (10.1) 0.304
 Prior PCI 21 (8.0) 22 (8.7) 10 (5.4) 9 (5.7) 0.471
 CABG in past 6 (2.3) 8 (3.2) 3 (1.6) 3 (1.9) 0.724
 History of Angina Pectoris 33 (12.6) 43 (17.5) 28 (15.6) 25 (15.8) 0.498
Nr. of risk factors
 0 39 (14.7) 31 (12.3) 12 (6.5) 20 (12.5) 0.063
 1-2 139 (52.5) 145 (57.3) 119 (64.3) 97 (60.6) 0.076
 3-4 73 (27.5) 63 (24.9) 45 (24.3) 37 (23.1) 0.747
 ≥ 4 36 (13.6) 39 (15.4) 23 (12.4) 15 (9.4) 0.352
Medication before MI (%)
 Beta-blocker 67 (25.4) 45 (18.0) 41 (22.4) 27 (17.0) 0.104
 Aspirin 51 (19.2) 52 (20.8) 33 (18.0) 20 (12.6) 0.195
 Statin 52 (19.7) 48 (19.2) 34 (18.6) 21 (13.2) 0.354
 ACE-inhibitor 35 (13.2) 33 (13.2) 20 (10.9) 17 (10.7) 0.779
 Angiotensine II-antagonist 15 (5.7)* 16 (6.4) 25 (13.7)* 10 (6.3) 0.008*
 Diuretic 31 (11.7) 25 (10.0) 22 (12.0) 23 (14.5) 0.598
 Ca-antagonist 30 (11.3) 25 (10.0) 21 (11.5) 15 (9.4) 0.893
Peak troponin T (µg/L) 3.45 (1.28-7.14) 2.81 (0.92-6.39) 3.34 (1.24-6.68) 3.95 (1.98-7.87) 0.083
Peak CPK (U/L) 1388 (587-2618) 997 (448-2165) 1323 (522-2727) 1586 (755-3146) 0.008*
LVEF 3 months post-MI (%) 56 (47-64) 56 (47-64) 55 (49-63) 55 (47-63) 0.887
Values expressed as n (%), normally distributed data as mean ± standard deviation, otherwise as me-
dian (interquartile range [IQR]: 25th-75th percentile). * p<0.05
ACE = Angiotensin-Converting Enzyme, Ca = Calcium, CABG = coronary artery bypass surgery, CPK 
= Creatine Phosphokinase, LVEF = Left ventricular ejection fraction, MI = myocardial infarction, PCI = 
percutaneous coronary intervention.
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risk profiles for CHD. Medication prior to AMI was similar between the 4 patient groups 
except for a significantly larger percentage of patients using AT2-antagonist living in region 
3 when compared to patients living in the region 1 (13.7% versus 5.7%, respectively).
Pre-hospital care
Pre-hospital time delays per area of residency are illustrated in Fig. 2. Patient delays were 
similar between the four areas of residency as revealed by the median time between onset of 
symptoms to alert of emergency services (Panel A: range of a median 51 min for region 2 to 
a median 74 min for region 1; p=0.796).
In addition, total time elapsing between the onset of symptoms and the arrival at the 
catheterization laboratory was also similar for patients of all four areas of residency (Panel 
B: median 148 min for region 3 to median 165 min for region 4; p=0.809). Panel C further-
more shows that median in-hospital delay was relatively short (median 17 min for region 
4 to median 28 min for region 2) and comparable between the patient groups (p=0.056).
Fig. 3 shows that significant differences were present between the four areas of residence 
in the total time needed for emergency services to arrive at the patient (from the moment 
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figure 2. Time to treatment delay.
Bar graphs showing: (Panel A) patient delay defined as time from onset of symptoms to alert of emer-
gency services, (Panel B) time interval from symptom onset to arrival at the catheterization room (“cath-
lab”), and (Panel C) hospital delay expressed as time from arrival at the hospital to arrival at the cath-
lab. Top of bar represents median time (minutes). Error bars indicate 25th and 75th percentile (minutes). 
Abbreviations as in figure 1.
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of the 911 call) in addition to the amount of time needed to transport the patient to the 
PCI center (p<0.001). Only two areas of residency did not differ significantly: Region 1 and 
region 2 (median of 45 min and 44 min respectively). Patients living outside of this area all 
needed significantly more time to reach the PCI center (≥50 min). Transportation time of 
patients from region 4 was the longest (median of 63 min). Of interest, these patients had 
the shortest door to Cath-Lab time (17 min) when compared to patients from other areas.
dIscussIon
The main findings of this study were: (1) the pre-hospital MISSION protocol succeeded in 
achieving equally high quality pre-hospital performance in all areas of the region Hollands-
Midden regardless of the distance from the PCI center, (2) time delay due to geographical 
distance (“Gouda”[region 4] patients) was counterbalanced by a short in-hospital delay, and 
(3) there was no significant difference in pre-AMI medication use and risk profile of patients 
between the four areas of residency.
structured care for AMI patients
Previous reports demonstrated that a standardized guideline-based treatment system can 
improve the quality of AMI care and can even result in a lower in-hospital and 1-year 
mortality.8-11 Collaboration between general practitioner, ambulance services and hospital 
is essential in prevention, acute care and rehabilitation of (potential) AMI patients. Results 
of this study demonstrate the efficacy of the pre-hospital MISSION! protocol in achieving 
predefined targets.6 Furthermore despite significant differences in transportation time (due 
to differences in distance from the PCI center) similar time intervals between the onset 
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figure 3. Time from alert of emergency services to arrival at PCI center.
Bars represent time interval (median minutes) from 911 call to the arrival at PCI center (represented by 
star) per region of residency. Abbreviations as in figure 1.
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of symptoms to arrival at the Cath-Lab in all 4 areas of residence demonstrate that the 
multidisciplinary pre-hospital care is uniformly distributed and well organized in the region 
Hollands-Midden. Furthermore, even though physical distance was of influence on the time 
needed to get the patient to the hospital (from the start of symptoms), the short door to 
Cath-Lab time (median 23 min) leveled out these differences.
Benefits of the standardized pre-hospital care program are also reflected in short admis-
sion duration (median 2 days) and low in-hospital mortality (2.3%). Peak cardiac enzyme 
levels per area of residency, such as troponin T levels demonstrated that final infarct size was 
similar, regardless of the geographical distance. Moreover, it corresponded well with left 
ventricular ejection fraction of patients as measured 3 months post myocardial infarction by 
stress/rest myocardial perfusion scanning (Table 2).
Hardly any significant differences were observed in medications prescribed by general 
practitioners prior to AMI and in risk factors for CHD between the four areas of residence 
within Hollands Midden. Investigators of the EUROASPIRE Study investigated risk factor 
control in several countries in Europe.12 Compared with their most recent data, risk factors 
for CHD were less prevalent in our study population, except for smoking (this study: 54.0% 
vs. EUROASPIRE: 18.3%) and BMI ≥30 kg/m2 (43% vs. 38.0%).13 Lower prevalence of 
hypertension (35.6% vs. 60.9%), hyperlipidemia (19.4% vs. 46.2%) and diabetes (12.5% 
vs. 28.0%) point to a relatively successful risk factor control in the region ‘Hollands Midden’. 
Possibly, greater attention for modifiable lifestyle factors, particularly smoking and obesity, 
may facilitate in further improving prevention of AMI in the region Hollands-Midden in the 
future.
Inconsistency of guideline implementation
Many organizations have recommended early reperfusion strategies and use of evidence-
based medicine, together with long-term support programs to stimulate healthier lifestyle 
for the treatment of patients with AMI.1;2 Although benefit of these guidelines has already 
been established, their implementation in the treatment of AMI patients is still inconsistent. 
Broer et al. showed that there were regional differences in pre-hospital time delays for AMI 
patients in the Netherlands.14 The EURASPIRE survey showed that there were significant 
differences in risk factor control and cardioprotective drug prescription between European 
countries.13
While guidelines recommend having at least 75% of patients treated within 90 minutes of 
presentation at the hospital, a study using the United States National Registry of Myocardial 
Infarction led investigators to conclude that this benchmark is rarely achieved for patients 
undergoing primary PCI in the United States. Only 4.2% of 4278 patients transferred for 
primary PCI at 419 hospitals were treated within 90 minutes and median door-to-ballon time 
was 180 minutes.15 More recently, the reported percentage of patients with door-to-balloon 
times of <90 minutes in a community-wide surveillance study of patients hospitalized with 
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AMI (in a large central New England community in the United States) was less than 10%.16 
In another Dutch study conducted by Broer et al, investigators reported hospital delays of 
60-72 min.14 In contrast, the present study achieved a median door-to-Cath-Lab time of 23 
minutes, with 90% of patients reaching the Cath-Lab in <90 minutes.
clinical implications
Standardized protocols like MISSION! contribute to improved adherence to evidence-based 
medicine in routine clinical practice and to the uniform implementation of structured care for 
patients with AMI, stressing the importance of close collaboration with all partners.
limitations
No comparisons could be made between the current study population and a population not 
treated according to the MISSION! protocol in the region Hollands-Midden. Nevertheless, 
compared to previous studies, the MISSION! protocol performed well in the care of AMI 
patients.14-16
As this was a single center, single region study conclusions may not pertain to larger 
regions. Furthermore, as data on prevalence of risk factors and medication use was derived 
in part from patient self-report, it should be considered with the necessary caution.
conclusIon
This study shows that a standardized regional AMI treatment protocol achieved optimal and 
uniformly distributed pre-hospital performance in the region Hollands-Midden, resulting in 
minimal time delays to treatment regardless of the area of residence. Furthermore hospital 
stay was short and in-hospital mortality low. Eighty-eight percent of patients had 1 or more 
modifiable risk-factors.
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AbsTrAcT
In order to compare long-term efficacy and safety of sirolimus-eluting stents (SES) to 
bare-metal stents (BMS) for ST-segment elevation myocardial infarction (STEMI), outcome 
was assessed in patients (n=310, age 59±11years, 78% male) included in the randomized 
MISSION!-intervention study after a median follow-up of 38 months. All patients were 
treated with aspirin (lifelong) and clopidogrel for 1 year after stent implantation. Except for 
a significant difference between reference vessel diameters (SES: 2.76mm vs. BMS: 2.92mm, 
p=0.02), there were no significant differences in baseline and angiographic characteristics 
between the treatment groups (158 SES, 152 BMS). A significant difference between SES 
and BMS patients for all revascularization endpoints was found after the first year of follow-
up. However, at 3 years of follow-up, although there was still a trend towards a better clinical 
outcome in SES treated patients, differences were no longer significant [death (4.4% vs. 
6.6%; p=0.41), target vessel related myocardial infarction (2.5% vs. 4.6%; p=0.32), target 
vessel revascularization (8.9% vs. 15.8%; p=0.06), target lesion revascularization (6.3% vs. 
12.5%; p=0.06) and target vessel failure (12.0% vs. 19.7%; p=0.06)]. Three cases of very 
late (definite) stent thrombosis were observed in the SES group (1.9%) versus 0 in the BMS 
group (p=0.14).
In conclusion, the significant SES benefit (compared to BMS) in STEMI patients at 1 
year follow-up in terms of target vessel revascularizations declined to some extent due to 
more similar target vessel revascularization rates during the 2 subsequent years. Rates of 
death and nonfatal recurrent MI remained comparable. (Current controlled trials number, 
ISRCTN628258620.)
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InTroducTIon
This randomized prospective study was designed to evaluate angiographic outcome and 
clinical efficacy of third-generation bare-metal stents (BMS) compared with that seen in 
sirolimus-eluting stents (SES) in ST-segment elevation myocardial infarction (STEMI) patients. 
Following the mid-term (12 months) angiographic and clinical results 1, the present study 
evaluated clinical outcome after 3 years of follow-up from the index event.
MeThods
study design
The MISSION! intervention study (Current Controlled Trials number, ISRCTN62825862 1) was 
a single-center, single-blind, randomized prospective study to evaluate clinical and 9-month 
angiographic results in STEMI patients treated with either BMS or SES. The study protocol 
was approved by the institutional ethical committee. Written informed consent was obtained 
from all patients before enrollment and before the follow-up catheterization. Patients and 
operators performing the follow-up were blinded to the treatment assignment. During the 
study period, all patients were treated according to the institutional STEMI protocol, which 
included standardized outpatient follow-up 2.
The study design, and methods have been described in detail previously 1. In brief, 
consecutive patients with de novo coronary lesions were eligible for participation if symp-
toms of STEMI started <9 hours before arrival at the catheterization laboratory and the 
ECG demonstrated a STEMI. Exclusion criteria were detailed previously,1 but in summary 
consisted of any “off-label” indication other than STEMI. Randomization to treatment with 
a BMS (Vision, Guidant Corp. Indianapolis, Indiana) or SES (Cypher, Cordis Corp., Miami 
Lakes, Florida) was performed in a 1:1 ratio.
Before the procedure all patients received 300 mg of aspirin, 300 to 600 mg of clopido-
grel, and an intravenous bolus of abciximab (25 µg/kg), followed by a continuous infusion 
of 10 µg/kg/min for 12 h. At start of the procedure, 5,000 IU of heparin was given. Lesions 
were treated according to current interventional practice.
follow-up and data collection
Both treatment groups received dual antiplatelet therapy for an equal treatment duration. 
Aspirin (100 mg/day) was prescribed indefinitely and clopidogrel (75 mg/day) for 12 months. 
Patients were seen at the outpatient clinic at 30 days, 3, 6, and 12 months according to the 
MISSION care program 2. During follow-up, patients were treated with beta-blocking agents, 
statins, and angiotensin-converting enzyme inhibitors or angiotensin II blockers. Follow-up 
angiography was performed at 9 months. Long-term follow-up data of each patient was 
C
ha
pt
er
 3
46
documented prospectively in an electronic patient file and data management system (EPD-
VISION 6.01) of the Leiden University Medical Center. Data was recorded after 3 years by 
patient visits at the out-patient clinic, or if not possible, by telephone inquiry. When a patient 
visit took place at another hospital, specific data inquiry was performed after written consent 
of the patient.
endpoint definition
Endpoints of the current study were death, myocardial infarction (MI), target vessel revas-
cularization, target lesion revascularization, target vessel failure and stent thrombosis. All 
deaths were defined as cardiac, unless it was unequivocally proven noncardiac. Myocardial 
infarction during follow-up was defined as a troponin-T rise >0.03 µg/l with symptoms 
or PCI, a rise of troponin-T >0.15 µg/l after coronary artery bypass grafting, or a rerise of 
troponin-T >25% after recent MI in the presence of symptoms or re-PCI, or the development 
of new Q waves on ECG 3;4. Infarctions were categorized as spontaneous or procedure 
related (non-index procedure)3, 4.
Target vessel and target lesion revascularization were defined as any revascularization 
procedure of the target vessel or target lesion, respectively. Target vessel failure was defined 
as the composite of cardiac death or recurrent nonfatal MI attributable to the target vessel 
or any revascularization procedure of the target vessel. If events could not unequivocally be 
attributed to a nonculprit vessel, they were considered culprit vessel related.
Stent thrombosis was defined as definite, probable and possible stent thrombosis (the 
composite of these being total stent thrombosis), further subdivided into acute (≤1day), 
subacute (>1day - ≤1month), late (>1month - ≤1year) and very late (>1year) stent throm-
bosis, according to the Academic Research Consortium definition 5. All clinical events were 
adjudicated by a clinical events committee whose members were blinded for the assigned 
stent type.
statistical Analysis
Since this study was planned as follow-up investigation of the MISSION! intervention study, 
sample size calculations were done for the original purpose only. Analyses were conducted 
according to the intention-to-treat principle. Continuous data are expressed as mean (±stan-
dard deviation) or as median (interquartile range (IQR) 25th/75th percentile); dichotomous 
data are presented as numbers and percentages. All continuous variables were compared 
between the treatment groups with a t test or, in the case of a non-Gaussian distribution, 
with a nonparametric test. Categorical variables were compared with Pearson’s chi-square 
test or Fisher exact test as appropriate. Event rates over time were analyzed by method of 
Kaplan-Meier with corresponding log-rank test for differences in distribution between the 
curves.
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Effect of a reference diameter ≥3mm on the risk of stent thrombosis was estimated by 
multivariate Cox regression analysis with treatment group as sole covariate. The rational 
to conduct analysis this way was as follows: Other potential (known and unknown) con-
founders have already been accounted for due to the randomized design of this study. 
Adding variables to the multivariate analysis after randomization may reduce comparability 
between the treatment groups. Therefore, only variables that were known to be different 
from baseline, such as stent type and (see also baseline characteristics table) reference vessel 
diameter were entered into the multivariate model. All p values were 2-sided, and a p 
value < 0.05 was considered statistically significant. All analyses were conducted with SPSS 
version 16.0 statistical analysis software (SPSS Inc., Chicago, Illinois).
resulTs
baseline characteristics
A total of 316 STEMI patients were enrolled in the study (Figure1). Six patients were sub-
sequently excluded because the assigned study stent was not available, and 310 patients 
(152 assigned to BMS and 158 assigned to SES) were included in the analysis 1. Baseline 
characteristics of the study population are reported in Table 1.
With exception of a slightly larger reference diameter in the BMS group, the groups were 
comparable. One patient crossed over from SES to BMS because of the inability to cross 
Screening N=575
Randomization N=316
Primary exclusion N=259 (45%)
•Clinical criteria N=108
•Angiographic criteria N=138
•Refusal to participate N=13
SES (Cypher) N=158 BMS (Vision) N=152
Study device not available N=6 (2%)
12 month follow-up N=158 12 month follow-up N=152
3 year follow-up:
•Clinical event data N=143 (91%)
•Survival data N=158 (100%)
Intention-to-treat analysis
3 year follow-up:
•Clinical event data N=141 (93%)
•Survival data N=152 (100%)
figure 1. Patient Flow Chart, Enrollment and Follow-up.
BMS = bare-metal stent; SES = sirolimus-eluting stent.
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the lesion with the SES. No patients were lost for follow-up and all patients were contacted 
(Figure 1). Complete clinical data were available for 91% of the patients assigned to the SES 
group and for 93% of the patients assigned to the BMS group.
Table 1. Clinical and angiographic characteristics
Characteristics SES (n = 158) BMS (n = 152) p value
Age (mean years ± SD) 59.2 ± 11.2 59.1 ± 11.6 0.99
Men 118 (74.7%) 123 (80.9%) 0.19
Diabetes mellitus 20 (12.7%) 10 (6.6%) 0.07
Current smoker 84 (53.2%) 85 (55.9%) 0.63
Hypercholesterolemia† 37 (23.4%) 25 (16.4%) 0.13
Hypertension‡ 48 (30.4%) 39 (25.7%) 0.36
Family history of coronary artery disease 73 (46.2%) 60 (39.5%) 0.23
Prior myocardial infarction 7 (4.4%) 5 (3.3%) 0.60
Prior percutaneous coronary intervention 4 (2.5%) 1 (0.7%) 0.37
Prior coronary artery bypass grafting 1 (0.6%) 1 (0.7%) 1.00
Symptoms onset to first electrocardiogram (median min 
[interquartile range])
88 (47–153) 106 (71–151) 0.11
Symptoms onset to balloon inflation (median min [interquartile 
range])
183 (133–258) 195 (153–257) 0.19
Target coronary artery
 Left 87 (55.1%) 83 (54.6%)
 Right 40 (25.3%) 51 (33.6%) 0.09
 Left circumflex 31 (19.6%) 18 (11.8%)
Multivessel disease 56 (35.4%) 50 (32.9%) 0.64
TIMI flow grade before
 0 96 (60.8%) 90 (59.2%)
 1 18 (11.4%) 15 (9.9%) 0.87
 2 20 (12.6%) 24 (15.8%)
 3 24 (15.2%) 23 (15.1%)
Maximal creatinine phosphokinase (U/l)
 Median 1,844 2,079 0.25
 Interquartile range 863–3,413 1,012–3,792
Quantitative coronary angiography pre-procedure
 Lesion length (mean mm ± SD) 13.9 ± 5.6 15.0 ± 8.6 0.47
 Reference diameter (mean mm ± SD) 2.76 ± 0.54 2.92 ± 0.56 0.02*
 Minimal luminal diameter (mean mm ± SD) 0.21 ± 0.35 0.27 ± 0.41 0.19
 Stenosis (mean % of luminal diameter ± SD) 91.0 ± 13.6 92.5 ± 12.4 0.35
*p <0.05
† Total cholesterol ≥190 mg/dl or previous pharmacological treatment.
‡ Blood pressure ≥140/90 mm Hg or previous pharmacological treatment.
Three-year outcome of sirolimus-eluting versus bare-metal stents 49
long-term follow-up
Clopidogrel was used up to 12 months by 93% (147/158; with 156 patients alive at follow-up) 
of patients in the SES group and by 96% (146/152; 148 patients alive at follow-up) of patients 
in the BMS group (p = 0.24). Aspirin treatment was continued by all patients during the entire 
follow-up of 3 years except when oral anticoagulation was indicated (n=39). Twenty-one 
patients (11 BMS, 10 SES) used clopidogrel >1 year. Reasons for prolongation of clopidogrel 
treatment were in most cases (n=17) the occurrence of an in-stent restenosis or stent thrombo-
sis, and in 4 cases because of patient/doctor miscommunication. All patients who experienced 
target lesion revascularization and/or stent thrombosis <1year post-MI used clopidogrel at the 
time the first event took place. This was true for patients of both treatment groups.
deaths
Clinical outcome data at long-term follow-up are reported in Table 2. As compared to the 
previously reported mid-term results 1, 11 additional deaths occurred of which 5 in the SES 
group and 6 in the BMS group (p=NS). About half of these additional deaths were noncar-
diac (6/11, 55%, all cancer related). A Kaplan-Meier estimates of the cumulative incidence 
of all-cause death for the SES and BMS group is shown in Figure 2. Both treatment groups 
demonstrate a similar probability of all-cause death over the years (log-rank test p=0.41).
Myocardial infarction
Table 2 furthermore shows that most of the (6/7) additional recurrent spontaneous myocardial 
infarctions after the first year were target vessel related. There was no significant difference 
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in the number of patients with spontaneous target vessel related myocardial infarction at 
three year follow-up (p=0.32). No additional procedure related myocardial infarctions were 
observed in the second and third year of follow-up. The Kaplan-Meier and landmark inci-
dence estimates of the cumulative incidence of the combined endpoint target vessel related 
death/nonfatal MI demonstrates that the distribution of this combined endpoint over time 
was similar in both SES and BMS groups from beginning to end of follow-up (first year: 
log-rank test p=0.28; three years: log-rank test p=0.19) (Figure 3).
Table 2. Clinical outcome at 12 months and at 3-year follow-up.
Event 12-month outcomes 3-year outcomes
SES
(n = 158)
BMS
(n = 152)
p value
SES
(n = 158)
BMS
(n = 152)
p-value
Death 2 (1.3%) 4 (2.6%) 0.44 7 (4.4%) 10 (6.6%) 0.41
 Noncardiac — 2 (1.3%) 0.24 3 (1.9%) 5 (3.3%) 0.68
 Cardiac 2 (1.3%) 2 (1.3%) 1.00 4 (2.5%) 5 (3.3%) 0.95
Recurrent myocardial infarction† 9 (5.7%) 14 (9.2%) 0.24 12 (7.6%) 17 (11.2%) 0.28
 Spontaneous 2 (1.3%) 3 (2.0%) 0.68 5 (3.2%) 7 (4.6%) 0.51
 Target vessel related 2 (1.3%) 3 (2.0%) 0.68 4 (2.5%) 7 (4.6%) 0.32
 Procedure related 7 (4.4%) 11 (7.2%) 0.29 7 (4.4%) 11 (7.2%) 0.29
 Target vessel related 2 (1.3%) 6 (3.9%) 0.17 2 (1.3%) 6 (3.9%) 0.17
Revascularization procedure† 19 (12.0%) 35 (23.0%) 0.01* 28 (17.7%) 39 (25.7%) 0.09
 PCI 17 (10.8%) 30 (19.7%) 0.03* 26 (16.5%) 33 (21.7%) 0.24
 CABG 2 (1.3%) 5 (3.3%) 0.28 3 (1.9%) 8 (5.3%) 0.11
Target vessel revascularization† 8 (5.1%) 20 (13.2%) 0.01* 14 (8.9%) 24 (15.8%) 0.06
 PCI 6 (3.8%) 17 (11.2%) 0.01* 11 (7.0%) 20 (13.2%) 0.07
 CABG 2 (1.3%) 3 (2.0%) 0.68 3 (1.9%) 6 (3.9%) 0.46
Target lesion revascularization† 5 (3.2%) 17 (11.2%) 0.006* 10 (6.3%) 19 (12.5%) 0.06
 PCI 3 (1.9%) 14 (9.2%) 0.005* 7 (4.4%) 15 (9.9%) 0.06
 CABG 2 (1.3%) 3 (2.0%) 0.68 3 (1.9%) 6 (3.9%) 0.46
 Clinically driven 4 (2.5%) 12 (7.9%) 0.03* 9 (5.7%) 14 (9.2%) 0.28
Target vessel failure 11 (7.0%) 23 (15.1%) 0.02* 19 (12.0%) 30 (19.7%) 0.06
Stent thrombosis
 Definite 1 (0.6%) 1 (0.7%) 1.00 4 (2.5%) 1 (0.7%) 0.39
 Probable 1 (0.6%) 2 (1.3%) 0.97 1 (0.6%) 2 (1.3%) 0.97
 Possible — — — 1 (0.6%) 1 (0.7%) 1.00
*p <0.05. † The first event per patient was counted.
CABG = Coronary artery bypass grafting; PCI = percutaneous coronary intervention.
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revascularization
An additional 13 patients underwent revascularization procedures after the first year of fol-
low-up (Table 2). Most were target vessel related (10/13, 77%) and approximately half were 
target lesion related (7/13, 54%). Though a significant difference was observed between SES 
and BMS groups for the number of patients undergoing a revascularization procedure (target 
vessel or target lesion related) during the first year of follow-up, this difference was no longer 
statistically significant after three year follow-up. This was due to the fact that relatively more 
SES patients underwent a revascularization procedure during the next 2 years of follow-up 
reducing the magnitude of the benefit of SES over BMS: an additional 9 patients in the SES 
group and another 4 patients in the BMS group. The same trend was observed for target 
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figure 3. Kaplan-Meier (panel A) and landmark incidence (panel B) estimates for the combined 
endpoint target vessel related nonfatal MI or death.
MI = myocardial infarction. Other abbreviations as in figure 1.
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vessel related revascularizations and for target lesion related procedures. Figure 4 shows the 
cumulative incidence of target lesion revascularization procedure over the complete follow-
up period (panel A) and for each year separately (panel B). The cumulative incidence of 
patients undergoing target lesion revascularization was significantly lower in the SES group 
during the first year of follow-up compared to the BMS group (log-rank test p=0.006). A 
more similar cumulative incidence was observed during the next years of follow-up (3 years: 
log-rank test p=0.05).
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figure 4. Kaplan-Meier (panel A) and landmark incidence estimates (panel B) for target lesion 
revascularization.
Abbreviations as in figure 1.
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Target vessel failure
Table 2 shows that the combined endpoint target vessel failure (death/MI-/revascularization 
related to target vessel) occurred overall less frequently in the SES group than in the BMS 
group, particularly due to the difference in events occurring during the first year (first year: 
7.0% vs. 15.1% of patients respectively, p=0.02; three year total: 12.0% vs. 19.7%, p= 
0.06). Correspondingly, figure 5 demonstrates that a statistically significant difference in the 
cumulative incidence of target vessel failure between SES and BMS patients was observed 
only in the first year after the index procedure (first year: log-rank test p=0.02; three years: 
log-rank test p=0.06).
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figure 5. Kaplan-Meier (panel A) and landmark incidence (panel B) estimates for the combined 
endpoint target vessel failure.
Abbreviations as in figure 1.
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stent thrombosis
In table 2 the number of patients experiencing definite, probable or possible stent thrombosis 
is reported for SES and BMS groups 5. Three cases of very late (definite) stent thrombosis were 
seen in the SES group (1.9%) versus none in the BMS group (p=NS). Figure 6 demonstrates 
the cumulative incidence of total stent thromboses (total of definite, probable and pos-
sible) for both stent type groups during 3 years of follow-up. Comparison of the cumulative 
incidence of stent thrombosis for the entire follow-up period, showed that the event rate 
was similar in the SES and BMS groups (Figure 6, log-rank test p=0.56).
Despite the low incidence of stent thrombosis, results of the multivariate analysis suggest 
that a reference diameter of ≥3mm was related to an increased hazard of definite stent 
thrombosis in the overall patient population (adjusted: HR 10.2, 95%CI 1.1-92.5; p=0.039), 
independent of stent type.
dIscussIon
Key findings of this randomized study were: (1) Clinical outcome at three year follow-up was 
comparable for STEMI patients treated with either SES or BMS, and (2) the overall benefit of 
SES offered over BMS reflected mostly the advantage achieved during one year of follow-up. 
Although the total number of events was relatively lower in the SES treated group compared 
to the BMS treated group, the statistical advantage in terms of target vessel revascularizations 
gradually declined during three year follow-up due to more similar event rates after one year.
Zie meeg stuurde pdf. 
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figure 6. Kaplan-Meier estimates of the cumulative incidence of stent thrombosis.
Abbreviations as in figure 1.
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drug-eluting vs. bare-metal stents in sTeMI patients
Though primary PCI has been shown to be superior to medical therapy alone in patients 
presenting for acute myocardial infarction, particularly for STEMI patients6-8, data regarding 
efficacy and safety of DES use in these patients is still relatively scarce. Randomized studies 
investigating DES use for off-label indications often excluded patients with acute myocardial 
infarction9;10. In addition, observational studies investigating DES use in patients with acute 
myocardial infarction had varying and sometimes conflicting results, or were unable to cor-
rect for dissimilar duration of dual antiplatelet therapy11-14. Most randomized studies thus 
far including this study reported DES (including SES) to be superior to BMS at 12 months 
follow-up when comparing DES with BMS treatment for primary PCI in STEMI patients1;15-21. 
In these studies DES mainly reduced the need for repeat revascularization procedures, but did 
not significantly reduce 12 month rates of death or myocardial infarction.
drug-eluting vs. bare-metal stents: short vs. long-term
Recent results of the current randomized trial suggest that the maximum benefit of SES 
over BMS, in terms of repeat revascularizations, is reached within the first year after index-
intervention. This is supported by data from investigators of large registry studies such as 
the study from Mauri et al 14 who reported that drug-eluting stents were associated with 
reduced rates of death and repeat revascularization at 2-years follow-up as compared to 
bare-metal stents. The significant difference of event rates consisted chiefly of the markedly 
reduced cumulative event rates of DES in the first year of follow-up, after which event rates 
were comparable between DES and BMS. Other studies reached the same conclusion22-24.
Similarly, at an update of the Trial to Assess the Use of the Cypher Stent in Acute Myo-
cardial Infarction Treated with Balloon Angioplasty (TYPHOON) presented at EuroPCR 2009, 
investigators reported that at 4 years, SES were able to maintain their initial advantage 
in terms of revascularization rates over BMS. Though it is perhaps questionable whether 
the trial’s follow-up was complete enough to draw definitive conclusions (only 70% of 
original cohort), again the same time-dependent trend was observed as demonstrated by 
equal increases in the rate of target vessel revascularizations in SES and BMS groups (4% 
each) after the first year of follow-up 18. Moreover, the recently published short- and long-
term data of the Paclitaxel- or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary 
Angioplasty (PASEO) Trial further confirms this pattern 21.
Results of the present study were also remarkably similar to the 3-year outcome of a 
large observational study by Applegate et al, who investigated DES versus BMS for “off-
label” indications (not restricted to patients with myocardial infarction) in 1246 DES treated 
patients and 1147 BMS treated patients 22. DES benefit seemed to occur entirely within the 
first year, with similar rates of target vessel revascularization, death and nonfatal MI in the 
second and third years. Abovementioned examples including results of the current study 
confirm a consistent pattern of time-dependent benefit of DES over BMS that decreases 
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in magnitude after the first year. Newer stents with better long term performance have 
not been tested in this study, but may potentially have a significantly better long-term 
performance.
limitations
The clinical results of this study cannot be seamlessly translated into general daily clinical 
practice, as this was a single-center study in a selected group of patients and patients were 
followed in a strict-guideline based out-patient protocol2, which is not common practice 
yet. Event rates in daily clinical practice can be expected to be in general higher than in this 
study. Furthermore, the follow-up study was not designed to detect small differences in the 
incidence of stent thrombosis between the groups. It is possible that with a larger sample 
size, the borderline non-significant differences of target vessel related events between SES 
and BMS groups may still have been significant after 3 years. A trend toward a “catch 
up phenomenon” is visible, but the results should be interpreted with caution. It deserves 
mentioning that the power calculation for sample size of the main MISSION! intervention 
study1 was based on angiographic late luminal loss which was not an endpoint in this 3-year 
follow-up study. In addition, complete clinical follow-up was not available for all patients. 
However, it is highly unlikely that patients lost to follow-up experienced a serious clinical 
event such as revascularization or MI, as this would probably have led to admission at the 
PCI center and therefore would not have gone unnoticed. Finally, the original study design 
dictated angiographic follow-up at 9-months which was discussed in a previous publication1. 
We cannot exclude that the routine angiographic follow-up did result in additional revas-
cularization procedures, perhaps magnifying differences between BMS and SES in the first 
year of follow-up. It did however not influence the long-term event rates. Furthermore, the 
1-year MISSION treatment program included regular visits and ischemia detection by stress/
rest myocardial perfusion scanning at 3 months after STEMI, which facilitated in treatment 
decision-making.
conclusIon
The significant SES benefit (compared to BMS) in STEMI patients at 1 year follow-up in terms 
of target vessel revascularizations declined to some extent due to more similar target vessel 
revascularization rates during the 2 subsequent years. Rates of death and nonfatal recurrent 
MI remained comparable.
Three-year outcome of sirolimus-eluting versus bare-metal stents 57
references
 1. van der Hoeven BL, Liem SS, Jukema JW et al. Sirolimus-eluting stents versus bare-metal stents 
in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravas-
cular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention 
Study. J Am Coll Cardiol 2008; 51: 618-626.
 2. Liem SS, van der Hoeven BL, Oemrawsingh PV et al. MISSION!: optimization of acute and chronic 
care for patients with acute myocardial infarction. Am Heart J 2007; 153: 14-11.
 3. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus docu-
ment of The Joint European Society of Cardiology/American College of Cardiology Committee for 
the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-969.
 4. Apple FS, Wu AH, Jaffe AS. European Society of Cardiology and American College of Cardiology 
guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for 
clinical trials. Am Heart J 2002; 144: 981-986.
 5. Cutlip DE, Windecker S, Mehran R et al. Clinical end points in coronary stent trials: a case for 
standardized definitions. Circulation 2007; 115: 2344-2351.
 6. Bavry AA, Kumbhani DJ, Quiroz R, Ramchandani SR, Kenchaiah S, Antman EM. Invasive therapy 
along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-
segment elevation acute coronary syndromes: a meta-analysis and review of the literature. Am J 
Cardiol 2004; 93: 830-835.
 7. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy 
for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 
13-20.
 8. Mehta SR, Cannon CP, Fox KA et al. Routine vs selective invasive strategies in patients with 
acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005; 293: 
2908-2917.
 9. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients 
with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
 10. Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with 
coronary artery disease. N Engl J Med 2004; 350: 221-231.
 11. Lemos PA, Saia F, Hofma SH et al. Short- and long-term clinical benefit of sirolimus-eluting stents 
compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll 
Cardiol 2004; 43: 704-708.
 12. Slottow TL, Steinberg DH, Roy P et al. Drug-eluting stents are associated with similar cardiovascu-
lar outcomes when compared to bare metal stents in the setting of acute myocardial infarction. 
Cardiovasc Revasc Med 2008; 9: 24-28.
 13. Steg PG, Fox KA, Eagle KA et al. Mortality following placement of drug-eluting and bare-metal 
stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coro-
nary Events. Eur Heart J 2009; 30: 321-329.
 14. Mauri L, Silbaugh TS, Garg P et al. Drug-eluting or bare-metal stents for acute myocardial infarc-
tion. N Engl J Med 2008; 359: 1330-1342.
 15. Stone GW, Lansky AJ, Pocock SJ et al. Paclitaxel-eluting stents versus bare-metal stents in acute 
myocardial infarction. N Engl J Med 2009; 360: 1946-1959.
 16. Laarman GJ, Suttorp MJ, Dirksen MT et al. Paclitaxel-eluting versus uncoated stents in primary 
percutaneous coronary intervention. N Engl J Med 2006; 355: 1105-1113.
C
ha
pt
er
 3
58
 17. Menichelli M, Parma A, Pucci E et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-
Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 2007; 49: 1924-1930.
 18. Spaulding C, Henry P, Teiger E et al. Sirolimus-eluting versus uncoated stents in acute myocardial 
infarction. N Engl J Med 2006; 355: 1093-1104.
 19. Kastrati A, Dibra A, Spaulding C et al. Meta-analysis of randomized trials on drug-eluting stents 
vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007; 28: 2706-
2713.
 20. Valgimigli M, Percoco G, Malagutti P et al. Tirofiban and sirolimus-eluting stent vs abciximab and 
bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005; 293: 2109-2117.
 21. Di LE, Sauro R, Varricchio A et al. Long-Term Outcome of Drug-Eluting Stents Compared With 
Bare Metal Stents in ST-Segment Elevation Myocardial Infarction. Results of the Paclitaxel- or 
Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty (PASEO) Randomized Trial. 
Circulation 2009.
 22. Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Little WC. 3-year comparison of 
drug-eluting versus bare-metal stents. JACC Cardiovasc Interv 2009; 2: 231-239.
 23. Pfisterer M, Brunner-La Rocca HP, Rickenbacher P et al. Long-term benefit-risk balance of drug-
eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up 
of BASKET. Eur Heart J 2009; 30: 16-24.
 24. Daemen J, Tanimoto S, Garcia-Garcia HM et al. Comparison of three-year clinical outcome of 
sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment eleva-
tion myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol 2007; 99: 
1027-1032.
Chapter 4
Impact of sirolimus-eluting stent implantation 
compared to bare-metal stent implantation 
for acute myocardial infarction on coronary 
plaque composition at 9 months follow-up: 
A virtual histology intravascular ultrasound 
analysis. Results from the Leiden MISSION! 
intervention study.
Jael Z. Atary1, Sandrin C. Bergheanu1, Bas L. van der Hoeven1, Douwe E. Atsma1, 
Marianne Bootsma1, Frank van der Kley1, Katja Zeppenfeld1, J. Wouter Jukema1,2, 
Martin J. Schalij1
1Department of cardiology, Leiden University Medical Center, Leiden, the Netherlands.
2Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, 
the Netherlands.
EuroIntervention. 2009 Nov;5(5):565-72.

Impact of sirolimus-eluting stent implantation compared to bare-metal stent implantation 61
AbbrevIATIons
AMI Acute myocardial infarction
BMS Bare-metal stent
CRP C-reactive protein
CSA Cross-sectional area
EEM External elastic membrane
IVUS Intravascular ultrasound
Mean LD Mean lumen diameter
MLD Minimum lumen diameter
PTCA Percutaneous transluminal coronary angioplasty
QCA Quantitative Coronary Angiography
SES Sirolimus-eluting stent
STEMI ST-segment elevation myocardial infarction
VH-IVUS Virtual histology intravascular ultrasound
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AbsTrAcT
Aims
To evaluate effects of sirolimus-eluting stents (SES) compared to bare-metal stents (BMS) at 
stent edges in patients with acute myocardial infarction (AMI).
Methods and results
Clinical, angiographic, intravascular ultrasound (lVUS) and virtual histology (VH)-IVUS results 
were obtained and analyzed in 20 SES and 20 BMS AMI patients at the index procedure 
and at 9 months follow-up. Quantitative angiography and IVUS showed a trend toward 
decreases in mean lumen diameter, vessel volume, minimum lumen area and mean lumen 
area at both stent edges of BMS, and at the proximal edge of SES. At the distal stent edge, a 
significant difference between BMS and SES treated patients in mean lumen area was found 
(Δ-0.8 ± 1.6mm2 versus Δ0.2 ± 0.8mm2 respectively, p =0.04). Furthermore, in-stent SES had 
a larger lumen volume (SES: 167.7 ± 59.2mm3 versus BMS: 125.1± 43.8mm3; p =0.02) and 
less neointima volume (7.3 ± 9.1mm3 versus 53.2 ± 35.1mm3; p <0.001). Neither SES nor 
BMS demonstrated a significant effect on plaque composition at follow-up VH-IVUS analysis.
conclusion
A significant difference between SES and BMS treated patients was observed with respect 
to mean lumen diameter distal to the stented segment which suggests a downstream effect 
of sirolimus elution.
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InTroducTIon
The treatment of patients with acute myocardial infarction (AMI) changed significantly over 
the last decades. Early pharmacological and more recently mechanical reperfusion strate-
gies improved the prognosis of AMI patients further supported by optimal medical treat-
ment (including antiplatelet therapy, ACE inhibitors, betablockers and statins) and life style 
changes in the chronic phase after the acute event. Procedural outcome also improved due 
to improved operator experience, continuous refinement of catheter and balloon technology, 
and the introduction of intracoronary stents. More recently drug eluting stents (DES) have 
been introduced. Although the efficacy of DES is proven in patients with stable coronary 
artery disease the role of DES in AMI patients is still under debate.1-4 Despite the positive 
effects of DES on restenosis, the increased risk of subacute thrombosis tempered the initial 
enthusiasm as subacute stent thrombosis is a devastating event associated with high mortal-
ity rates and myocardial infarction.5-9 In AMI patients the initial event is caused by disruption 
or erosion of a vulnerable plaque10-12 leading to acute thrombosis. The increased risk of 
stent thrombosis associated with DES is caused by incomplete/delayed neointimal coverage 
and may be prevented to some extent in most patients with stable coronary artery disease 
by prolonged dual antiplatelet therapy. Although after implantation of a stent the ruptured 
plaque will be covered it is unclear what happens proximal and distal to the stent segments. 
Some studies suggest that the eluted drug in case of a DES may not only have an effect on 
the stented segment but also on adjacent segments.13-15 It is therefore of interest to study 
these segments during the initial procedure and during follow-up. In this study we evaluated 
the effects of DES compared to bare-metal stents (BMS) on the proximal and distal segments 
using Intravascular Ultrasound imaging (IVUS) in AMI patients at baseline and at 9 months 
follow-up. Although IVUS allows cross-sectional imaging of coronary arteries and provides 
a comprehensive assessment of the atherosclerotic plaque, it cannot provide detailed data 
about its tissue components. Detecting changes in tissue components may increase our com-
prehension of in vivo development of potentially vulnerable plaque. Therefore, additionally 
Virtual histology (VH-) IVUS using spectral analysis of the radiofrequency ultrasound back-
scatter signals to analyze plaque composition and morphology was used. VH-IVUS allows 
identification of four different components of atherosclerotic plaques: fibrous, fibro-fatty, 
dense calcium, and necrotic core.16
MeThods
study design and population
Patients for this substudy were selected from the randomized MISSION! intervention study 
(Current Controlled Trials number, ISRCTN62825862,4). The original MISSION! study was 
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designed to compare the outcome of the sirolimus coated Cypher stent (Cypher Select™, 
Cordis Corp., Miami Lakes, Florida) with the bare-metal Vision stent (Multilink Vision™, 
Guidant Corp., Indianapolis, Indiana) in patients with AMI.4 The study was approved by the 
institutional ethical committee. Written informed consent was obtained from all patients 
before enrollment and before the follow-up catheterization at 9 months. The study protocol, 
inclusion and exclusion criteria, endpoint definition and main outcomes of the study were 
published previously.4
For this substudy, a group of consecutive patients were included for whom not only 
clinical, angiographic and IVUS data were performed, but for which also Virtual Histology 
analysis was performed from both the index procedure and the 9 months follow-up study. 
Throughout the study period all patients were treated according to the institutional STEMI 
protocol which included standardized out-patient follow-up.17 In brief, all patients had 
symptoms of STEMI that started <9 hours before arrival at the catheterization laboratory 
and an ECG that demonstrated a STEMI (ST segment elevation ≥0.2mV in ≥2 contiguous 
precordial leads [V1-V4], or ≥ 0.1mV ST elevation in other leads, or a new left bundle branch 
block).
Key exclusion criteria were age <18 years or >80 years; the presence of a left main lesion 
of ≥50% stenosis; triple vessel disease, defined as ≥50% stenosis in three major epicardial 
vessels; previous percutaneous coronary intervention or bypass grafting of the culprit vessel; 
failed thrombolytic therapy for the index infarction; reference diameter of the culprit lesion 
of less than 2.25mm or larger than 3.75mm; and lesion length ≥24mm.
Procedure protocol
Before the index procedure all patients received 300mg of aspirin, 300-600mg of clopido-
grel, and an intravenous bolus of abciximab (25µg /kg), followed by a continuous infusion of 
100µg/kg for 12 hours. At the start of the procedure 5000IU of heparin was administered. 
Coronary lesions were treated according to current interventional practice. If more than one 
stent was required, the additional stent was of the same assigned study type.
After intervention IVUS imaging was performed to document angiographic result. Each 
angiogram and ultrasound sequence was preceded by 200-300µg of intracoronary nitro-
glycerin.
After the procedure aspirin (100mg/day) was prescribed indefinitely and clopidogrel 
(75mg/day) for 12 months. During follow-up, patients were treated with beta-blockers, 
statins and ACE-inhibitors or ATII-blockers, according to current guidelines.17 Patients were 
seen at the out-patient clinic at 30 days, 3, 6, and 12 months. Follow-up angiography and 
(VH-) IVUS image acquisition was performed at 9 months follow-up.
Impact of sirolimus-eluting stent implantation compared to bare-metal stent implantation 65
Quantitative coronary angiography (QcA)
Coronary angiograms obtained at baseline and at 9 months follow-up were digitally recorded 
and analyzed blinded to the assigned treatment.
The analysis was performed using automated edge-detection software (CMS version 6.0, 
Medis Medical Imaging Systems, Leiden, The Netherlands) at a single projection showing 
the most severe stenosis. The same projection was used at follow-up. The proximal and 
distal edges were evaluated up to 5mm from the stent.
Ivus analysis
IVUS imaging was performed with motorized pull-back (0.5mm/s) starting at least 10mm 
distal to the stent, ending at the coronary ostium. A 2.9F 20MHz catheter and a dedicated 
IVUS console (Eagle Eye, Volcano Corp. Rancho Cordova, California, USA) were used.18 
Before imaging, 200-300µg of intracoronary nitroglycerin were administered. Analysis 
was performed by analysts that were blinded to the assigned treatment using customized 
software (QCU-CMS 4.14, Medis, Leiden, The Netherlands) for analysis of the quantitative 
grayscale data.
External elastic membrane (EEM) cross sectional area (CSA) and lumen CSA of segments 
5mm proximal and distal to the stent were determined per frame and vessel volume, mean 
lumen area and minimal lumen area for these segments were compared to the same param-
eters at follow-up.
virtual histology analysis
VH images were generated simultaneously during motorized pull-back (figure 1). Images 
were acquired at every R-peak during continuous ECG registration. Data were stored digitally 
on CD for off-line analysis. Atherosclerotic coronary lesions were characterized by classifica-
tion trees based on mathematical autoregressive spectral analysis of IVUS backscattered data 
(pcVH software version 2.2, Volcano Therapeutics). Fibrous areas were marked in green, 
fibro-fatty in yellow, dense calcium in white and necrotic core in red on the reconstructed 
color-coded tissue map. The area and volumes of each plaque component were calculated 
automatically by the pcVH software. PcVH analysis software is commercially available image 
analysis software developed by Vocano Therapeutics and the technique has been validated 
in past histopathological validation studies of VH-IVUS.19;20
Measurements were made for the region of interest, which was defined as the segment 
of minimal 5mm to maximal 10mm distal and proximal to the stented segment. This range 
was chosen instead of the conventional 5mm distance because: 1) it was unclear, assuming 
that there would be a downstream effect of the drug on plaque composition, how far the 
effect would reach and 2) as it was expected that these effects were likely to be small, it 
was considered preferable to include as much potentially affected longitudinal distance as 
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possible. Catheterization images of the index procedure and of 9 months follow-up were 
analyzed side-by-side to ensure that the same segments were studied.
Although the volumetric analysis of the software could not be adjusted for repeated 
frames (implicating that the volume analysis of the same segment at different points of 
time could slightly differ) this problem was solved by using relative plaque volumes for final 
analysis (percentage of total plaque). Repeated frames were caused by the catheter getting 
stuck during pullback. In the 40 cases presented in this study only a small number of such 
frames were observed. Nevertheless, to minimize their influence on results for absolute 
plaque areas, repeated frames were ignored during this analysis.
statistical analysis
Continuous data are reported throughout this text and in the tables as mean ± standard 
deviation. Evenly distributed continuous data were analyzed by utilizing the independent 
sample t-test. Unevenly distributed continuous data were analyzed using an equivalent 
non-parametric test and the Mann-Whitney U test. For comparison to follow-up, analysis 
of continuous data at different points in time was performed by the paired Student’s t-test. 
Categorical data are summarized as proportions and were compared with Pearson’s χ2 -test 
or Fisher exact test in case of one or more cells in the contingency table with expectation 
less than 5, as appropriate. All tests weretwo-sided, a p-value of <0.05 was considered 
significant.
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figure 1. Illustration of creating an image with virtual histology intravascular ultrasound.
IVUS = intravascular ultrasound; VH-IVUS = virtual histology intravascular ultrasound.
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resulTs
Forty patients who received a SES (n=20) or BMS (n=20) during a primary PTCA were included 
in this substudy. There were no significant differences in baseline patient characteristics 
between the two patient groups (Table 1).
Table 1. Baseline characteristics.
BMS (n=20) DES (n=20) p-value
Male 18 (90) 13 (65) 0.130
Mean age 62 (41-79) 59 (29-75) 0.418
Cardiovascular risk factors:
 Hypertension 5 (25) 7 (35) 0.731
 Hyperlipidemia 5 (25) 4 (20) 1.000
 Smoking 12 (60) 15 (75) 0.501
 Diabetes Mellitus 1 (5) 5 (25) 0.184
 Prior MI 3 (15) 1 (5) 0.598
 Family History of CAD 8 (40) 13 (65) 0.205
Medication at discharge:
 Aspirin 20 (100) 20 (100) 1.000
 Statin 20 (100) 20 (100) 1.000
 β-Blocker 20 (100) 20 (100) 1.000
 Clopidogrel 20 (100) 20 (100) 1.000
 ACE/AT2-inhibitor 19 (95) 20 (100) 1.000
 Anticoagulant 0 0
Medication at 12 months:
 Aspirin 20 (100) 17 (85) 0.230
 Statin 20 (100) 20 (100) 1.000
 β-Blocker 19 (95) 19 (95) 1.000
 Clopidogrel 20 (100) 17 (85) 0.230
 ACE/AT2-inhibitor 19 (95) 19 (95) 1.000
 Anticoagulant 0 3 (15) 0.230
Target vessel:
 LAD 9 (45) 11 (55) 0.752
 RCA 8 (40) 2 (10) 0.065
 LCX 3 (15) 7 (35) 0.273
No. of vessels diseased:
 1 9 (45) 8 (40) 1.000
 2 9 (45) 10 (50) 1.000
 3 2 (10) 2 (10) 1.000
Values are expressed as number (%) or as age (min-max).
BMS = bare-metal stent; CAD = coronary artery disease; MI = myocardial infarction; LAD = left anterior
descending artery; RCA = right coronary artery; LCX = left circumflex artery; SES = sirolimus-eluting stent.
Hyperlipidemia= Total cholesterol ≥190 mg/dl or previous pharmacological treatment.
Hypertension = Blood pressure ≥140/90 mm Hg or previous pharmacological treatment.
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Angiographic results
Index-procedure and follow-up QCA-results for minimum lumen area and mean lumen 
diameters are reported in table 2. In BMS patients both minimum and mean lumen diameter 
decreased at both sides of the stent at follow-up though this did not reach statistical signifi-
cance at the distal stent edges (MLD proximal edge: from 2.76 ± 0.42mm to 2.62 ± 0.46mm; 
p =0.03 and Mean LD proximal edge: from 3.05 ± 0.48mm to 2.94 ± 0.46mm; p =0.03, 
MLD distal edge: from 2.43 ± 0.48mm to 2.21 ± 0.67mm; p =0.10 and Mean LD from 2.65 
± 0.55mm to 2.48 ± 0.69mm; p =0.19).
In SES patients a similar (although non-significant) decline in lumen area was observed 
at the proximal stent edge, the distal MLD and Mean LD however tended to increase (MLD) 
or remained unchanged (Mean LD) during follow-up (MLD proximal edge: from 2.74 ± 
0.37mm to 2.68 ± 0.46mm; p =0.40 and Mean LD from 3.04 ± 0.57mm to 2.94 ± 0.57mm; 
p =0.09, MLD distal edge: from 2.38 ± 0.39mm to 2.44 ± 0.53mm; p =0.41 and Mean LD 
from 2.61 ± 0.37mm to 2.61 ± 0.5 mm; p =0.97).
Ivus grayscale results
Quantitative post procedural and follow-up IVUS data are summarized in tables 3 and 4. 
At the proximal stent edge, vessel volume and lumen areas decreased in both BMS and SES 
patients at 9 months follow-up (BMS: -3.6% and -0.5% and SES: -7.2% and -8.2%). The 
mean lumen area decreases significantly in the SES group at the proximal stent edges (p 
=0.03).
At follow-up, vessel volume and mean lumen area of the distal stent edge of the BMS 
group tended to decline (overall decrease of -5.0% and -6.3% respectively, p=ns), while 
they increased in the SES group (vessel volume increase of 1.5% and mean lumen area 
increase of 3.4%, p=ns). There were no significant differences between BMS and SES 
groups in vessel volume and mean lumen area changes except for mean lumen area at the 
distal stent edge (Δ-0.8 ± 1.6mm2 versus Δ0.2 ± 0.8mm2 respectively, p =0.04; table 4). 
Within the stented segment however, the SES group demonstrated a significantly larger 
Table 2. Results of Quantitative Coronary Angiography at baseline and at follow-up.
BMS SES
Baseline Follow-up p-value Baseline Follow-up p- value
Proximal stent edge:
 Minimal lumen diameter (mm) 2.8 ± 0.4 2.6 ± 0.5 0.03* 2.7 ± 0.4 2.7 ± 0.5 0.40
 Mean lumen diameter (mm) 3.1 ± 0.5 2.9 ± 0.5 0.03* 3.0 ± 0.6 2.9 ± 0.6 0.09
Distal stent edge:
 Minimal lumen diameter (mm) 2.4 ± 0.5 2.2 ± 0.7 0.10 2.4 ± 0.4 2.4 ± 0.5 0.41
 Mean lumen diameter (mm) 2.7 ± 0.6 2.5 ± 0.7 0.19 2.6 ± 0.4 2.6 ± 0.5 0.97
Data expressed as lumen diameters (mm) ± standard deviation. *p = <0.05
BMS = bare-metal stent; SES = sirolimus-eluting stent.
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Table 3. Results of Coronary Ultrasound at stent edges at baseline and at follow-up
BMS SES
Baseline Follow-up p-value Baseline Follow-up p- value
Proximal stent edge:
 Vessel volume (mm3) 83.2 ± 27.6 80.7 ± 25.6 0.54 76.0 ± 34.5 66.7 ± 37.9 0.22
 Minimal lumen area (mm2) 6.9 ± 2.7 6.3 ± 2.5 0.14 6.5 ± 1.7 6.6 ± 1.6 0.82
 Mean lumen area (mm2) 8.5 ± 3.1 8.0 ± 3.6 0.24 8.6 ± 2.3 7.9 ± 2.3 0.03*
Distal stent edge:
 Vessel volume (mm3) 72.6 ± 29.7 67.1 ± 26.0 0.09 54.3 ± 22.2 56.1 ± 20.3 0.21
 Minimal lumen area (mm2) 6.3 ± 2.7 5.7 ± 2.5 0.11 5.3 ± 1.7 5.5 ± 1.7 0.52
 Mean lumen area (mm2) 7.8 ± 3.5 7.0 ± 3.0 0.07 6.5 ± 1.6 6.7 ± 1.7 0.34
Data expressed as volumes (mm3) or as areas (mm2) ± standard deviation.
*p= <0.05.
Abbreviations as in table 2.
Table 4. Results of Coronary Ultrasound for the stented segment and stent edges at 9 months follow-up
BMS SES p-value
Stented length 24.5 ± 7.0 23.4 ± 7.1 0.65
Mean number of stents 1.4 ± 0.5 1.3 ± 0.5 0.42
Stented segment
 Area (mm2)
 Minimal stent area 6.1 ± 1.1 6.0 ± 1.5 0.72
 Mean stent area 7.3 ± 1.0 7.5 ± 1.7 0.59
Volume (mm3)
 Stent volume 178.4 ± 56.3 175.1 ± 59.0 0.87
 Lumen volume 125.1± 43.8 167.7 ± 59.2 0.02*
 Neointimal volume 53.2 ± 35.1 7.3 ± 9.1 <0.001*
 Percentage neointimal volume 30.0 ± 14.8 4.6 ± 5.6 <0.001*
Proximal stent edge:
 Δ Vessel volume (mm3) -2.5 ± 14.7 -9.4 ± 27.1 0.42
 Δ Minimal lumen area (mm2) -0.6 ± 1.4 0.1 ± 1.1 0.17
 Δ Mean lumen area (mm2) -0.5 ± 1.4 -0.7 ± 1.1 0.66
Distal stent edge
 Δ Vessel volume (mm3) -5.6 ± 12.5 0.5 ± 3.9 0.08
 Δ Minimal lumen area (mm2) -0.6 ± 1.5 0.2 ± 1.3 0.09
 Δ Mean lumen area (mm2) -0.8 ± 1.6 0.2 ± 0.8 0.04*
Data expressed as volumes (mm3) or as areas (mm2) ± standard deviation.
*p= <0.05.
Δ = alteration in volume (mm3) or area (mm2) from baseline.
Abbreviations as in table 2.
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lumen volume (SES: 167.7 ± 59.2mm3 versus BMS: 125.1± 43.8mm3; p =0.02) at follow-up. 
Also in SES, less neointima volume (7.3 ± 9.1mm3 versus 53.2 ± 35.1mm3; p <0.001) and 
lower percentage neointimal volume (4.6 ± 5.6% versus 30.0 ± 14.8%; p <0.001) were 
found at follow-up when compared to BMS.
virtual histology results
Post procedural and follow-up VH-IVUS results for relative volumes of the different plaque 
components are reported in table 5. The relative increase and decrease of each plaque com-
ponent volume is illustrated in figure 2. Except for a significant decrease of the fibrous plaque 
component volume of the distal edge segment of BMS (p =0.05), plaque composition did 
not change significantly in either group. The data for mean areas at baseline and follow-up 
are summarized in table 6 and the relative increase/decrease of mean area of every plaque 
component at follow-up is depicted in figure 3. Again, no significant difference in mean 
area of the four plaque components is discernable between follow-up and baseline in either 
group.
As it was considered possible that by using the calculated means of data from the edge 
segments any differences between baseline and follow-up in both stent type groups may 
have been obscured, it was decided to perform an additional VH-IVUS analysis of the frame 
just distal from the stent edge at baseline and at follow-up for all 40 cases. However, this 
analysis too revealed no significant differences for plaque composition areas between post-
intervention and follow-up and between the two stent types (not shown).
Table 5. Results of Virtual Histology Analysis for relative plaque volume per component at baseline and 
at follow-up.
BMS SES
Baseline Follow-up p-value Baseline Follow-up p-value
Proximal segment
 Fibrous (%) 56.3 ± 7.2 57.3 ± 7.3 0.56 57.0 ± 8.9 58.4 ± 7.7 0.49
 Fibro-fatty (%) 31.1 ± 12.4 27.7 ± 8.0 0.18 31.0 ± 15.4 31.6 ± 14.9 0.87
 Necrotic core (%) 9.0 ± 7.8 10.7 ± 5.2 0.36 8.4 ± 7.3 9.2 ± 7.9 0.46
 Dense Calcium (%) 3.6 ± 3.4 4.2 ± 3.3 0.44 3.7 ± 4.5 4.3 ± 4.8 0.40
Distal Segment
 Fibrous (%) 62.8 ± 9.7 57.2 ± 12.4 0.05* 57.7 ± 20.7 52.8 ± 24.1 0.35
 Fibro-fatty (%) 25.0 ± 14.3 27.2 ± 12.8 0.41 25.0 ± 12.9 22.7 ± 13.9 0.60
 Necrotic core (%) 8.9 ± 6.2 10.2 ± 8.4 0.40 5.7 ± 5.3 6.7 ± 6.2 0.55
 Dense Calcium (%) 3.3 ± 3.9 5.5 ± 10.5 0.25 1.6 ± 1.8 2.9 ± 3.6 0.09
Data expressed as relative proportions of plaque volume (%) ± standard deviation. *p = <0.05
Abbreviations as in table 2.
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clinical outcome
One BMS patient and one SES patient underwent a target lesion revascularization due to 
restenosis. No patient died during the follow-up period of 12 months. Three BMS patients 
and two SES patients underwent revascularization of a vessel other than the culprit vessel at 
different points of time within a 12 months follow-up period. Adherence to medication was 
high (table 1), no sub-acute thrombosis was observed.
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figure 2. Relative volume changes over 9 months time (Δ%).
Measurements for BMS are set out next to SES. P-values are reported to indicate statistical significance 
of differences in plaque component changes between BMS and SES. None are significant.
BMS = Bare-metal stents; SES = Sirolimus-eluting stents; Δ = change in relative volume of mentioned 
plaque component; Fi = fibrous; FF = fibro-fatty; DC = dense calcium; NC = necrotic core.
Table 6. Results of Virtual Histology Analysis for relative plaque area per component at baseline and at 
follow-up
Bare-metal stent SES
Baseline Follow-up p-value Baseline Follow-up p-value
Proximal segment
 Fibrous (mm2) 3.2 ± 1.3 3.2 ± 1.3 0.76 3.6 ± 2.0 3.4 ± 1.8 0.15
 Fibro-fatty (mm2) 1.7 ± 1.1 1.5 ± 0.7 0.27 1.6 ± 0.9 1.5 ± 1.0 0.43
 Necrotic core (mm2) 0.6 ± 0.6 0.6 ± 0.4 0.64 0.6 ± 0.7 0.7 ± 0.8 0.94
 Dense Calcium (mm2) 0.3 ± 0.3 0.3 ± 0.3 0.93 0.3 ± 0.4 0.3 ± 0.4 0.81
Distal Segment
 Fibrous (mm2) 2.1 ± 1.1 1.9 ± 1.0 0.06 1.0 ± 1.5 0.9 ± 1.1 0.27
 Fibro-fatty (mm2) 0.9 ± 0.6 1.0 ± 0.7 0.56 0.4 ± 0.5 0.4 ± 0.7 0.89
 Necrotic core (mm2) 0.3 ± 0.2 0.3 ± 0.3 0.96 0.1 ± 0.2 0.1 ± 0.3 0.68
 Dense Calcium (mm2) 0.1 ± 0.2 0.1 ± 0.2 0.92 0.1 ± 0.1 0.1 ± 0.2 0.16
Data expressed as mean areas of the plaque components (mm2) ± standard deviation.
Abbreviations as in table 2.
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dIscussIon
To our knowledge, this is the first follow-up study that compares vascular plaque composition 
and remodeling at stent edges between BMS and SES treated patients. The main findings of 
this study are: (1) at distal and proximal stent edges in BMS patients there is a trend towards 
negative vascular remodeling while there is a trend towards positive remodeling at the distal 
stent edges in SES treated patients resulting in a significant difference between the two 
groups; (2) plaque composition at the stent edges did not change significantly during the 9 
months follow-up in either SES or BMS patients.
Sirolimus-eluting stent implantation results in a significant reduction of restenosis com-
pared to the results obtained with bare-metal stents in patients with stable and unstable 
angina.14;21 However, inconsistent and limited data have been presented about their safety 
and efficacy in patients with acute myocardial infarction.1-4 Sirolimus is a potent anti-
inflammatory, immunosuppressive and antiproliferative drug effective in inhibiting in-stent 
neointimal hyperplasia.22 These potent antiproliferative effects can also induce positive 
remodeling and stent malapposition and may cause deleterious local phenomena such as 
necrosis or apoptosis. 4;13;22 These effects may potentially affect plaque composition behind 
the stent, the vessel wall, and as a result of downstream effects of the eluted drug may also 
affect plaque composition at the distal stent edge.
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figure 3. Mean area changes over 9 months time.
Measurements for BMS are set out next to SES. P-values are reported to indicate statistical significance 
of differences in plaque component changes between BMS and SES. None are significant.
Δ mm2 = change in mean area of mentioned plaque component; Other abbreviations as in figure 2.
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Clinical data support the hypothesis of drug elution distal to the stent. In recent trials, SES 
implantation resulted in higher restenosis rates at the proximal edge of the stent compared 
to the distal edge.14 One expects the concentration and therefore the effects of the drug 
to be strongest in the direction of the blood flow. This seems to be confirmed by a study 
by Degertekin et al. showing a trend towards positive remodeling only at the distal stent 
edge but not at the proximal edge.13 Comparative results have been found in several other 
studies. Investigators of the RAVEL trial reported a trend toward larger lumen areas at distal 
edge which was thought to be due to higher downstream effect of the drug. A study from 
Jimenez-Quevedo et al further confirmed these findings by reporting a significant increase 
in lumen dimensions at stent edges of SES compared to lumen reduction at stent edges in 
BMS in patients with diabetes.22;23 Our findings are in agreement with this, as we observed 
a trend towards positive remodeling at the distal stent edges in SES patients, though, similar 
to Degertekin et al, not statistically significant.
Several studies reported that stent edge burden is an important periprocedural predictor 
of stent edge restenosis after BMS and SES implantations.24-26 In the present study popula-
tion the stent edge plaque burden may have been too small to be affected significantly by 
the drug.
Thus far, effects of sirolimus on proximal and distal stent edges have not been fully 
evaluated. Serruys et al reported a vascular response at the proximal and distal stent edges 
after paclitaxel-eluting stent implantation.15 The paclitaxel-eluting stent induced positive 
remodeling 1mm proximal and 3 to 4mm distal to the stent edges which resulted in less late 
luminal loss compared to BMS.
Little is known about the effects of sirolimus on the plaque composition at the proximal 
and distal stent edges. Our findings suggest that plaque composition at the stent edges 
was not affected by the drug since no significant differences could be detected between 
BMS and SES patients at follow-up. This is interesting given that an effect of sirolimus on 
vascular lumen dimensions was clearly present distal to the stent as well as a detectable 
effect on neointima volume inside the stent as demonstrated by the IVUS grayscale data. As 
expected, within the stented segment, SES was associated with significantly less neointimal 
hyperplasia when compared to BMS, a well known effect.4;22 At the stent edges however, 
a decrease in local drug delivery may have occurred, which may have caused the drug to be 
ineffective in inducing changes in plaque composition at stent edges. However, changes in 
plaque composition caused by the drug may be subtle and missed by the VH-IVUS technique.
Similar data were observed in a study from Aoki et al who reported in a long-term follow-
up study of 23 event-free patients treated with SES that no significant changes in plaque 
echogenicity at the distal stent edges (5mm) had taken place across multiple time points 
of follow up.27 At the same time investigators did see a change of plaque echogenicity 
behind the stent struts between 2 years and 4 years of follow up. This is interesting as this 
suggests that alterations in plaque composition take place very late (>2 years) after stent 
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implantation and that they are very localized, therefore possibly not involving a measurable 
downstream edge effect.
It may be that the remodeling effect on the vessel at the distal stent edge is a general 
effect that is caused merely by a delayed healing response. Caramori et al. demonstrated 
persistent vasomotor dysfunction distal to coronary stents implanted 6 months earlier.28 The 
anti-proliferative effect of sirolimus may merely cause a prolonged healing response with 
concomitant delayed recovery of endothelial function as suggested by Hofma et al.29 It has 
been suggested before that delayed vascular healing may cause positive remodeling and 
incomplete stent apposition.30;31
In addition, past studies suggested that sirolimus or the polymer might induce apoptosis 
or necrosis.32;33 It was suggested that the strong hydrophobic property of the compound 
partitions highly into arterial tissue resulting in drug concentrations that exceed the applied 
bulk concentration.33;34 This highly concentrated local delivery of a potent drug may lead to 
increased vascular toxicity which in turn may lead to an inflammatory response. Pires et al, 
investigated histopathological effects of sirolimus- and paclitaxel-eluting cuffs in a murine 
model for restenosis on underlying diseased atherosclerotic arteries.33 While paclitaxel 
significantly increased apoptosis, internal lamina elastic disruption, and decreased medial 
and intimal smooth muscle cells and collagen, vascular histopathological analysis revealed 
that sirolimus had no significant adverse effects on vascular pathology. This further supports 
our finding of unaffected plaque composition in SES.
limitations
This study is limited by the fact that it was a single-center study and that, due to the complex 
nature of the study design, the patient sample size for which all the above mentioned imaging 
modalities were available was relatively small.4 Nonetheless, though it may not be possible to 
firmly conclude that no difference of effect on plaque composition exists between SES and 
BMS on stent edges after 9 months of follow up, the data indicates that these differences are 
possibly of smaller magnitude than anticipated. The relatively short follow-up of 9 months 
may have been a possible limitation, as changes in plaque composition may take much 
longer to develop than was presumed. Larger and longer follow-up studies of well-matched 
patient populations will be able to tell just how much of a difference there truly is.
Secondly, using VH-IVUS analysis at the index procedure made the border detection a 
more complex process.35;36 Inaccurate detection of borders shared by thrombus, plaque and 
lumen might have caused measurement errors of plaque composition.
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conclusIon
This study demonstrates a trend towards positive remodeling at the distal stent edges in SES 
patients and a significant inhibition of neointimal hyperplasia within the stented segment at 
follow-up as compared to BMS treated patients. The effect on the distal stent edge suggests 
a downstream effect of sirolimus elution despite the fact that an effect on plaque composi-
tion was not observed.
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AbsTrAcT
background
The benefits of early abciximab administration and thrombus aspiration in STEMI patients 
undergoing PPCI have been previously elaborated. However, whether there is adjunctive 
effect of thrombus aspiration among STEMI patients, with angiographic evidence of throm-
bus, receiving early abciximab prior to hospital arrival remains unclear. Methods
In the context of a fixed protocol for PPCI, 158 consecutive patients with STEMI were 
enrolled, in whom abciximab was started early before arrival at the hospital (in-ambulance); 
79 patients who had PPCI with thrombus aspiration (thrombectomy-facilitated PCI group), 
were compared to 79 who had PPCI without thrombus aspiration (Conventional PCI group) 
in a prospective non-randomized study. The primary end point was complete ST-segment 
resolution within 90min. Secondary endpoints included enzymatic infarct size as well as 
LVEF assessed by Gated-SPECT. MACE were evaluated up to 12 months.
results
Both groups were comparable for baseline clinical and angiographic characteristics. The rate 
of ST-segment resolution was significantly higher in the thrombectomy-facilitated group 
(p=0.002), and multivariable logistic regression analysis identified only thrombectomy as an 
independent predictor of ST-segment resolution (odds ratio= 6.7, 95% CI = 2.4-18.4, p< 
0.001). No difference was observed between both groups in enzymatic infarct size assessed 
by peak CK (p=0.8), and peak Tn-T levels (p=0.5). Also the LVEF at 3-months was similar 
(p=0.9). At 12 month clinical follow-up, thrombus aspiration was however associated with 
reduced all-cause mortality (log-rank p= 0.03). Conclusion
Among STEMI patients treated with PPCI and in-ambulance abciximab, it appears that a 
selective strategy of thrombus aspiration still has additive benefit.
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InTroducTIon
It has been widely observed that primary percutaneous coronary intervention (PPCI) offers 
greater reperfusion benefits in the setting of acute myocardial infarction (MI) compared 
to intravenous thrombolytic therapy.1 However, despite a good epicardial flow after PPCI, 
a considerable percentage of patients have impaired myocardial perfusion mainly due to 
embolization of the microcirculation.2 Poor myocardial reperfusion is associated with adverse 
outcome including reduced left ventricular function and mortality.3-5
Recent studies demonstrated that GP IIb,IIIa platelet receptor antagonists have positive 
effects on reperfusion in the setting of primary percutaneous coronary interventions, with 
improved clinical outcome.6 Many studies showed that these benefits are more apparent 
when GP IIb IIIa platelet receptor antagonists are introduced as early as achievable in the 
setting of acute myocardial infarction.7-12
Additionally, numerous adjunctive coronary devices have been developed in an attempt 
to decrease or prevent distal embolization during revascularization and thereby trying to 
improve clinical outcome as well.
Recent randomized trials demonstrated that patients treated with a thrombectomy 
catheter showed better angiographic and electrocardiographic signs of myocardial reperfu-
sion, as well as improved 1 year clinical outcome.13-16 These data have been confirmed by 
recent meta-analyses demonstrating that adjunctive manual thrombectomy in the setting 
of primary PCI is associated with improved epicardial and myocardial perfusion, less distal 
embolization 17, as well as improved clinical outcome.18
However, it is still unknown whether there is a possible benefit of using thrombus aspira-
tion devices in the setting of PPCI among STEMI patients receiving early GP IIb IIIa platelet 
receptor antagonists. Therefore, in this study the results of adjunctive manual thrombus 
aspiration using aspiration thrombectomy catheter were compared to no thrombus aspira-
tion in a consecutive group of STEMI patients treated with PPCI and early “in-ambulance” 
abciximab administration according to the adapted Mission protocol.19,20
MeThods
study design
This is a single center non-randomized prospective study. All patients were treated according 
to the institutional STEMI protocol (MISSION!) implemented at Leiden University Medical 
Centre (LUMC) since February 2004, which includes a standardized prehospital, in-hospital 
and outpatient clinical framework for decision making and treatment.19,20 The tertiary center 
provides a round-the-clock service of PPCI with highly experienced PCI physicians and dedi-
cated nurses.
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Inclusion and exclusion criteria
The inclusion criterion was a diagnosis of acute MI defined by chest pain suggestive of 
myocardial ischemia for at least 30 minutes, with a time from onset of symptoms of <9 hours 
before hospital admission, and an ECG with ST-segment elevation of >0.1 mV in ≥2 leads. 
Exclusion criteria were recent surgery, recent stroke, hemorrhagic diatheses, and known 
contraindications for therapy with abciximab, aspirin, clopidogrel or heparin.
study groups
A total of 158 consecutive patients; who fulfilled the inclusion and exclusion criteria for 
this study, and who received early in-ambulance abciximab, were enrolled: 79 consecutive 
patients, in whom a thrombectomy catheter was used at the start of the procedure (the 
thrombectomy facilitated PCI group); were compared to 79 consecutive patients within the 
same period, in whom thrombectomy catheter was not used (the conventional PCI group). 
The study complies with the Declaration of Helsinki. The MISSION! protocol has been 
approved by the local ethics committee.
Medication
All patients received abciximab (Centocor B.V., Leiden, The Netherlands) as a bolus injection 
of 0.25 mg/ kg bodyweight, followed by 0.125 mcg/kg/min with a maximum of 10 mcg/
min as a continuous infusion for 12 hr. Abciximab administration started early in the ambu-
lance according to the adapted MISSION! Protocol.19,20 Furthermore all patients received 
an equivalent of 300 mg of acetylsalicylic acid, 600 mg clopidogrel as a loading dose in 
the ambulance and heparin given as a bolus of 5000 IU at the start of the PCI procedure. 
After the procedure, all patients received aspirin (75 mg/day) indefinitely and clopidogrel (75 
mg/day) for one year. Other medications, including b-blockers, ACE-inhibitors, nitrates, and 
statins, were prescribed according to MISSION! protocol.
Invasive Procedure and Angiographic evaluation
All PPCI was performed through a 6F femoral sheath. Patients underwent PPCI and stent-
ing of the IRA according to standard techniques. The choice of stent (bare-metal stent or 
drug-eluting stent) was left to the operator’s discretion. Direct stenting, which is stent place-
ment without balloon pre-dilatation, was performed only in cases presenting clear views 
of the arterial lesion with adequate flow. We also considered stent placement which was 
only preceded by thrombectomy as direct stenting. Otherwise, the patient was subjected to 
balloon angioplasty and stenting was done subsequently. The choice of the balloon size was 
left to the operator’s decision. Stent implantation was successfully completed in all patients, 
apart from only one patient in the thrombectomy facilitated PCI group where the procedure 
was complicated by a spiral dissection occurring after thrombectomy and had to undergo 
emergency coronary artery bypass graft (CABG), and this patient survived and completed the 
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follow-up period. The choice of performing thrombectomy was left to the operator’s discre-
tion. Thrombectomy was often, but not exclusively, performed when high thrombus burden 
was observed at the initial angiographic image of the target vessel. There was no change 
in the frequency of use of thrombectomy over the time period of the study. Thrombus was 
assessed according to the criteria summarized by Mabin et al.21 These criteria include the 
presence of an intraluminal central filling defect or lucency surrounded by contrast material 
that is seen in multiple projections; the absence of calcium within the defect; and persistence 
of contrast material within the lumen. Thrombus score was graded as previously described by 
the TIMI Study Group.22,23 We further categorized the thrombus score into 2 overall grades; 
a high thrombus grade (grades 4 and 5), and a low thrombus grade (grades 1-3). We decided 
to use this cut-off value in line with 2 recent studies24,25 suggesting prognostic implications 
of this cutoff. Coronary flow was graded according to thrombolysis in myocardial infarction 
(TIMI) criteria.26 TIMI flow grade was evaluated at baseline and after the PCI procedure. 
Procedural success was defined as residual stenosis <20% and TIMI flow grade 3. The coro-
nary angiograms were reviewed off-line by two independent interventional cardiologists who 
were blinded to the clinical data.
Thrombectomy catheter
The Export Aspiration Catheter (Medtronic Corporation, USA) is a 6F thrombus aspiration 
catheter.13 Thrombosuction was started proximal to the occluded site, gently pushing the 
catheter through the occlusion and then pulling it in a proximal direction, keeping negative 
pressure once the occlusion was crossed or if there was no longer backflow in the syringe. 
This could be repeated several times. Withdrawal of the catheter from the artery and from 
the guiding catheter was performed with permanent negative pressure. After each pass the 
catheter was flushed and the syringe emptied over a filter, to show the retrieved debris.
end-points and clinical follow-up
According to the MISSION! Protocol all patients were seen at the dedicated out-patient clinic 
after 1, 3, 6, and 12 months. The primary endpoint was ST-segment resolution within 90 
min. after PPCI; secondary endpoints were enzymatic infarct size and LVEF as assessed by 
Gated-SPECT. Also major adverse cardiac events (MACE) occurring within one year of follow-
up were recorded. These include all-cause death, cardiac death, reinfarction, target vessel 
and target lesion revascularization; death was regarded as cardiac unless an unequivocal 
non-cardiac cause of death was established. Reinfarction was defined as recurrent symptoms 
with new ST-segment elevation and elevation of cardiac markers to at least twice the upper 
limit of normal. Target vessel (TVR) and target lesion (TLR) revascularization were defined as 
any revascularization procedure of the target vessel or target lesion (from 5 mm distally to the 
stent up to 5 mm proximally to the stent), respectively. All major adverse cardiac events were 
assessed and classified by an interventional cardiologist unaware of the treatment allocation.
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electrocardiographic data
The 12-lead ECG was recorded at presentation and within 90 min after PPCI. The magni-
tude of ST-segment elevation is measured 60 milliseconds from J point. ST-segment score is 
calculated as the sum of ST-segment elevation > 0.1 mV for leads V1 through V6 and I, II, 
and aVL in anterior infarction and I, II, aVF, V5, and V6 in non-anterior infarction (27). All 
ECGs were collected and analyzed by an investigator blinded to the assigned treatment. 
Total ST-segment elevation at inclusion was compared with that taken within 90 min after 
PPCI. A complete ST-segment resolution was calculated, defined as resolution of the initial 
ST-segment elevation of ≥70%.28
enzymatic Infarct size
Creatine kinase (CK) activity and cardiac troponin-T (Tn-T) concentration in plasma were 
determined at admission and every 6 hr in the first 48 hr after PPCI. Subsequently these 
levels were determined every day up to discharge, unless clinical events suggested repeat 
measurements. Peak levels of CK and Tn-T in plasma were calculated as a measure of infarct 
size in each patient by an investigator blinded to the assigned treatment.
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figure 1. Flow diagram of the study patients.
LVEF: left ventricular ejection fraction; PPCI: primary percutaneous coronary intervention; SPECT: single 
photon emission computed tomography; STEMI: ST elevation myocardial infarction; IH: in hospital.
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Myocardial Perfusion Imaging
According to the MISSION! Protocol all included patients were enrolled for a myocardial per-
fusion study at 90 days post-PPCI. An ECG gated SPECT acquisition at rest using intravenous 
Technetium 99 m Tetrofosmin (MYOVIEW, Amersham, Buckinghamshire, UK) was used to 
measure the left ventricular ejection fraction (LVEF) 90 days after PPCI. LVEF was calculated 
using an automated and validated method (QGS software, version 2.0; Cedars-Sinai Medi-
cal Center, Los Angeles, CA, USA). Detailed methods are described elsewhere.29 Patients in 
whom the gated SPECT could not be performed due to technical difficulties, LVEF estimated 
by echocardiographic biplane method was used instead. LVEF assessment was done by an 
investigator blinded to the assigned treatment.
statistical analysis
Categorical variables were compared using the X2 test or Fisher’s exact test. Continuous 
normally distributed data were tested by student t-test or in the case of a non-Gaussian 
distribution by a nonparametric test for independent samples (Mann Whitney U test). One 
year clinical outcomes were analyzed using Kaplan Meier methodology and were compared 
with log-rank test pooled over strata. Multivariable linear regression and logistic regression 
analyses were used to create models for both PCI groups (as the variable of interest) cor-
rected for thrombus grade, infarct related artery, proximal location of the culprit lesion and 
symptoms to balloon time (as potential confounders), to identify whether thrombectomy is 
an independent predictor for the end points of ST-segment resolution, infarct size assessed 
by cardiac enzymes or LVEF. All tests were two-sided, and a p-value of < 0.05 was considered 
significant. All analyses were performed with PASW version 17.0 statistical software (SPSS 
Inc. - An IBM Company, Chicago, IL, USA).
resulTs
study population
One-hundred and fifty-eight patients were included in the study according to the eligibil-
ity criteria (Figure 1 Flow diagram). The baseline clinical characteristics were comparable 
between the two groups (Table 1).
Angiographic and peri-procedural findings
Angiographic and procedural data are summarized in Table 2. There was a significantly higher 
rate of high grade thrombus in the thrombectomy facilitated group (p<0.001), also there was 
a significantly higher rate of balloon predilatation in the conventional PCI group (p= 0.002).
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electrocardiographic evaluation:
The rate of post-PCI complete ST-segment resolution of ≥ 70% was observed more frequently 
in the thrombectomy facilitated PCI group (87% vs. 65%, p=0.002) (Table 3).
Multivariable logistic regression analysis using the aforementioned potentially relevant 
factors identified only aspiration thrombectomy as an independent predictor of complete 
ST-segment resolution within 90 min. Post-PPCI (odds ratio= 6.7, 95% CI = 2.4-18.4, p< 
0.001).
enzymatic infarct size assessment
Peak levels of CK and Troponin-T were comparable in both PCI groups (p = 0.8 and 0.5, 
respectively) (Table 3.). Multivariable linear regression analysis for Peak levels of CK and Tn-T 
including the aforementioned factors did not identify PCI groups as an independent predic-
tor of higher peak CK (B = 186.3, 95% CI= -515.1 – 887.6, p=0.6) and Troponin T (B = 2.04, 
95% CI= -0.51 – 4.58, p=0.1).
Table 1. Baseline characteristics.
Conventional
PCI
N=79
Thrombus aspiration
N=79
p
Age in years 59±10 56±12 0.1a
Male, n (%) 59(75) 62(78) 0.6b
History, n (%)
 Hypertension 28(35) 24(30) 0.5b
 Hypercholesterolemia 17(21) 24(30) 0.2b
 Smoking 53(67) 49(62) 0.7b
 Family history 31(39) 36(45) 0.4b
 Diabetes mellitus 7(9) 6(8) 0.7b
 Previous MI 8(10) 8(10) 1.0b
 Previous PCI 5(6) 7(9) 0.5b
 Previous CABG 1(1) 4(5) 0.2b
Symptoms to balloon (min) 135(90-195) 140(93-225) 0.7c
Previous aspirin 16(20) 10(13) 0.2b
Previous clopidogrel 0(0) 1(1) 1.0b
Previous statins 12(15) 13(16) 0.8b
Data are presented as mean ± standard deviation, number (%) of patients or median (Interquartile 
range).
MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass 
grafting. Hypercholesterolemia= Total cholesterol ≥190 mg/dl or previous pharmacological treatment.
Hypertension = Blood pressure ≥140/90 mm Hg or previous pharmacological treatment.
a Compared using unpaired t test.
b Compared using Chi-square or Fisher exact test.
c Compared using Mann-Whitney U test.
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Three-month lv function evaluation
One-hundred and thirty-eight patients underwent LV function assessment by myocardial 
perfusion scintigraphy (MYOVIEW) (Figure 1). Patients who did not undergo scintigraphy 
had their LV function assessed using biplane 2-D echocardiographic evaluation at 3 months, 
and one patient had unavailable data regarding the LV function assessment post-PCI due to 
in-hospital death. LVEF was not significantly different between both groups (p=0.9) (Table 4). 
Table 2. Angiographic and procedural results.
Conventional
PCI
N=79
Thrombus
Aspiration
N=79
P
Infarct related artery, n (%) 0.2b
 Left main a. 1(1) 2(2)
 Left anterior descending a. 31(39) 28(35)
 Circumflex a. 15(19) 7(9)
 Right coronary a. 32(40) 42(53)
Diseased vessels, n (%) 0.2b
 1-vessel 44(56) 48(61)
 2-vessel 26(33) 28(35)
 3-vessel 9(11) 3(4)
Proximal culprit lesion, n (%) 35(44) 40(50) 0.4b
Abciximab 78(98.7) 79(100) 0.9b
Initial TIMI flow grade, n (%) 0.8b
 0 41(52) 39(49)
 1 14(18) 15(19)
 2 13(16) 17(21)
 3 11(14) 8(10)
Final TIMI flow grade, n (%) 0.3b
 1 0(0) 2(2)
 2 11(14) 13(16)
 3 68(86) 64(81)
Drug eluting stents, n (%) 45(57) 52(70) 0.1b
Stent number 1.5±0.7 1.5±1.0 0.8a
Multiple stents, n (%) 31(39) 24(32) 0.4b
Predilatation, n (%) 66(83) 49(62) 0.002b
Thrombus detected, n (%) 75(95) 78 (98.5) 0.8b
Thrombus grade, n (%) <0.001b
 High thrombus grade
 (Grades 4, 5)
29(39) 65(83)
 Low thrombus grade
 (Grades 1, 2, 3)
46(61) 13(17)
Data are presented as mean ± standard deviation, number (%) of patients.
TIMI, Thrombolysis In Myocardial Infarction.
a Compared using unpaired t test. b Compared using Chi-square or Fisher exact test.
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Multivariable linear regression analysis including the aforementioned factors did not identify 
PCI groups as an independent predictor of improved LVEF (B = -1.8, 95% CI= -6.5 – 2.9, 
p=0.5).
clinical outcomes
All patients were followed for a median of 367 days, 5 patients died in the conventional 
PCI group (including one in-hospital death) vs. 0 patients in the thrombectomy facilitated 
PCI group (p= 0.02), three (4%) of those deaths were cardiac (p=0.08). The 2 non-cardiac 
deaths were due to hepatic failure and terminal renal failure. Three (4%) patients underwent 
a target vessel revascularization in the conventional PCI group vs. 5(6%) patients in the 
Table 3. Postprocedural electrocardiographic and laboratory results.
Conventional PCI
N=79
Thrombus aspiration
N=79
p
90-min. complete
ST-segment resolution, (%)
45/69(65) 66/76(87) 0.002b
Peak CK (U/I) 2095±1873 2286±2168 0.8a
Peak Tn-T(µg/l) 6.2±8.5 5.8±6.1 0.5a
Data are presented as mean ± standard deviation, number (%) of patients
CK, creatine kinase; Tn-T, Troponin T.
a Compared using Mann-Whitney U test.
b Compared using Chi-square or Fisher exact test.
Table 4. Three months scintigraphic and 1-year clinical outcomes.
Conventional
PCI
N=79
Thrombus aspiration
N=79
p
LVEF by Gated-SPECT 53.35±13.8 53.46±11.8 0.9a
Clinical follow up period 368(362-397) 367(188-391) 0.1c
Clinical end-points, n (%):
 Cardiac death 3(4) 0(0) 0.08b
 All-cause death 5(6) 0(0) 0.02b
 Reinfarction 2(0) 0(0) 0.1b
 TVR 3(4) 5(6) 0.7b
 TLR 4(5) 2(2) 0.6b
 MACEs 10(13) 7(9) 0.4b
Data are presented as mean ± standard deviation, number (%) of patients or median (Interquartile 
range).
LVEF, left ventricular ejection fraction; SPECT; Single Photon Emission Computed Tomography; TVR, tar-
get vessel revascularization; TLR, target lesion revascularization; MACE, Major adverse cardiac events.
a Compared using unpaired t test.
b Compared using Chi-square or Fisher exact test.
c Compared using Mann-Whitney U test.
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thrombectomy facilitated group (p= 0.7). Target lesion revascularization occurred in 4(5%) 
patients in the conventional PCI group vs. 2(2%) patients in the thrombectomy facilitated 
group (p= 0.6). Recurrent myocardial infarction occurred in 2 patients in the conventional PCI 
group vs. 0 patients in the thrombectomy facilitated group (p= 0.1). Overall MACE occurred 
in 10(13%) patients in the conventional PCI group vs. 7(9%) in the thrombectomy facilitated 
group (p= 0.4) (Table 4).The Kaplan-Meier curves showed that allocation to thrombectomy 
was associated with a significant reduction in 1-year all-cause mortality (log-rank p= 0.03); 
( Figure 2), and a trend towards a reduction of the combined endpoint of cardiac death or 
reinfarction (log-rank p= 0.056); (Figure 3)
dIscussIon
The main findings of this study are: 1) A strategy of thrombus aspiration before stenting 
during primary PCI among patients treated with early abciximab was associated with a higher 
rate of complete ST-segment resolution (≥ 70%) within 90 min post-PCI. 2) Thrombus aspira-
tion was associated with a lower incidence of all-cause mortality, and a trend towards a lower 
incidence of combined end-point of cardiac death or reinfarction through a 1-year median 
clinical follow up. TVR, TLR and overall MACE were similar in both groups.
Unlike the TAPAS trial 16, where abciximab was administered during the procedure 
of PPCI, our study provides a unique experience of the adjunctive influence of throm-
bus aspiration to early abciximab administration before PPCI. In the ATTEMPT study 18, 
Burzotta and colleagues have interestingly shown that the benefit of thrombectomy was 
 
Figure 3 
 
 
 
Figure 3 
 
 
figure 2. Kaplan-Meier 12 month cumulative 
event free survival from the endpoint of all-cause 
death.
TF-PCI: Thrombectomy facilitated PCI group; 
C-PCI: conventional PCI group.
figure 3. Kaplan-Meier 12 month cumulative 
event free survival from the combined endpoint 
of cardiac death or reinfarction. TF-PCI: 
Thrombectomy facilitated PCI group, C-PCI: 
conventional PCI group.
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more evident in patients who received IIb,IIIa-inhibitors thus suggesting a possible additive 
benefit of thrombectomy in patients treated with IIb,IIIa-inhibitors. It might be speculated 
that pharmacological and mechanical thrombus remodeling are synergic to obtain the 
best myocardial reperfusion and, consequently, the best clinical outcome. Indeed, in the 
ATTEMPT study, patients treated by both thrombectomy and IIb,IIIa-inhibitors had the low-
est mortality rate, those who had none of these treatments had the highest mortality rate, 
while patients receiving only one of these therapies exhibiting intermediate outcome. On 
the other hand, in the VAMPIRE trial40, where GP IIb,IIIa receptor antagonists were not used 
at all, patients presenting late after STEMI (>6 hours after symptoms) appeared to benefit 
the most from thrombectomy, suggesting that the use of GP IIb,IIIa receptor antagonists 
would have influenced the results. In our study, patients received abciximab prior to PCI, 
where abciximab was started before the arrival to the hospital. The benefits of this has been 
investigated in previous RCTs7,8,10-12, and in the study conducted by Hassan et al 9 in the 
context of the MISSION protocol, where it has been found that very early administration of 
abciximab (in-ambulance) significantly improves early reperfusion in STEMI patients treated 
with PPCI, this was also reflected clinically with smaller infarct size, improved LV function 
and a lower risk of heart failure on follow up. This may explain why some of our study 
outcomes including enzymatic infarct size, LVEF, and some of the clinical end-points did not 
differ between the 2 groups, as it is likely that the early abciximab administration supersedes 
the influence of thrombectomy catheter.
Procedural characteristics
In the current study there was a significantly higher rate of direct stenting among the throm-
bectomy facilitated group, a finding which is consistent with other randomized controlled 
trials.13,14,16,30-34 This can be explained by the fact that thrombus aspiration establishes a 
better antegrade coronary flow which allows selection and placement of a stent of appropri-
ate length and diameter without the need for further balloon predilatation.
sT-segment resolution
The effect of manual thrombus aspiration on the surrogate markers of myocardial reperfu-
sion has been widely discussed in many studies. ST-segment resolution post-PCI is one of 
the most widely used and assessed markers. In our study there was a significantly higher 
rate of complete ST-segment resolution within 90 min in the thrombectomy facilitated 
PCI group. This outcome is in accordance with some previous randomized controlled trials 
(RCTs)14,16,31,34-37, and two recent large meta-analyses38,39 On the other hand, some other 
RCTs revealed no significant difference in the rate of ST-segment resolution among both 
randomized groups.13,30,33,40,41
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enzymatic infarct size:
In our study there was no significant difference between both study groups regarding the 
enzymatic infarct size as estimated by peak levels of CK and Tn-T. Several trials assessing 
thrombus aspiration devices measured infarct size using biochemical markers with variable 
results. The largest study published to date, using the Export catheter system, the TAPAS trial, 
also showed no difference in peak CK and CKMB levels between groups with and without 
thrombus aspiration.16. The same was also noted in the EXPIRIA trial.14 On the contrary, 
it has been noted by Kaltoft and colleagues in their randomized trial that peak Tn-T was 
significantly higher in the thrombus aspiration group 41, a result that has also been reported 
in the randomized trial by Anderson and colleagues.42
left ventricular ejection fraction (lvef)
There is a variety of conflicting data about the effect of thrombus aspiration on the infarct 
size which is the best surrogate end point for the assessment of new therapeutic tools in 
the setting of acute myocardial infarction43,44, and which is reflected by improved LV systolic 
function. In our study there was no benefit in terms of LVEF after thrombus aspiration, which 
is consistent with some previous trials.14,30,31,33,40-42,45 Other trials showed different results 
from our study.36,46
clinical follow-up
In our study clinical data of the patients were available for a relatively long follow-up period 
(around 1 year), revealing that allocation to export aspiration thrombectomy was associated 
with lower incidence of all-cause mortality, in accordance with the findings of the 2 large 
RCTs using the export catheter; TAPAS16 and EXPIRIA14, the meta-analysis conducted by 
Bavry and colleagues38, and the large patient-data pooled analysis; ATTEMPT study.18 In our 
study also there was a trend towards lower incidence of the combined end-points of cardiac 
death or re-infarction, in agreement with TAPAS trial16 and ATTEMPT study.18 On the other 
hand, the incidence of cardiac death in our study was not different between both groups, 
unlike the findings in the TAPAS16 and EXPIRIA14 trials; however the large meta-analysis 
presented by Bavry et al38, as well as the ATTEMPT study 18 only showed benefits in terms 
of all-cause mortality and not in cardiac mortality, moreover in the TAPAS trial16 analysis 
of cardiac death after 30 days showed no significant difference between export aspiration 
group and conventional PCI group. Our study, in consistence with the TAPAS trial16, showed 
no difference between both groups regarding TVR/TLR, suggesting that thrombus aspiration 
has no influence on neointima hyperplasia.
limitations
Our study is a single-center, non-randomized, prospective study. However, we tried to over-
come this limitation by taking two groups of consecutive patients within the same time 
C
ha
pt
er
 5
92
period, who were comparable regarding the baseline clinical and procedural characteristics. 
All patients were submitted to the fixed MISSION protocol throughout the study period. This 
is a rigorously standardized protocol concerning pre-, peri-, and post-PPCI treatment up to 
1 year19,20, so it is unlikely that procedural changes over time would have influenced the 
outcome.
In our study, there was a higher tendency to use the thrombus aspiration catheter in patients 
with higher thrombus grades. In Kishi et al47, the size of the thrombus was not a predictor of 
no-reflow phenomenon or distal embolization. Moreover, in our study there was comparable 
base-line TIMI flow rate between both groups (TIMI flow 0 was 52% in the conventional PCI 
group vs. 49% in the export facilitated PCI group).
Better techniques are required to analyze the thrombus burden, especially with the fact 
that most of the patients are presented with totally occluded infarct related artery on the 
initial angiography which limits the analysis of the thrombus burden; most of those patients 
subtend large thrombus burden but still some do not.
conclusIon
Among STEMI patients treated with PPCI and receiving early (in-ambulance) abciximab, 
it appears that the adjunctive use of manual thrombectomy significantly improves post-
procedural ST-segment resolution, and may be associated with a lower clinical event rate. 
Therefore, although no benefit was observed regarding the enzymatic infarct size or LV func-
tion as assessed by Gated-SPECT, it appears that a selective strategy of thrombus aspiration 
still has an additive benefit, even with early abciximab administration. This needs further 
confirmation in appropriately powered randomized trials.
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AbsTrAcT
Aims
Data regarding the distribution of vulnerable lesions in the coronary arteries are scarce. 
The aim was to evaluate the frequency and distribution of culprit lesions in patients with 
ST-segment elevation acute myocardial infarction (AMI). In addition, the location of culprit 
lesions was related to infarct size.
Methods and results
Consecutive patients (N=1533, mean age 61±12 years) were evaluated. All patients were 
treated with primary percutaneous coronary intervention and underwent 2-dimensional 
echocardiography <48 hours of admission. The majority of the culprit lesions were located 
in the left anterior descending coronary artery (LAD,45%), followed by the right coronary 
artery (RCA,38%) and left circumflex coronary artery (LCX,14%). Subanalysis demonstrated 
that patients with a culprit lesion in the LAD and LCX had significantly higher peak cardiac 
enzymes compared to patients with culprit lesions in the RCA. In addition, patients with 
proximal LAD and LCX lesions had significantly worse left ventricular function compared to 
patients with mid or distal lesions.
conclusion
Plaque rupture resulting in AMI is more likely to occur in the proximal parts of the LAD 
and RCA. In addition, the location of culprit lesions was related to infarct size. Therefore, 
knowledge of the distribution of vulnerable lesions is important for identifying patients at 
risk for acute coronary events.
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InTroducTIon
Acute coronary syndromes are primarily due to rupture of an atheromatous plaque with 
superimposed thrombosis. Therefore, identification of vulnerable lesions which are prone 
to rupture is important and has been studied extensively. Previous studies have particularly 
focused on characteristic histomorphologic features of vulnerable lesions.1,2 Besides in the 
setting of randomized trials, no data have been reported regarding the distribution of culprit 
lesions among the different coronary arteries in patients presenting with a ST-segment eleva-
tion acute myocardial infarction (AMI).3-5 Furthermore, data about the distribution of culprit 
lesions within the different segments of the coronary arteries in patients presenting with AMI 
are scarce.
Accordingly, the aim of the current study was to evaluate the frequency and distribution 
of culprit lesions within the 3 coronary arteries and within the different segments of the 
coronary arteries in a large population of patients presenting with ST-segment elevation 
AMI. In addition, the location of the culprit lesions was related to infarct size as assessed 
with peak cardiac enzymes and residual left ventricular (LV) systolic function.
MeThods
Since February 2004, all patients admitted with ST-segment elevation AMI were identified 
and included in an ongoing registry (MISSION!).6 The diagnosis ST-segment elevation AMI 
was defined based on criteria of typical chest pain, elevated cardiac enzyme levels, and 
typical changes on the electrocardiogram.7 All patients underwent immediate coronary 
angiography to identify the location of the culprit lesion followed by primary percutaneous 
coronary intervention (PCI). Patient data were prospectively collected in the departmental 
Cardiology Information System (EPD-Vision®, Leiden University Medical Center, Leiden, the 
Netherlands) and analyzed retrospectively.8,9 Standardized angiographic projections were 
chosen for the visual classification of the coronary artery map into segments according to 
the guidelines of the American College of Cardiology/American Heart Association.10,11 The 
infarct-related vessel was determined on the coronary artery territory subtended by the 
regions of acute electrocardiographic changes. If the culprit vessel had more than 2 lesions, 
the most severe proximal stenosis or a stenosis identified with thrombus was considered as 
the culprit lesion. Patients were not included if no clear culprit lesion could be identified on 
coronary angiography. Patients were treated according to the institutional AMI protocol, 
which includes 2-dimensional echocardiography performed within 48 hours of admission 
to assess residual LV function using LV ejection fraction calculated by the biplane Simpson’s 
technique from the apical 2- and 4-chamber views.6,12
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Continuous data are presented as mean ± standard deviation and categorical data are 
presented as frequencies and percentages. Differences in baseline characteristics between 
the 3 coronary arteries or the different segments of the coronary arteries were evaluated 
with 1-way analysis of variance or chi-square test, as appropriate. Of note, patients with 
a bypass graft identified as culprit vessel were not included in these analyses. Post-hoc 
comparisons were performed using the Bonferroni adjustments for multiple comparisons. 
For all tests, a p value <0.05 was considered statistically significant.
resulTs
A total of 1533 consecutive patients were evaluated. Mean age of the patient population 
was 61.3 ± 12.2 years and mean LV ejection fraction was 45.8 ± 8.6% (Table 1). Before 
primary PCI, mean TIMI flow of all patients was 0.6 ± 1.0. Among the 1533 culprit lesions 
studied, the majority of the patients showed a 100% stenosis (1013 patients, 66%) or 99% 
stenosis (279 patients, 18%). Only 6 (0.4%) patients showed a culprit lesion with 50% 
stenosis, 78 (5%) patients with 75% stenosis and 157 (10%) patients with 90% stenosis as 
determined by semiquantitative grading.
Table 2 shows the distribution of the culprit lesions. The majority of the culprit lesions 
were located in the left anterior descending coronary artery (LAD, 668 patients, 45%) and 
Table 1. Baseline characteristics of the patient population
All patients (N = 1533)
Clinical characteristics
 Age (years) 61.3 ± 12.2
 Male gender 1158 (76%)
Medical History
 Current smoking 715 (47%)
 Diabetes 182 (12%)
 Family history of coronary artery disease 618 (40%)
 Hyperlipidemia 299 (20%)
 Hypertension 533 (35%)
 Prior myocardial infarction 140 (9%)
Infarct size
 Peak creatine phosphokinase level (U/l) 2229 ± 2890
 Peak cardiac troponin T level (µg/l) 5.9 ± 6.5
 TIMI flow 2.9 ± 0.4
 Multivessel disease 718 (54%)
 Left ventricular ejection fraction (%) 45.8 ± 8.6
Hyperlipidemia= Total cholesterol ≥190 mg/dl or previous pharmacological treatment.
Hypertension = Blood pressure ≥140/90 mm Hg or previous pharmacological treatment.
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the right coronary artery (RCA, 588 patients, 38%) and only a small number of culprit 
lesions were located in the left circumflex coronary artery (LCX, 214 patients, 14%). Culprit 
lesions were not uniformly distributed, but tended to be clustered in the proximal or mid 
vessel segments. In addition, a relatively high percentage was located in the first obtuse 
marginal branch (41 patients, 19% of all LCX lesions). No differences in baseline character-
istics were observed between lesion localization within the coronary arteries except for prior 
myocardial infarction. Patients with prior myocardial infarction more often had the culprit 
lesion located in the distal part of the coronary artery compared to the mid and proximal 
parts (17% vs. 7% and 8%, respectively, p = 0.002).
Infarct size was assessed with peak cardiac enzymes (peak creatine phosphokinase (CPK) 
level and peak cardiac troponin T (cTnT) level) and residual LV function. Both peak CPK level 
and peak cTnT level were significantly lower in patients with a RCA culprit lesion compared 
to patients with a LAD culprit lesion (1634 ± 3424 U/l vs. 2674 ± 2565 U/l, p <0.001 and 4.0 
± 4.2 µg/l vs. 7.2 ± 7.4 µg/l, p <0.001, respectively) or a LCX culprit lesion (1634 ± 3424 U/l 
vs. 2282 ± 1830 U/l, p = 0.02 and 4.0 ± 4.2 µg/l vs. 6.0 ± 5.3 µg/l, p <0.001, respectively). 
Table 2. Distribution of coronary occlusions
Vessel segment Number of occlusions LV ejection fraction (%)
Left main (segment 11) 16 (1%) 37.1 ± 8.1
Ramus intermedius (segment 28) 15 (1%) 47.9 ± 7.5
RCA 588 (38%) 46.8 ± 8.2
 Proximal (segment 1) 249 (42%) 46.2 ± 8.4
 Mid (segment 2) 218 (37%) 47.2 ± 7.7
 Distal (segment 3) 96 (16%) 47.2 ± 8.0
 Posterior descending (segment 4) 14 (2%) 48.7 ± 11.2
 Posterior lateral (segment 6) 11 (2%) 43.8 ± 9.3
LAD 688 (45%) 44.6 ± 8.9
 Proximal (segment 12) 401 (58%) 43.7 ± 8.8
 Mid (segment 13) 243 (35%) 45.5 ± 8.9
 Distal (segment 14) 20 (3%) 45.6 ± 11.2
 Diagonal 1 branch (segment 15) 23 (3%) 50.5 ± 7.3
 Diagonal 2 branches (segment 16) 1 (0.1%) 48.0 ± 0
LCX 214 (14%) 47.4 ± 7.8
 Proximal (segment 18) 82 (38%) 45.1 ± 8.7
 Mid (segment 19) 81 (38%) 48.8 ± 6.9
 Distal segment 19a) 3 (1%) 47.7 ± 2.9
 Obtuse marginal 1 (segment 20) 41 (19%) 48.9 ± 7.0
 Obtuse marginal 2 (segment 21) 7 (3%) 49.4 ± 7.3
Bypass graft 12 (0.8%) 44.3 ± 8.6
LAD: left anterior descending coronary artery; LCX: left circumflex artery; RCA: right coronary artery 
and LV: left ventricular.
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No significant differences in peak cardiac enzymes were observed between patients with a 
LAD and LCX infarction.
In addition, the level of peak cardiac enzymes was evaluated for the proximal, mid and 
distal segments of the coronary arteries. The RCA and LCX demonstrated no significant 
differences for the proximal, mid or distal culprit lesions (RCA: p = 0.71 and p = 0.37 and 
LCX: p = 0.11 and p = 0.07 for peak CPK level and peak cTnT level, respectively). However, 
LAD proximal culprit lesions resulted in significant higher peak cardiac enzymes compared 
to lesions in the mid part (3192 ± 2886 U/l vs. 2092 ± 1885 U/l, p <0.001 and 8.4 ± 8.0 
µg/l vs. 5.8 ± 6.5 µg /l, p <0.001) or the distal part of the LAD (3192 ± 2886 U/l vs. 1261 ± 
1219 U/l, p = 0.005 and 8.4 ± 8.0 µg/l vs. 4.0 ± 4.2 µg/l, p = 0.04).
Residual LV function assessed with LV ejection fraction differed significantly between 
patients with different culprit vessels (ANOVA p <0.001) (Table 1). Post-hoc analysis dem-
onstrated that patients with the LAD as culprit vessel had significantly lower LV ejection 
fraction as compared to patients with the RCA or LCX as culprit vessel (44.6 ± 8.9% vs. 
46.8 ± 8.2%, p <0.001 and 44.6 ± 8.9% vs. 47.4 ± 7.8%, p = 0.001, respectively). Further 
subanalysis of the different segments per culprit vessel revealed that patients with proximal 
culprit lesions in the LAD and LCX had significantly worse LV function compared to patients 
with mid and distal lesions (43.7 ± 8.8% vs. 45.5 ± 8.9% and 45.6 ± 11.2%, p = 0.04 for 
proximal, mid and distal LAD lesions and 45.1 ± 8.7% vs. 48.8 ± 6.9% and 47.7 ± 2.9%, 
p = 0.02 for proximal, mid and distal LCX lesions). However, no differences in LV function 
were observed for the different locations of culprit lesions in the RCA (p = 0.37).
dIscussIon
Patients with ST-segment elevation AMI treated with primary PCI were more likely to have a 
LAD or RCA culprit lesion than a LCX culprit lesion. However, infarct size assessed with peak 
cardiac enzymes demonstrated no significant differences between LAD and LCX infarctions, 
whereas RCA infarctions were significantly smaller. In addition, patients with proximal lesions 
in the LAD or LCX demonstrated worse LV function as compared to patients with lesions in 
the mid and distal parts, whereas no significant difference was observed between patients 
with proximal, mid or distal occlusions of the RCA.
The results of the present study provide further evidence for what has been described 
in smaller populations.11 Wang et al. determined the location of coronary lesions in 208 
consecutive patients with ST-segment elevation AMI.11,13 The authors showed that culprit 
lesions tended to cluster within the proximal third of the coronary vessels. However, the 
distance from the ostium to the lesion depended upon which coronary artery was involved. 
Gibson et al. described that median distances from the ostium to the culprit lesion differed 
according to the coronary artery and the distance was the smallest in the LAD, followed by 
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the LCX and the RCA.13 Interestingly, the same phenomenon has been observed in a large 
population of 30,386 patients with non-ST elevation AMI undergoing PCI described by 
Dixon et al, and thus, the current findings may be generalized for all culprit lesions including 
those of patients with unstable angina.14
Although information about the distribution of culprit lesions is important, understand-
ing why plaque ruptures are less likely to occur in the LCX and why proximal occlusions 
are more prone to rupture remains challenging. To some extent, these observations may 
be explained by the fact that ischemic events of the LCX artery are underdiagnosed due to 
limited sensitivity of the 12-lead ECG for detection of ischemia on the lateral and posterior 
walls.15,16 Previous studies have reported that only 33% of patients with a LCX occlusion 
present with ST-segment elevation on the ECG.17 Recently, From et al. confirmed this 
hypothesis by demonstrating that in a group of 1500 patients with ST-segment elevation 
and non-ST-segment elevation AMI, patients with a LCX occlusion were less likely to present 
with ST-segment elevation on ECG and were referred less frequently for primary PCI.15 How-
ever, among the group of patients presenting with non-ST-segment elevation AMI, patients 
with a LCX occlusion had the highest peak enzymes. Another explanation for the lower 
frequency of culprit lesions observed in the LCX may be the greater variation in anatomy as 
compared to the LAD and RCA. In a large proportion of the population, the LCX is relatively 
small with few pronounced side-branches, which may also explain why patients with an 
occlusion of the LCX may be more likely to present with a non-ST-segment elevation AMI or 
without any changes on the ECG.15,17 Moreover, since vessel diameter plays an important 
role in the development of atherosclerosis, it is conceivable that as a consequence also 
plaque rupture may differ among the coronary arteries. The anatomy of the LCX may result 
in lower wall shear stress, whereas proximal segments of the coronary arteries conversely 
may be areas of high shear stress which determine the risk of plaque rupture.
In conclusion, the present study demonstrates that plaque rupture resulting in ST-segment 
elevation AMI is more likely to occur in the proximal parts of the LAD and RCA. In addition, 
the location of the culprit lesions in the different coronary arteries was related to infarct size. 
Therefore, knowledge of the distribution of vulnerable lesions is important for the identifica-
tion of patients at risk for acute coronary events.
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AbsTrAcT
background
Lack of data about outcome of aggressive acute myocardial infarction (AMI) treatment in 
older patients may potentially contribute to significant underutilization of optimal treatment 
in this cohort. The authors evaluated clinical success of AMI treatment in the elderly popula-
tion and analyzed several contributing factors.
Methods
A total of 1002 consecutive and unselected AMI patients were admitted between 2006 and 
2009. Patients were divided into 2 groups according to age: 841(84%) patients <75years 
and 161(16%) patients ≥75years. All were treated according to the MISSION! AMI protocol. 
Baseline characteristics, time delay from onset of symptoms to arrival at the catheterization 
room, 1year mortality, medication at discharge and compliance at 12months were docu-
mented.
results
Age group ≥75years had 20% less male patients, as well as lower prevalence of risk factors 
for coronary artery disease. More than 90% of AMI patients in both age groups were treated 
with primary PCI, with similar initial procedural success. Patients ≥75years had significantly 
longer time delays than patients <75years (median 193minutes vs. 150minutes respectively, 
p=0.033). In-hospital mortality was significantly higher in older AMI patients. However, age 
was only a significant independent predictor of 90day mortality. After 3months, low ejec-
tion fraction and diabetes were more important predictors. Patients ≥75years attending the 
outpatient clinic 1year post MI were as persistent with their medication as younger patients.
conclusions
Despite a significantly higher mortality <3months post-MI in older patients, surviving patients 
have the potential to gain significant advantage from aggressive reperfusion, optimal medi-
cation and regular follow-up in the first year post-MI.
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InTroducTIon
Despite the greater incidence and risk of acute myocardial infarction (AMI) among older 
patients1-3, there is still a considerable lack of data regarding success of aggressive AMI treat-
ment in this group and factors contributing to clinical outcome. Several factors thought to 
contribute to the higher AMI mortality associated with older age are a higher prevalence of 
atypical clinical presentation delaying diagnosis3, less persistent use of medication4, as well as 
cardiovascular structural and physiological changes that predispose patients to more adverse 
outcomes with and without reperfusion therapy5-8. Nevertheless, patients 75 years of age 
and older with AMI, constitute a heterogeneous group and lack of data about outcome of 
aggressive AMI treatment may potentially contribute to significant underutilization of optimal 
AMI treatment in this cohort3;9. Moreover, the need for data regarding clinical characteristics 
and outcome of elderly AMI patients is ever increasing, as they constitute a rapidly growing 
group in the Western world10. The present study aims to provide more insight into the clinical 
profile, presentation delays, medication compliance and outcome of treatment in the elderly 
AMI population up to one year post myocardial infarction (MI).
MeThods
Patient population and protocol
Consecutive and unselected patients presenting from January 2006 to January 2009 with 
AMI at the Leiden University Medical Center were included in the present study. Patients were 
all treated according to the MISSION! AMI protocol, as previously described in detail11. The 
protocol is based on ACC/AHA/ESC guidelines2 for the treatment of AMI and focuses on the 
reduction of onset of symptoms-to-balloon time, optimization of pharmacological treatment, 
and structured secondary prevention during follow-up. In brief, all patients considered eligible 
for primary percutaneous coronary intervention (PCI) had electrocardiographic ST segment 
changes and additional evidence supporting the clinical diagnosis of an acute MI, including 
prolonged ischemic signs and symptoms (≥20 minutes), biomarker evidence of myocardial 
necrosis, or both12. Eligible patients were transferred directly to the PCI center’s Cardiac Care 
Unit. The catheterization room was operational within 20 minutes, 24 hours a day, 7 days 
a week. Before the procedure all patients received 300 mg of aspirin, 300 to 600 mg of 
clopidogrel, and an intravenous bolus of abciximab (25 µg/kg), followed by a continuous 
infusion of 10 µg/kg/min for 12 h. At start of the procedure, 5,000 IU of heparin was given. 
Lesions were treated according to current interventional practice. MI was confirmed by detec-
tion of rise and/or fall of cardiac biomarkers with at least one of the following: (1) symptoms 
of ischemia: (2) ECG changes indicative of new ischemia development of the pathological Q 
wave, (3) imaging of new loss of viable myocardium or new regional wall motion abnormality.
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follow-up
After hospital discharge, patients were offered a cardiac rehabilitation program and benefited 
from intensive out-patient follow up for the period of 1 year11. Outpatient clinic visits were 
scheduled for 30 days, 3 months, 6 months and 12 months after the index event.
data collection
Data of all patients (including baseline characteristics, time delay, cardiac history, and medica-
tion up to one year) was recorded by medical staff at the department of cardiology. All data 
was documented in the departmental electronic patient system (EPD-Vision®, LUMC, Leiden, 
The Netherlands). Survival status at 12 months was ascertained by medical records and data 
from the community population registry.
endpoints
Baseline clinical characteristics, time delay (minutes) from onset of symptoms to arrival at 
the catheterization room, 1-year mortality, medication at hospital discharge, and medication 
compliance at 12 months were all points of interest.
statistical analysis
Continuous data are expressed as mean (±standard deviation) or as median (25th-75th per-
centile); dichotomous data are presented as numbers and percentages. Differences between 
categorical data were tested for statistical significance using a Pearson chi-square test using 
continuity correction where appropriate. Continuous normally distributed data were tested 
by student t-tests or in the case of a non-Gaussian distribution by a nonparametric test for 
independent samples. Survival was analyzed by method of Kaplan-Meier with corresponding 
log-rank test for differences in distribution between the curves. Univariate and multivariate 
Cox regression analysis was performed to determine a relation between potential risk factors 
at baseline and the incidence of all cause death. All variables with an unadjusted p value of 
<0.10 entered the multivariate regression model. A wide range of variables were considered 
including age, gender, clinical characteristics such as risk factors for CAD, cardiac history, 
treatment delay, and procedure and infarction related characteristics (see table 1). Only 
adjusted Hazard Ratio (HR) is reported in the text with the corresponding 95% confidence 
interval (CI). Also, univariate and multivariate logistic regression analysis was performed 
using the same methodology as described above to determine a relation between potential 
risk factors at baseline and time delay ≥150 minutes. Variables considered included age, 
gender, risk factors for CAD and cardiac history. Only adjusted Odds Ratio (OR) is reported in 
the text with the corresponding 95% CI. All tests were two-sided, a p-value of < 0.05 was 
considered significant.
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resulTs
Patient population
A total of 1002 consecutive AMI patients were admitted at the PCI center between 2006 
and 2009. For study purposes, patients were divided into two groups according to age at 
presentation: 841 (84%) patients younger than 75 years and 161(16%) patients ≥75 years.
clinical characteristics
Clinical characteristics according to age group are shown in Table 1 and figure 1. The statisti-
cally most significant differences between patients ≥75 years and patients <75 years were a 
20% lower proportion of male patients in the older patient group (Figure 1, panel A), as well 
as a lower prevalence of risk factors such as smoking, hyperlipidemia, BMI ≥30 kg/m2 and 
family history of coronary artery disease (CAD). In addition, Figure 1, Panel B demonstrates 
that older patients were less likely to have ≥3 risk factors for CAD. Table 1 furthermore shows 
that more patients aged ≥75 years were using cardiovascular and antiplatelet agents prior to 
the index event compared to younger patients.
More than 90% of AMI patients in both age groups were treated with percutaneous 
coronary intervention (Table 1). Significantly more patients in the age group ≥75 years 
were observed with multi-vessel disease, however LAD related infarctions were equally 
distributed between the two age groups. A similar percentage of patients failed to attain a 
postprocedural Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 in both age groups 
(Table 1).
Time delay and infarct size
Figure 1, Panel C, shows that older patients had significantly longer time delays from onset of 
symptoms to arrival at the catheterization room than patients younger than 75 years (median 
193 minutes versus 150 minutes respectively, p=0.033). Due to the larger proportion of 
female patients in the older group, an additional analysis was conducted to evaluate how 
gender influenced the difference in time delay between the age groups. When split up by 
gender, male patients ≥75 years had a median 20 minute longer time delay than younger 
male patients. Older female patients had a median 45 minute longer time delay when 
compared to female patients <75 years. When considering age and gender in a multivariate 
logistic regression analysis, age ≥75 years remained a significant predictor of time delay 
≥150 minutes from symptom onset to arrival at the catheterization room (OR 1.51, 95% CI 
1.05-2.16, p=0.026), while gender did not (OR 1.31, 95% CI 0.95-1.80, p=0.098). However, 
interaction between age ≥75 years and female gender was observed, increasing the OR to 
2.15 (95% CI 1.25-3.70, p=0.006) for a time delay ≥150 minutes.
In line with these findings, peak troponin T values were significantly higher in older 
patients compared to the younger patients (median 4.31 µg/L versus 3.22 µg/L respectively, 
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p=0.008) (Table 1). Of note, when patients who died in-hospital were excluded from this 
Table 1. Baseline characteristics
Age group (years)
<75y
(n=841)
≥75y
(n=161)
p-value
Male gender 669 (79%) 93 (58%) <0.001*
Mean age (years±SD) 57±10 80±4 <0.001*
   Range (min-max) 22-74 75-91
Risk factors
  Smoking 494 (59%) 47 (29%) <0.001*
  Family History 380 (45%) 30 (19%) <0.001*
  Hyperlipidemia † 181 (22%) 18 (11%) 0.003*
  Hypertension ‡ 287 (34%) 75 (47%) 0.002*
  Diabetes Mellitus 104 (12%) 28 (18%) 0.08
  BMI ≥30 kg/m2 156 (19%) 21 (13%) 0.19
Cardiac History
  Prior Myocardial Infarction 90 (11%) 21 (13%) 0.36
  Prior percutaneous coronary intervention 72 (9%) 8 (5%) 0.14
  Prior coronary artery bypass grafting 17 (2%) 9 (6%) 0.018*
Medication before MI
  Beta-blocker 163 (19%) 44 (27%) 0.020*
  Aspirin 137 (16%) 48 (30%) <0.001*
  Statin 165 (20%) 30 (19%) 0.81
  ACE-inhibitor 97 (12%) 31 (19%) 0.007*
  Angiotensine II-antagonist 61 (7%) 17 (11%) 0.14
  Diuretic 85 (10%) 31 (19%) 0.001*
  Ca-antagonist 76 (9%) 28 (17%) 0.001*
Time delay:
   Onset symptoms-cath. room 
(median min [interquartile range])
150 (101-281) 193 (120-288) 0.033*
Procedure related:
   Percutaneous coronary intervention 788 (94%) 149 (93%) 0.59
   Coronary artery bypass grafting 5 (1%) 2 (1%) 0.70
   Conservative treatment 48 (6%) 10 (6%) 0.80
   Multivessel disease 427 (51%) 106 (66%) 0.001*
   Related to left anterior descending artery 340 (40%) 65 (40%) 0.99
   Postprocedural TIMI flow grade <3 66 (8%) 16 (10%) 0.34
Infarction size related:
   Peak troponin T (median µg/L [interquartile range]) 3.22 (1.20-6.75) 4.31 (1.71-8.08) 0.008*
   Peak CPK (median U/L [interquartile range]) 1322 (586-2635) 1366 (634-2442) 0.96
   LVEF 3 months post-MI (%) 56 (46-63) 57 (47-66) 0.44
In-hospital deaths 6 (1%) 17 (11%) <0.001*
* p<0.05; † Total cholesterol ≥190 mg/dl or previous pharmacological treatment. 
‡ Blood pressure ≥140/90 mm Hg or previous pharmacological treatment.
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figure 1. Baseline characteristics according to age group.
Panel A: Gender distribution (%).
Panel B: Prevalence of 0, 1-2 and ≥3 risk factors for coronary artery disease per age group (%).
Panel C: Bar graph showing time interval from onset of symptoms to arrival at the catheterization room 
(minutes) per age group. Top of bar represents median time (minutes). Error bars indicate 25th and 75th 
percentiles.
analysis, peak troponin T values were not significantly different between the old and young 
age groups (median 3.83 µg/L versus 3.19 µg/L respectively, p=0.083). Correspondingly, at 
3 months post-MI the mean left ventricular ejection fraction (LVEF, derived 99m tetrofosmin 
gated myocardial perfusion SPECT) of surviving patients was similar between the age groups 
(Table 1).
survival
One year survival data was complete for all patients (n=1002). In-hospital mortality was 
significantly higher in patients aged 75 years and older when compared to younger patients 
(17/161, 11% versus 6/841, 0.7%, respectively; p<0.001). All of these early deaths were 
caused by complications related to the index event.
Figure 2 demonstrates 1-year cumulative all-cause mortality stratified by age group. Panel 
A demonstrates that the trend of higher mortality in the age group ≥75 years compared 
to the age group <75 years was continued throughout the first year (p<0.001). Eighteen 
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percent of patients (n=29) died within the first year post-MI in the age group ≥75 years, 
compared to 2% of patients (n=20) in the age group <75 years. Panel B emphasizes the more 
pronounced difference in the cumulative rate of relatively early deaths post-MI (landmark 
set at 90 days) and shows that both early and late (from 90 days to 1 year) mortality was sig-
nificantly higher in the group aged ≥75 years. Multivariable Cox regression analysis of 0 to 
90 day mortality revealed that age (adjusted HR 1.14, 95%CI 1.08-1.19, p<0.001), post-
procedural TIMI flow grade <3 (adjusted HR 8.74, 95%CI 3.72-20.52, p<0.001), and time 
from onset of symptoms to arrival at the catheterization room (adjusted HR 1.001, 95%CI 
1.00-1.001, p=0.009) were strong independent predictors of early mortality with TIMI flow 
grade <3 being the strongest predictor (Table 2). Multivariable Cox regression analysis of 90 
day -1 year mortality revealed only diabetes (adjusted HR 4.39, 95% CI 1.24-15.6, p=0.022) 
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figure 2. Mortality
Panel A: Kaplan-Meier plot of the cumulative incidence of all-cause death.
Panel B: Landmark incidence analysis plot of the cumulative incidence of all-cause death.
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and left ventricular ejection fraction (adjusted HR 0.94, 95% CI 0.89-0.98, p=0.005) as 
significant independent predictors of death (Table 2).
Medication prescription and compliance
Table 3 shows medication prescription at hospital discharge, the number of (alive) patients 
that failed to attend the 12 month appointment at the outpatient clinic and the percentage 
of patients (as proportion of the patient group that did attend) that were still on optimal 
medication at 12 months.
Medication prescription at discharge was more or less optimal in both age groups. 
When aspirin was not prescribed at discharge, it was often due to anticoagulant treatment 
(alongside clopidogrel). In such cases aspirin was withheld in order to avoid increased risk of 
bleeding complications. Anticoagulants were prescribed in case of atrial fibrillation, severely 
impaired LV function or LV aneurysm.
A significantly larger percentage of patients in the age group ≥75 years failed to return to 
the outpatient clinic at 12 months when compared to the younger age group (37% of 132 
alive patients versus 16% of 820 alive patients, respectively; p<0.001). However, medication 
compliance in the patients that did attend at 12 months was high and similar between the 
age groups.
Table 2. Association with mortality 0-90 days post-MI and 90 days - 1 year post-MI.
Mortality 0 - 90 days
Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value
Age 1.12 (1.10-1.16) <0.001 1.14 (1.08-1.19) <0.001*
Male gender 0.55 (0,27-1.11) 0.093 1.01 (0.40-2.50) 0.99
Treatment delay 1.000 (1.00-1.001) 0.014 1.001 (1.00-1.001) 0.009*
Multivessel disease 1.97 (0.90-4.32) 0.091 1.37 (0.52-3.60) 0.53
TIMI flow grade <3 6.29 (3.03-13.0) <0.001 8.74 (3.72-20.52) <0.001*
Mortality 90 days – 1 year
Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value
Age 1,05 (1.01-1.10) 0.020 1.05 (0.98-1.12) 0.19
Diabetes Mellitus 4.06 (1.48-11.18) 0.007 4.39 (1.24-15.6) 0.022*
Prior MI 2.73 (0.88-8.46) 0.082 1.81 (0.43-7.63) 0.42
LVEF 0.94 (0.90-0.98) 0.001 0.94 (0.89-0.98) 0.005*
Only significant variables shown. These were the variables that were incorporated into the multivariate 
model (variables with an unadjusted p-value of <0.10). Unadjusted and adjusted Hazard Ratio (HR) is 
reported with the corresponding 95% confidence interval (CI). * p<0.05
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dIscussIon
Key findings of this study were (1) AMI patients in the age group of ≥75 years presented with 
significantly less modifiable risk factors of CAD than younger AMI patients; (2) In-hospital 
mortality was significantly higher in older AMI patients than in younger AMI patients despite 
similar postprocedural TIMI flow grades, and: (3) Despite a significantly higher cumulative 
incidence of mortality 1 year post-MI in older AMI patients, age was only a significant 
independent predictor of 90 day mortality. In the period of 90 days to 1 year post-MI other 
contributing risk factors such as LV ejection fraction and diabetes were more important 
predictors of mortality.
Elderly patients included in this study had less modifiable risk factors of CAD than younger 
patients, a so-called “survivor effect” that was also seen in other studies 3;13. It is not unrea-
sonable that older patients, who experience MI at a later stage in life, are likely to have 
less risk factors for CAD than those who experience MI at a younger age. Furthermore, 
as patients were unselected and consecutively enrolled in the study, they truly reflect the 
patient population in the region of the PCI center, which may be a more healthy population 
than the patients enrolled in other studies 14;15. The significantly longer treatment delays in 
the older patient group were in part caused by the larger proportion of female patients as 
demonstrated by multivariate logistic regression analysis, but other contributing factors that 
were not considered may include atypical symptoms, electrocardiographic presentations that 
Table 3. Medication prescription, follow-up and compliance.
Age group (years) <75y ≥75y p-value
Hospital discharge: (n=841) (n=161)
Alive at discharge 835/841 (99%) 144/161 (89%) <0.001*
   Aspirin 793/835 (95%) 135/144 (93%) 0.49
   Statin 818/835 (98%) 140/144 (97%) 0.60
   Beta blocker 793/835 (95%) 132/144 (92%) 0.28
   Clopidogrel 810/835 (97%) 140/144 (97%) 1.00
   ACE inhibitor 810/835 (97%) 135/144 (94%) 0.08
Alive 1 year post-MI 820/841 (98%) 132/161 (82%) <0.001*
Failed to attend 12 month visit 131/820 (16%) 49/132 (37%) <0.001*
12 Month Visit: (n=689) (n=83)
   Aspirin 623/689 (90%) 72/83 (87%) 0.29
   Statin 664/689 (96%) 78/83 (94%) 0.44
   Beta blocker 636/689 (92%) 75/83 (90%) 0.54
   Clopidogrel 656/689 (95%) 78/83 (94%) 0.82
   ACE inhibitor 666/689 (97%) 78/83 (94%) 0.36
* p<0.05
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were difficult to interpret, a greater likelihood that patients were first transported to a center 
without PCI facility as seen in previous studies, and perhaps a greater inclination of elderly 
patients to wait longer before alerting emergency services 3;16;17.
It is well known that elderly patients are more likely to experience an AMI and to die after 
a MI than younger patients 18. However, though it is well known that age is a significant 
risk factor for post-MI death, not all older patients are equally vulnerable to poor functional 
outcomes 14;19.
Older patients surviving the index event had similar cardiac function compared to the 
younger patients at three months post-MI. After 3 months the difference in mortality 
between the two age groups was less pronounced than in the first three months post-MI 
(borderline significant: p=0.049) and results of the multivariate analysis confirmed that age 
was no longer a significant predictor of 1-year mortality in patients surviving the first three 
months post-MI. This outcome is consistent with findings from a recent large registry study, 
which found that two out of three patients experienced a favorable functional outcome 
(neither death nor functional decline) at 1 year post-MI regardless of age 14. Other studies 
often included a patient population in which older patients were treated less aggressively 
and with less patients undergoing primary PCI than the younger patients 3 or included 
patients from a time period when AMI treatment was not up to current standards 13. Also, 
most of these studies divided mortality into 30 day mortality and 1 year mortality, not 
looking at other time windows.
Although older post-MI patients have consistently been shown to receive fewer evidence-
based treatments, even when eligible20-23, patients surviving the acute phase post-MI have 
similar potential for favorable outcomes to those of younger patients as evidenced by results of 
the present study and other studies 14 where patients of both age groups were treated equally 
aggressive. Prescription of beneficial cardiovascular medication at discharge was optimal in 
post-MI patients of all ages in the population studied, an encouraging finding as medication 
underuse at discharge is not uncommon in older patients 15. Of the surviving patients at 1 year 
post-MI 20% more patients of the older age group failed to return to the outpatient clinic 
compared to younger patients, possibly related to more comorbidities or the perception that 
follow-up was not needed. It has been reported before that older patients are less likely to be 
persistent with evidence-based cardiovascular medicine after discharge from an acute coro-
nary syndrome event 4. However, surviving patients of the older age group that returned to 
the outpatient clinic were as persistent with their medication regimen as the younger patients, 
possibly a positive effect of the intensive follow-up of the MISSION! outpatient protocol 11.
limitations
There are potential limitations to the present study that should be considered when interpret-
ing the results. As this was a single center, single region study, conclusions may not pertain 
to patients of other centers or regions. Furthermore, as data on prevalence of baseline risk 
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factors and baseline medication use was derived largely from patient self-report, it should be 
considered with the necessary caution.
Finally, as this is an observational study, there is a possibility of unmeasured confounding. 
However, due to the large amount of data that was available for the study population, 
it was possible to adjust for a wide range of potential confounders in the multivariable 
analysis, and these did not alter the findings.
conclusIon
Given that old age is associated with greater morbidity and mortality after a MI, most cli-
nicians would have considered age to remain the most important risk factor of mortality 
throughout the first year post-MI. However, results demonstrated that older patients surviv-
ing the first 3 months post-MI have similar outcomes to younger patients in terms of cardiac 
function and that age was a not a significant risk factor of 1-year mortality in survivors three 
months after MI. Therefore, though conservative treatment may be the adequate choice for 
some patients, results of this study suggest that older patients have the potential to gain 
significant advantage from aggressive and invasive AMI treatment and that age alone should 
not preclude intensive treatment after an MI.
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AbsTrAcT
objectives
The aim was to evaluate the prognostic value of heart rate in patients with acute myocardial 
infarction (AMI) treated with primary percutaneous coronary intervention (PCI).
background
Recently, heart rate has been described as an important risk factor for reinfarction, revascular-
ization and heart failure in patients with left ventricular dysfunction. Currently, most patients 
with AMI are treated with primary PCI and left ventricular function is relatively preserved. The 
clinical relevance of heart rate in this patient population is unknown.
Methods
A total of 1102 consecutive AMI patients treated with primary PCI were evaluated. Heart 
rate was measured by 12-lead electrocardiography at time of admission. The endpoint was 
a composite of all-cause mortality, nonfatal reinfarction, coronary revascularization and 
hospitalization for heart failure.
results
During a mean follow-up of 20 months, 89 patients died (8%), 38 patients (3%) had a 
nonfatal reinfarction, 169 patients (15%) underwent revascularization and 45 patients (4%) 
were hospitalized for heart failure. After adjustment for known risk factors, a heart rate of 
72bpm or higher was associated with a significant increased risk for the composite endpoint 
and all separate events. In addition, every increase of 5bpm resulted in an increased adjusted 
relative risk of 8% for the composite endpoint, 9% for mortality, 17% for reinfarction, 7% 
for revascularization and 11% for hospitalization for heart failure.
conclusions
Baseline resting heart rate is a strong risk factor for adverse outcome in AMI patients and 
preserved left ventricular function. The present study provided further evidence for targeting 
low heart rate in patients after AMI.
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InTroducTIon
Resting heart rate is a simple cardiovascular parameter and has been well established as a 
strong predictor of mortality in patients with coronary artery disease.1,2 Recently, heart rate 
has also been described as a risk factor for cardiovascular morbidity including reinfarction, 
revascularization and hospitalization for heart failure in patients with left ventricular dysfunc-
tion. The BEAUTIFUL study demonstrated that an elevated heart rate of 70 bpm or greater 
identified patients at increased risk of cardiovascular outcomes in patients with coronary 
heart disease and left ventricular dysfunction.3 Acute myocardial infarction (AMI) is a major 
health problem in the western world despite the improved treatment strategies including 
reperfusion therapy.4 Currently, most patients with AMI are treated with primary percutane-
ous coronary intervention (PCI), and therefore, left ventricular function is relatively preserved. 
The clinical relevance of resting heart rate in that currently growing population of post-AMI 
patients with preserved left ventricular function is unknown. Accordingly, the aim of the 
current study was to evaluate the relation between resting heart rate and long-term mortality 
and cardiovascular morbidity in patients with AMI treated with primary PCI. Importantly, all 
patients in the present patient population were treated with structurized evidence-based 
medical therapy including a high level of beta-blockers, initiated early after admission.5,6
MeThods
Patient population and study design
Since February 2004 consecutive patients admitted with an AMI with ST-segment elevation 
to our university hospital were included in an ongoing registry. All patients were treated 
with primary PCI according to the institutional AMI protocol, which is based upon the most 
recent American College of Cardiology/American Heart Association guidelines.7 This pro-
tocol, designed to improve care around AMI, includes structurized evidence-based medical 
therapy, two-dimensional echocardiography and standardized follow-up at the outpatient 
clinic during 1 year after the index infarction, as described previously.5 Echocardiography 
was performed within 48 hours of admission to quantify left ventricular ejection fraction 
according to the recommended biplane Simpson’s method.8 In addition, resting heart rate 
was measured by 12-lead electrocardiography at time of admission.
follow-up and endpoint definitions
All patients were followed prospectively according to the institutional protocol and the 
occurrence of adverse cardiac and non-cardiac events after the index infarction was noted.5 
Patients of whom more than 6 months follow-up data were lacking, were considered as lost 
to follow-up, and were excluded from further analysis. The primary endpoint was a composite 
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of all-cause mortality, nonfatal reinfarction, coronary revascularization and admission to 
hospital for new-onset of worsening heart failure. In addition, all clinical outcomes included 
in the composite endpoint were evaluated as individual endpoints. Nonfatal reinfarction was 
defined based on criteria of typical chest pain, elevated cardiac enzyme levels, and typical 
changes on the electrocardiogram.9 All coronary revascularizations after discharge of the 
index infarction were included for the secondary endpoint.
statistical analysis
Continuous data are presented as mean ± standard deviation and categorical data are pre-
sented as frequencies and percentages. Differences between groups were evaluated using 
the unpaired Student’s t test and chi-square test, where appropriate.
Elevated baseline heart rate was analyzed as a continuous variable, dichotomized accord-
ing to a cutoff value of 72 bpm and categorized into intervals of 5 bpm. The cutoff of 72 
bpm was derived from the patient population as the median heart rate of the total popula-
tion and is in line with previous studies assessing the risk associated with an elevated heart 
rate.1-3,10 Cox proportional hazards regression analyses were performed to relate elevated 
baseline heart rate to the different endpoints, adjusting for all variables with significant 
baseline differences between the patients with a heart rate less than 72 bpm and 72 bpm 
or greater. Peak creatine phosphokinase level and diastolic blood pressure were excluded 
from multivariate analysis to avoid co-linearity with peak cardiac troponin T level and systolic 
blood pressure.
Event rates were plotted in Kaplan-Meier curves for the composite endpoint and all 
separate clinical outcomes and the study population divided by the cutoff of 72bpm, and 
groups were compared using the log-rank test.
Finally, the incremental value of baseline resting heart rate as a continuous variable in 
addition to clinical risk factors for adverse outcome was assessed by comparison of model 
chi-square values. For this purpose, those characteristics were entered in the Cox proportional 
hazard model in a stepwise fashion. Subsequently, heart rate was entered individually. All sta-
tistical tests were two-sided, and a P value <0.05 was considered to be statistically significant.
resulTs
Patient characteristics and follow-up
A total of 1193 patients were included. Four (0.3%) patients died before an electrocardio-
gram could be performed and 87 (7.3%) patients were lost to follow-up and were excluded 
from further analysis. The final patient population therefore comprised 1102 patients. The 
baseline characteristics of the patients are shown in Table 1. Patients with a heart rate of 
72 bpm or greater were more likely to have diabetes, the left anterior descending coronary 
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artery as the culprit vessel, higher peak cardiac enzymes, higher blood pressures, lower left 
ventricular ejection fraction and were less likely to be treated with beta-blockers at discharge.
During a mean follow-up duration of 20 ± 14 months, 277 patients (25%) reached the 
composite endpoint: 89 patients died (8%), 38 patients (3%) had a nonfatal reinfarction, 
169 patients (15%) underwent revascularization and 45 patients (4%) were hospitalized 
for heart failure.
Table 1. Baseline characteristics of patients
All Patients
(n =1102)
Heart rate <72 bpm
(n=537)
Heart rate ≥72 bpm
(n=565)
P*
Age (years) 61 ± 12 61 ± 12 60 ± 12 0.32
Male gender 852 (77%) 422 (79%) 430 (76%) 0.33
Killip class ≥2 76 (7%) 30 (6%) 48 (9%) 0.06
Current smoking 536 (49%) 270 (49%) 284 (53%) 0.19
Diabetes 127 (12%) 47 (9%) 80 (14%) 0.004
Family history of CAD 454 (43%) 226 (43%) 228 (42%) 0.89
Hyperlipidemia 214 (20%) 95 (18%) 119 (22%) 0.12
Hypertension 351 (32%) 169 (32%) 182 (33%) 0.63
Prior myocardial infarction 91 (8%) 40 (7%) 51 (9%) 0.34
LAD culprit vessel 513 (47%) 214 (40%) 299 (53%) <0.001
Multivessel disease 551 (50%) 256 (48%) 295 (52%) 0.13
Peak CPK level (U/l) 2406 ± 3132 2154 ± 3659 2685 ± 2471 0.01
Peak cTnT level (µg/l) 6.4 ± 6.9 5.6 ± 5.5 7.1 ± 7.9 <.001
Heart rate at admission (bpm) 74 ± 18 60 ± 9 88 ± 14
TIMI flow 2.9 ± 0.4 2.9 ± 0.4 2.9 ± 0.4 0.15
Systolic blood pressure (mm Hg) 135 ± 25 133 ± 25 137 ± 24 0.001
Diastolic blood pressure (mm Hg) 81 ± 16 78 ± 15 83 ± 16 <0.001
Left ventricular ejection fraction (%) 45 ± 9 46 ± 8 44 ± 9 <0.001
ACE inhibitor / ARB at admission 173 (16%) 81 (15%) 92 (16%) 0.57
Antiplatelets at admission 171 (16%) 81 (15%) 90 (16%) 0.68
Beta-blocker at admission 203 (19%) 111 (21%) 92 (16%) 0.07
Statins at admission 181 (17%) 82 (15%) 99 (18%) 0.28
ACE inhibitor / ARB at discharge 1037 (97%) 513 (97%) 524 (98%) 0.24
Antiplatelets at discharge 1065 (100%) 530 (100%) 535 (100%) 1.00
Beta-blocker at discharge 1003 (94%) 490 (93%) 513 (96%) 0.02
Statins at discharge 1056 (99%) 528 (100%) 528 (99%) 0.10
*P values are given for the comparison of patients who died of all-cause mortality versus patients who 
survived.
Hyperlipidemia= Total cholesterol ≥190 mg/dl or previous pharmacological treatment.
Hypertension = Blood pressure ≥140/90 mm Hg or previous pharmacological treatment.
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; CAD = coronary artery 
disease; CPK = creatine phosphokinase; cTnT = cardiac troponin T; LAD = left anterior descending 
coronary artery.
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Increased risk of adverse outcome associated with elevated heart rate
Table 2 shows the increased risk of adverse events associated with an elevated heart rate 
adjusted for all variables with significant differences between the groups with a heart rate less 
than 72 bpm and 72 bpm or greater. A resting heart rate of 72 bpm or higher was associated 
with a significant increased risk of all endpoints (Table 2). In addition, analyses with heart 
rate as a continuous variable showed that every increase of 5 bpm resulted in a significant 
higher risk for every endpoint. An increased adjusted relative risk of 8% was observed for the 
composite endpoint, 9% for mortality, 17% for reinfarction, 7% for revascularization and 
11% for hospitalization of heart failure for every increase of 5 bpm.
Table 2. Adjusted hazard ratios for elevated heart rate at admission
Events, n (%) Heart rate ≥72 versus <72 bpm Heart rate higher by 5 bpm
Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
Composite endpoint 277 (25%) 1.57 (1.20 – 2.05) 0.001 1.08 (1.04 – 1.12) <.001
Mortality 89 (8%) 1.94 (1.04 – 3.63) 0.04 1.09 (1.02 – 1.16) 0.01
Reinfarction 38 (3%) 2.41 (1.16 – 5.00) 0.02 1.17 (1.09 – 1.25) <0.001
Revascularization 169 (15%) 1.40 (1.02 – 1.91) 0.04 1.07 (1.03 – 1.11) 0.001
Heart Failure 45 (4%) 2.50 (1.21 – 5.16) 0.01 1.11 (1.03 – 1.19) 0.006
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figure 1. Cumulative risk of adverse events after acute myocardial infarction.
Kaplan-Meier time-to-event plots for baseline resting heart rate with a cutoff of 72 bpm and the com-
posite endpoint, all-cause mortality, reinfarction, revascularization and hospitalization for heart failure.
Prognostic value of heart rate in patients after acute myocardial infarction 127
Kaplan-Meier curves for the cutoff of 72 bpm and all endpoints are shown in Figure 1. 
The 4 year event rate in patients with a heart rate lower than 72 bpm compared to patients 
with a heart rate of 72 bpm or higher was 28% vs. 45% (P <.001) for the composite end-
point, 8% vs. 17% (P <0.001) for all-cause mortality, 4% vs. 7% (P <0.001) for reinfarction, 
19% vs. 28% (P = 0.009) for revascularization and 3% vs. 12% (P <.001) for hospitalization 
of heart failure.
Analyses of more comprehensive classification of baseline resting heart rates relative 
to a heart rate lower than 67 bpm are shown in Table 3. Interestingly, for all endpoints 
only a heart rate of 77 bpm or higher showed a significant increase in relative risk and the 
intermediate heart rate groups of 67 – 72 bpm and 72 – 77 bpm showed no increased risk.
The incremental prognostic value of baseline resting heart rate was assessed by calculating 
global chi-square values. Figure 2 shows that heart rate demonstrated to provide incremen-
tal value to baseline clinical information (diabetes, left anterior descending coronary artery 
as the culprit vessel, peak cardiac troponin T level, systolic blood pressure, left ventricular 
ejection fraction and treatment with beta-blockers at discharge) for the prediction of all 
clinical endpoints.
Table 3. Hazard ratios according to heart rate group
Hazard Ratio (95% CI) P
Composite endpoint Heart rate <67 bpm 1.00
Heart rate 67 – 72 bpm 0.92 (0.58 – 1.44) 0.70
Heart rate 72 – 77 bpm 1.18 (0.73 – 1.90) 0.50
Heart rate ≥77 bpm 1.96 (1.49 – 2.59) <0.001
Mortality Heart rate <67 bpm 1.00
Heart rate 67 – 72 bpm 0.57 (0.19 – 1.66) 0.30
Heart rate 72 – 77 bpm 0.79 (0.27 – 2.31) 0.67
Heart rate ≥77 bpm 2.72 (1.64 – 4.51 <0.001
Reinfarction Heart rate <67 bpm 1.00
Heart rate 67 – 72 bpm 0.28 (0.04 – 2.18) 0.22
Heart rate 72 – 77 bpm 1.19 (0.33 – 4.34) 0.79
Heart rate ≥77 bpm 2.20 (1.05 – 4.59) 0.04
Revascularization Heart rate <67 bpm 1.00
Heart rate 67 – 72 bpm 0.92 (0.54 – 1.57) 0.76
Heart rate 72 – 77 bpm 1.18 (0.67 – 2.06) 0.57
Heart rate ≥77 bpm 1.41 (1.00 – 1.99) 0.05
Heart failure Heart rate <67 bpm 1.00
Heart rate 67 – 72 bpm 1.88 (0.53 – 6.66) 0.33
Heart rate 72 – 77 bpm 2.01 (0.50 – 8.05) 0.32
Heart rate ≥77 bpm 5.13 (2.14 – 12.28) <0.001
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dIscussIon
The major finding of the current study was that baseline resting heart was a strong predictor 
of all-cause mortality, reinfarction, revascularization and heart failure in patients with AMI 
and relatively preserved left ventricular function. Moreover, for the prediction of all endpoints, 
resting heart rate provided incremental value to the traditional risk factors including the pres-
ence of diabetes, the left anterior descending coronary artery as culprit vessel, peak cardiac 
enzymes, blood pressure, left ventricular ejection fraction and treatment with beta-blockers.
The current results indicate for the first time the importance of heart rate control in patients 
with AMI and preserved left ventricular function. In patients with left ventricular dysfunction, 
an elevated heart rate has been described as an important risk factor for mortality and adverse 
events.3 However, data about the relation between heart rate and patients with preserved 
left ventricular function after AMI are scarce. Several large trials have demonstrated the 
A B
C D E
Composite endpoint
Heart failureRevascularizationReinfarction
All-cause mortality
Clinical Clinical + HR
Clinical
Clinical
Clinical ClinicalClinical + HR Clinical + HR Clinical + HR
Clinical + HR
p = 0·02
p <0·001
p = 0·001
p = 0·004
p <0·001
 
 
En in tiff 
 
figure 2. Incremental value of heart rate for the prediction of adverse events.
Incremental value of heart rate to baseline clinical information (diabetes, left anterior descending coro-
nary artery as the culprit vessel, peak cardiac troponin T level, systolic blood pressure, left ventricular 
ejection fraction and treatment with beta-blockers at discharge) for the prediction of the composite 
endpoint, all-cause mortality, reinfarction, revascularization and hospitalization for heart failure.
HR = heart rate.
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relation between beta-blocker treatment and decreased mortality after AMI.11,12 Of note, in 
the current population, all patients were treated according to the institutional protocol with 
evidence-based medical therapy including a high level of beta-blocker usage, and resting 
heart rate at admission remained an independent predictor of all endpoints after adjusting 
for treatment with beta-blockers at discharge. Every increase of 5 bpm in resting heart rate 
resulted in a significant higher adjusted risk ranging from 7% to 17% for each individual 
endpoint. These findings suggest that more aggressive lowering of heart rate in patients 
after AMI may have a beneficial effect on adverse events.
Although the association of heart rate and outcome has been investigated extensively, 
understanding the relation between heart rate and adverse events remains challenging. 
It is likely that heart rate is both a causative factor and an indicator of pathophysiologic 
processes. Heart rate influences myocardial oxygen demand and supply and consequently, 
also myocardial perfusion which may explain the strong relationship observed in the cur-
rent study with outcome in patients after AMI.13,14 In addition, an elevated heart rate has 
been associated with an increased risk of plaque rupture. Heidland et al. analyzed 106 
patients who underwent 2 coronary angiography procedures within 6 months and reported 
a positive association between plaque rupture and a mean heart rate higher than 80 bpm, 
whereas medication with beta-blockers was associated with a reduced incidence of disrup-
tion of vulnerable plaques.15
Recently, the BEAUTIFUL investigators reported that ivabradine reduced the incidence of 
myocardial infarction and revascularization in patients with stable coronary artery disease, 
left ventricular dysfunction and a heart of 70 bpm or higher.3,16 Conversely, ivabradine did 
not affect mortality and hospitalization for heart failure, suggesting that ivabradine protects 
patients more from ischaemia than from heart failure. A high resting heart is a modifiable 
risk factor, but existing medications including beta-blockers and calcium-channel blockers 
have other cardiovascular effects besides decreasing the heart rate. Ivabradine has been 
reported not to affect blood pressure, myocardial contractility, intracardiac conduction or 
ventricular repolarisation and therefore may provide pure lowering of the heart rate.17-19 
Thus far, only 1 study has been performed in patients after AMI with ivabradine demonstrat-
ing that the treatment was safe, feasible and well tolerated by the patients. Fasullo et al. 
investigated 155 patients with first anterior AMI randomized to metoprolol or ivabradine 
and reported a significant improvement in left ventricular volumes and ejection fraction in 
patients randomized to ivabradine compared to patients treated with metoprolol, but no 
difference in achieved heart rate.20 In addition, several experimental studies in pigs and rats 
have demonstrated promising results including preservation of coronary reserve, attenua-
tion of the decline in ejection fraction after AMI and significant reduction in infarct size.21-23 
Evidently, large prospective studies are needed to further determine whether a reduction in 
heart rate by ivabradine, beta-blockers or another strategy is the best approach to reduce 
the occurrence of adverse events in patients after AMI.
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limitations
Finally, although baseline resting heart rate was a strong predictor of outcome in patients 
after AMI, the predictive value of heart rate at different periods after AMI could not be 
addressed. The assessment of the time course and changes in resting heart rate in relation 
to adverse events during follow-up would be interesting and will provide more insight in 
the mechanism between heart rate and adverse events. Another potential limitation of the 
study is that all-cause mortality rather than cardiac mortality was examined, because the 
classification of cardiac death is often problematic. However, because the mean age of the 
current population was 61 ± 12 years, it is likely that most deaths were cardiac in origin.
conclusIon
In patients after AMI treated with primary PCI and preserved left ventricular function, resting 
heart rate at admission was a strong independent risk factor for all-cause mortality, rein-
farction, revascularization and hospitalization for heart failure. The present study provides 
further evidence for targeting low heart rate in the currently growing population of post-AMI 
patients with preserved left ventricular function.
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AbsTrAcT
Aim
To assess the number of patients in daily clinical practice that meets criteria for implantation 
of an implantable cardioverter defibrillator (ICD) following acute myocardial infarction (AMI) 
when treated according to an aggressive treatment protocol.
Methods
Patients were treated according to the MISSION! protocol. The protocol encompasses pre-
hospital, in-hospital and out-patient clinical framework for the acute and chronic treatment 
of AMI patients and the decision making regarding primary prevention of Sudden Cardiac 
Death (SCD).
results
A total of 676 consecutive AMI patients (78% male, mean age 59±12 years) treated accord-
ing to the MISSION! protocol were included in this analysis. LVEF at 3 months was 54±10%. 
Only 39 (6%) patients met criteria for implantation of an ICD <1 year post-MI. These patients 
suffered more extensive infarctions as indicated by higher peak troponin T values (mean 
14.5±8.3µg/l vs. 6.5±14.7µg/l; p<0.001) and had more LAD related infarctions (79% vs. 
46%; p<0.001). Cumulative first appropriate therapy rate was 15% at 3 years follow-up. No 
sudden cardiac death was observed in the study population.
conclusions
Aggressive treatment of AMI patients and close monitoring after the index event according 
to a standardized protocol, results in only a small number of patients becoming candidate for 
prophylactic ICD implantation. An easy-to-use protocol combining aggressive reperfusion, 
optimal medication and a risk stratification algorithm tailored to fit within routine practice 
may help to maintain ICD implantation rates within manageable proportions.
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InTroducTIon
Patients after acute myocardial infarction (AMI) are at risk of sudden death due to life threat-
ening ventricular arrhythmias.1 Large randomized trials demonstrated that both arrhythmic 
death and total mortality can be lowered by implantation of an Implantable Cardioverter 
Defibrillator (ICD) in post-MI patients with a low left ventricular ejection fraction (LVEF) with 
or without ventricular arrhythmias.2-4 These findings resulted in a Class I indication for all 
patients with an ischemic cardiomyopathy and a low LVEF, even in the absence of ventricular 
arrhythmias.5;6 Most of these trials however included patients years after the index event 
(more than 75% of patients in the two Multicenter Automated Defibrillator Trials [MADIT] 
were enrolled >6 months after MI and 89% in the Multicenter Unsustained Tachycardia Trial 
[MUSTT] were enrolled >1 year post MI). Furthermore with the current practice of aggressive 
reperfusion strategies to limit the extent of damage caused by the infarction it is not known 
how many patients will become candidate for ICD implantation in the year following the 
index event.
A regional AMI guideline implementation program (MISSION!) was developed to opti-
mize the use of evidence-based medicine in practice.7 MISSION! contains a pre-hospital, 
in-hospital and out-patient clinical framework for decision making and treatment of AMI 
patients. This prospective and well-defined cohort offers a unique opportunity to evaluate 
and follow patients after AMI and to assess the need for ICD treatment.
MeThods
Patients and protocol
Since 2004, all patients presenting with AMI at Leiden University Medical Center were 
treated according to the MISSION! protocol, as previously described in detail.7 The protocol 
is based on the ACC/AHA/ESC guidelines for AMI and focuses on the reduction of onset of 
symptoms-to-balloon time, optimization of pharmacological treatment, and the structured 
prevention of SCD during follow-up.8-10 The global in-hospital and out-patient clinical frame-
work for the decision-making process and treatment up to one year following the index 
event is outlined in Figure 1.
AMI diagnosis was confirmed by the presence of an unstable coronary lesion on angi-
ography and/or the elevation of cardiac biomarker(s) above normal levels. Patients without 
typical ST-elevation in-hospital, but with ischemic symptoms and elevated cardiac enzymes 
(CKMB and troponin T) were also diagnosed and included as AMI patients in the program.11 
In the absence of complications, the hospital admission was limited to three days. Patients 
on mechanical ventilation at the time of the index event were excluded from the pre-
hospital and in-hospital MISSION! protocol. These patients did, however, receive the same 
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out-patient treatment after discharge. Patients were excluded from the study population 
in case of death prior to the acquisition of the gated single photon emission computed 
tomography (SPECT) three months after the index event, or if the assessment of LV function 
on gated SPECT was not possible due to poor image quality.
Data of each MISSION! patient was collected prospectively in an electronic patient file 
and data management system (EPD-VISION 6.01, Leiden University Medical Center).
follow-up
In the outpatient phase all patients were scheduled for regular clinical visits 30 days after 
the index event and after that every 3 months in the course of a year. Gated SPECT (99m 
tetrofosmin gated myocardial perfusion SPECT) was used as the preferred method for the 
assessment of LVEF and was conducted at 3 months follow-up.12;13
Icd eligibility
The ICD screening part of the protocol was designed at a time when the guidelines for 
primary prevention of SCD were still evolving and was therefore based primarily on the large 
primary prevention ICD trials at the time.2-4;6
Patients were subsequently divided into the following groups, according to the LVEF: (1) 
LVEF ≤30%; (2) LVEF 31-35%; and (3) LVEF >35%. Patients with LVEF ≤30% as determined 
from gated SPECT were directly assigned to ICD therapy as in MADIT II.4 Patients with LVEF 
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figure 1. MISSION! protocol flowchart.
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30-35% were considered eligible for ICD therapy when non sustained ventricular tachycar-
dias (nsVT) were observed on 24-hour Holter monitoring similar to protocols of trials like 
MADIT I or MUSTT.2;3 Patients with a LVEF ≥35% and abnormal 24-hour Holter monitoring 
revealing nsVT were also referred for an electrophysiological test to evaluate indication for 
antiarrhythmic therapy. It should be noted that this protocol differs from the most current 
guidelines that elevated ICD therapy for patients with LVEF <35% to a Class I indication 
regardless of the presence of nsVT.
endpoints
The primary endpoint was ICD eligibility, as determined by the described protocol. Secondary 
endpoints were all-cause death, further subdivided into death from cardiac causes, sudden 
death (unwitnessed), or non-cardiac death.
Furthermore, in patients receiving an ICD, a secondary endpoint was appropriate defibril-
lator therapy (antitachycardia pacing [ATP] or shock).
Icd evaluation
Device interrogation was scheduled every 3 months. All printouts were checked for appropri-
ate and inappropriate ICD therapy (ATP or shocks). Therapies were classified as appropriate 
when they occurred in response to VT or ventricular fibrillation (VF) and as inappropriate 
when triggered by sinus or supraventricular tachycardia, T-wave oversensing, or electrode 
dysfunction. Cutoff rate of the monitor or first therapy zone was noted.
statistical Analysis
Continuous data are expressed as mean ± SD; dichotomous data are presented as numbers 
and percentages. Differences at baseline were assessed using a Chi-square test using Yate’s 
correction or student t-test for independent samples where appropriate. Event rates over 
time were analyzed by method of Kaplan-Meier. Univariable and multivariable cox regres-
sion analyses were performed as appropriate to determine a relation between potential risk 
factors at baseline and the incidence of all cause death. All variables with a p value of <0.25 
entered the multivariable regression analysis. Only adjusted Hazard Ratio (HR) is reported 
with the corresponding 95% confidence interval (CI). All tests were two-sided, a p-value of 
< 0.05 was considered significant.
resulTs
Patient population
From February 2004 until December 2006 799 patients were admitted with AMI at the 
Leiden University Medical Center and were treated according to the MISSION! protocol. 
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Forty-seven (6%) patients died < 3 months after the index event (before the gated SPECT 
test). Causes of death included progressive heart failure (41/47, 87%), sudden cardiac death 
(4/47, 9%), and non cardiac death (2/47, 4%). Additional patients were excluded from the 
analysis due to incomplete gated SPECT data (n=76, 10%).
Table 1. Patient characteristics.
Total
n=676
No ICD indication
n=637
ICD indication
n=39
p-value
Demographics
Male 529 (78) 499 (78) 30 (77) 0.8
Age (years) 59 ± 12 59 ± 12 57 ± 13 0.2
Medical History
Diabetes 69 (10) 66 (10) 3 (7) 0.8
Hyperlipidemia 149 (22) 144 (23) 5 (13) 0.2
Hypertension 212 (31) 199 (31) 13 (33) 0.7
Current smokers 336 (50) 314 (49) 22 (56) 0.4
Family History 291 (43) 273 (43) 18 (46) 0.7
Previous myocardial infarction 42 (6) 39 (6) 3 (7) 1.0
Previous PCI 29 (4) 26 (4) 3 (7) 0.5
Previous CABG 7 (1) 7 (1) 0 (0) 1.0
Clinical characteristics
Culprit vessel LAD 325 (48) 294 (46) 31 (79) <0.001
Killip class at admission
 I 632 (93) 595 (93) 37 (95) 1.0
 II 23 (3) 22 (3) 1 (3) 1.0
 III/IV 21 (3) 20 (3) 1 (3) 1.0
Troponine T max (µg/l) 6.9 ± 14.5 6.5 ± 14.7 14.5 ± 8.3 <0.001
CK (µg/l) 2309 ± 1947 2185 ± 1820 4403 ± 2730 <0.001
Body mass index (kg/m²) 26.4 ± 4.0 26.4 ± 4.0 25.3 ± 3.9 0.1
Symptom-onset-balloon (minutes) 288 ± 1282 287 ± 1317 303 ± 321 0.1
Primary PCI 655 (97) 620 (97) 35 (90) 0.2
Duration of hospitalization (days) 3 ± 2 3 ± 2 6 ± 5 <0.001
LVEF 54 ± 12 55 ± 11 31 ± 9 <0.001
Medication at discharge
 Aspirin 642 (95) 604 (95) 38 (97) 0.7
 Statin 670 (99) 631 (99) 39 (100) 1.0
 ACE-inhibitor 651 (96) 612 (96) 39 (100) 0.7
 Beta-blocker 627 (93) 589 (93) 38 (97) 0.4
 Clopidogrel 671 (99) 632 (99) 39 (100) 1.0
 Anticoagulant 33 (5) 32 (5) 1 (3) 0.7
Values are expressed as n (%) or mean ± standard deviation.
Hyperlipidemia= Total cholesterol ≥190 mg/dl or previous pharmacological treatment.
Hypertension = Blood pressure ≥140/90 mm Hg or previous pharmacological treatment.
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Accordingly, a total of 123 (15%) patients were excluded from the analysis. The remain-
ing 676 were included and were followed for a median of 32 months with an interquartile 
range (IQR) of 25 months (25th percentile) and 40 months (75th percentile).
study population
Baseline characteristics of the study population are reported in Table 1. Patients were mostly 
male (78%) and had a mean age of 59 ± 12 years (range 22-88). Frequent risk factors for 
cardiovascular disease included current smoking (50%), a family history of cardiovascular dis-
ease (43%), and hypertension (31%). Nearly all patients underwent a primary PCI procedure 
(97%); the remaining patients received thrombolytic therapy. Medication at discharge was 
optimal. When aspirin was not prescribed at discharge anticoagulant treatment was pre-
scribed instead (alongside clopidogrel treatment) in order to avoid increased risk of bleeding 
complications. Anticoagulants were prescribed in case of atrial fibrillation, severely impaired 
LV function or LV aneurysm.
evaluating Icd eligibility
The mean LVEF, 3 months after the index event, was 54 ± 10%, as derived from gated SPECT. 
Twenty-five (4%) patients had a LVEF ≤30%, warranting ICD treatment. LVEF between 30% 
and 35% was observed in 27 (4%) patients, of whom 7 demonstrated nsVT on 24-hour 
Holter monitoring, indicating them for defibrillator implantation. Of the remaining 624 (92%) 
patients with LVEF ≥35%, another 7 patients were candidates for ICD based on inducible 
VT/VF during electrophysiological (EP) testing. Additionally, one patient received an ICD due 
to late (>48 hr) sustained VTs following the AMI and another 3 patients were treated with 
an ICD as a result of deterioration of LV function during the year following the index event.
Accordingly, 39 (6%) patients underwent ICD implantation, which was successful in all, 
without major complications.
Icd group characteristics
As is shown in Table 1, the statistically most significant differences between patients with 
an indication for ICD therapy and patients without an indication for ICD therapy were more 
extensive infarctions in the implanted group, evidenced by a higher maximum troponin T 
and creatine kinase, longer duration of hospitalization, and more anterior infarctions. By 
definition, LV function was less in the ICD indicated group.
device therapy
During a median follow-up of the ICD treated population of 31 months (IQR 19 months and 
42 months), 6 patients (15%) received appropriate device therapy for ventricular arrhythmias. 
Cumulative event rate was 8% (95% CI 0-16%) after 6 months, 15% (95% CI 4-27%) after 
one year, and 15% (95% CI 4-27%) after 3 years (Figure 2). No appropriate ICD discharge 
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was observed in the implanted group with LVEF ≥35%. The group with LVEF ≤30% and 
those with LVEF between 30 and 35% did not demonstrate differences in the occurrence of 
appropriate ICD therapy (appropriate therapy in LVEF ≤30%: 19% vs. LVEF 30-35%: 29%, 
p=0.8). Inappropriate therapy occurred in 3 of 39 (8%) ICD recipients.
Mortality
In the population, 12 patients (2%) died during follow-up. The 2 deaths occurring in the ICD 
treated group were related to progressive heart failure. Causes of death in the group without 
a defibrillator were progressive heart failure in 5 (50%), and non-cardiac in the other 5 
(50%) patients. Of note, no cases of sudden death were observed. The 4 sudden deaths that 
occurred <3 months after the acute MI happened due to uncertain, but likely cardiac etiology 
and took place after hospital discharge. They are best described as sudden unexplained 
death and took place at day 13, 16, 25 and 51 post-MI respectively. All four patients had a 
left ventricular ejection fraction calculated with biplane echocardiography of >35%.
As is shown in Figure 3, the cumulative event-free follow-up after 3 years is 98% (95% CI 
96-99%) for all-cause mortality, 99% (95% CI 98-100%) for cardiac mortality, and 100% 
for sudden death.
Multivariate cox regression analysis for mortality > 3 months after the index event 
revealed hyperlidemia (HR 5.9, 95%CI 1.3-26.1), no aspirin use at hospital discharge (HR 
8.4, 95%CI 1.5-46.0) and no ACE-inhibitor use at discharge (HR 7.9, 95%CI 1.2-50.4) as 
independent predictors of death. Age, gender, peak troponine T, ICD treatment, culprit 
target vessel, other risk factors for CAD (including hypertension, smoking, diabetes, his-
tory of MI, family history of coronary artery disease) and LVEF could not be identified as 
independent predictors of death.
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figure 2. Kaplan-Meier curve for the cumulative rate of first appropriate ICD-therapy.
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dIscussIon
In the assessment of an easy-to-use, structured protocol for the treatment of AMI patients 
and prevention of SCD, the findings can be summarized as follows: (1) Defibrillator implanta-
tion was warranted in only 6% of AMI patients; (2) No SCD occurred in the study population; 
(3) Compliance to evidence based medicine was excellent; (4) In ICD recipients, the cumula-
tive event rate for appropriate ICD therapy was 15% at 3 years follow-up.
structured care for AMI patients
In past decades important insights have been gained into the management of patients with 
AMI. Measures such as rapid triage and quick access to reperfusion therapy can reduce 
treatment delay, prevent unnecessary infarct extension, and save lives.14;15 Furthermore, 
the efficacy of early optimal pharmacological therapy has been recognized.16 International 
guidelines on the optimal treatment of patients with AMI advocate early and aggressive 
reperfusion strategies and recommend use of a combination of evidence-based medicine 
and support programs to stimulate a healthier lifestyle.8;10 The degree of compliance to 
these guidelines has proven to be independently correlated to 1-year mortality after AMI.17 
The pre-hospital, in-hospital and out-patient AMI treatment protocol called MISSION! was 
therefore designed to increase use of evidence-based medicine in daily clinical practice.7
Prevention of scd
AMI survivors are at increased risk for sudden death from cardiac causes, in most patients 
due to a ventricular arrhythmia.1;18 Thus far, LV function has proven to be a strong indicator 
for an increased risk of SCD.19-21 Prevention of severe LV dysfunction post-MI was addressed 
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figure 3. Kaplan-Meier curve for the event-free follow-up for mortality.
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by focusing on minimal treatment delays, aggressive reperfusion therapy and the use of early 
and consistent optimal pharmacological therapy.
Nuclear imaging (gated SPECT) functioned as gatekeeper for risk stratification at 3 
months post-MI. It facilitated the first step toward the detection of patients at increased risk 
for SCD. A previous study highlighted the importance of scintigraphic evaluation of patients 
with coronary artery disease.13
Icd indication
Large randomized trials have proven the beneficial effect of primary prevention ICD treat-
ment in post-MI patients with a severely depressed LVEF.3;4;22 Implementation of these find-
ings in the current international guidelines significantly and rapidly expanded the indications 
for ICD implantation.5 Correspondingly, while patients with LVEF 30-35% included in the 
present study were only considered eligible for ICD implantation when nsVT was observed 
on 24-hour Holter, the most current guidelines elevated ICD therapy for patients with LVEF 
<35% to a Class I indication regardless of the presence of nsVT.5 Due to these rapid changes, 
clinicians have expressed concern that the population, eligible for primary prevention ICD 
treatment, is of such magnitude that provision of ICD therapy will strain financial resources 
and the pool of trained personnel.23 Despite the in some ways more lenient ICD eligibility 
criteria as compared to current guidelines, the present study showed successfully that the 
proportion of post-MI patients potentially eligible for an ICD, when treated optimally and 
aggressively for AMI, is smaller than anticipated.24-26 By using the pre-specified protocol 
merely 6% of AMI patients were identified as candidates for ICD implantation and no sud-
den deaths occurred in the study population.
device therapy
In the ICD treated population, the cumulative event rate for first appropriate ICD therapy at 
3 years follow-up was 15% (95% CI 4-27%), which is lower than the event rates reported 
from trials like MADIT II (35%).27 A possible explanation for this difference is the smaller ICD 
patient group in the current study and the more preserved LV function in the current study’s 
ICD treated population (LVEF 31 ± 9%), when compared to the MADIT II population (LVEF 23 
± 5%). Furthermore, in MADIT II 42% of patients who underwent coronary revascularization, 
had the procedure >60 months before enrollment in the study (median 107 months) whereas 
patients in the current study were risk stratified for ICD implantation <1 year post-MI. The 
low arrhythmic event rate in the population selected with the MISSION! protocol suggests a 
low rate of potential SCD in these patients. As expected, appropriate ICD therapy was more 
frequent in patients with lowest LVEF. In the group with a more preserved LVEF (≥35%) none 
of the patients had appropriate ICD therapy.
Interestingly, all incidents of first appropriate therapy took place within the first year 
after ICD implantation, although the small number of ICD patients warrants caution in the 
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interpretation of the data. An increased tendency for arrhythmic events in the first year 
after implant is consistent with prior reported data on ICD patients.28;29 The low percentage 
of patients benefiting from appropriate ICD therapy demonstrates that despite use of a 
structured protocol, accurate SCD risk stratification is difficult. Nevertheless, results from 
the eight year follow-up of the MADIT II trial 30 provides substantial evidence for long term 
mortality benefit of ICD therapy.
clinical implications
Using a standardized clinical protocol like the MISSION! algorithm can not replace personal 
judgment and individualized risk assessment, but can aid in applying evidence-based medi-
cine in clinical practice and can help in achieving optimal results at the lowest possible cost, 
in terms of health, quality of life and finance.
Interestingly, results of the multivariable analysis suggested that ICD implantation in all 
patients with low LVEF, reduced the value of low LVEF as independent predictor of death. 
When ICD treatment was removed from the multivariable cox regression analysis low LVEF 
did regain its significant association with increased death rate. This seems to confirm that 
ICD treatment is probably the reason why low LVEF was not associated with (all-cause) 
death in the study population after the 3-month screening period. It remains possible that 
relatively short follow-up and small patient numbers in the low LVEF group were not suf-
ficient to see a significantly different distribution of (particularly heart failure related) deaths 
between the low LVEF and the high LVEF group.
limitations
This is a single-center study based on the data of real clinical practice without the strict 
controlled conditions of a trial. Only patients with conclusive gated SPECT LVEF results were 
included in the study population in order to avoid confusion about the protocol. Excluded 
patients (n = 76, 10%) had either poor quality gated SPECT result due to irregular heartbeat 
or attenuation artifacts, or did not undergo gated SPECT because they either refused protocol 
or were involved in other treatment protocols. They did however undergo echocardiography 
at 3 months follow-up and had estimated biplane ejection fractions above 35% which 
excluded them as likely candidates for ICD implantation. Their inclusion would therefore not 
have changed the main outcome of the study.
Of note, screening for SCD prevention commenced 3 months after the acute event in 
contrast to current guidelines recommending a period of 40 days post MI. However, of all 
deaths occurring in the first 3 months after MI, the vast majority (46/47, 98%) occurred 
<40 days after AMI and therefore could not have been prevented by commencing screening 
after 40 days. Finally, three-year event rates should be interpreted with caution due to 
relatively short follow-up and the small number of patients that received an ICD.
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conclusIon
Aggressive treatment of AMI patients and close monitoring after the index event according 
to a standardized protocol, results in only a small number of patients becoming candidate for 
prophylactic ICD implantation. An easy-to-use protocol combining aggressive reperfusion, 
optimal medication and a risk stratification algorithm tailored to fit within routine practice 
may help to maintain ICD implantation rates within manageable proportions.
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AbsTrAcT
background
Myocardial excitability is known (amongst other reasons) to be related to the degree of isch-
emia, contractile dysfunction and heart failure. It was hypothesized that the right ventricular 
(RV) stimulation threshold has prognostic value with respect to the occurrence of ventricular 
arrhythmias (VAs) and patient survival in recipients of an implantable cardioverter defibrillator 
(ICD).
Methods
Ischemic heart disease patients receiving an ICD at Leiden University Medical Center as 
primary prevention for sudden cardiac death were included in this study. RV-thresholds were 
determined at ICD implant. Data was collected on VAs triggering ICD therapy and on all-
cause mortality.
results
A total of 689 consecutive patients were included (87% male, age 63±11 years, left ven-
tricular ejection fraction [LVEF] 29±11%) and followed for a median 28 months. Post-implant 
RV-threshold was 0.7±0.5volt (V) at 0.5ms pulse duration. Best dichotomous separation was 
reached at a cut-off of 1V. During follow-up, 167 (24%) patients received appropriate ICD 
therapy, 88 (13%) had appropriate shocks and 134 (19%) died. Cumulative appropriate 
shock incidence for patients with RV-threshold ≥1V (n=166) was 16% at 1 year, 24% at 3 
years and 34% at 5 years compared to 4%, 11% and 17% for patients with a RV-threshold 
<1V (n=523). Adjusted Hazard Ratio (HR) of RV-threshold ≥1V was 2.0 (95% CI 1.4-2.9) for 
appropriate therapy, 3.3 (95%CI 2.0-5.4) for appropriate shocks and 1.6 (95%CI 1.1-2.5) 
for mortality.
conclusion
The RV stimulation threshold at ICD implant has a strong independent prognostic value for 
the occurrence of ventricular arrhythmias triggering appropriate ICD therapy, appropriate 
shocks and mortality.
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InTroducTIon
Following the results of several large randomized trials, current guidelines for prevention of 
sudden cardiac death (SCD) advocate implantation of an implantable cardioverter defibril-
lator (ICD) in patients with a low left ventricular ejection fraction (LVEF) without a prior 
life-threatening ventricular arrhythmia.1-5 This strategy has led to an increasing number of 
ICD implantations in recent years and currently, a low LVEF is still the most effective and con-
sistent parameter used to select patients at risk of SCD.6-9 However, the rate of ventricular 
arrhythmias, triggering appropriate device therapy is relatively low (35-40%)10 in this group 
of patients, warranting better risk-stratification for ICD implantation.
As the structure of cardiac tissue is affected by the pathological processes of infarction 
and subsequent fibrosis, the electrophysiological properties of the myocardium are altered 
significantly.11-13 The changes in cardiac tissue structure caused by myocardial infarction 
may increase the risk of ventricular arrhythmias to occur. Furthermore these changes may 
increase the myocardial excitability threshold.11-13 Consequently an increased excitability 
threshold may reflect an increased risk of ventricular arrhythmias.
In the current study, it was hypothesized that alterations of myocardial excitability caused 
by ischemic heart disease and reflected in part by changes in the stimulation threshold, may 
be of clinical use as a risk parameter for ventricular arrhythmias in primary prevention ICD 
patients.
MeThods
Patients and protocol
Since 1996, all patients who received an ICD system in the Leiden University Medical Center 
were prospectively documented in the departmental Cardiology Information System (EPD-
Vision®, Leiden University Medical Center). Patients included in this study received an ICD 
between 1999 and 2007. Characteristics at baseline, data of the implant procedure, and 
data of all follow-up visits were recorded. For the current study, only patients with ischemic 
heart disease and a primary indication for defibrillator implantation were evaluated. We 
excluded patients with congenital structural, monogenetic heart disease, or non-ischemic 
heart disease for the present analysis. Furthermore, patients without a documented RV-
threshold at implant were excluded for the present analysis.
Eligibility for ICD implantation in this population was based on international guide-
lines for the prevention of sudden cardiac death which, due to evolving guidelines may 
have changed over time. In the majority of patients, indication for an ICD was based on 
a depressed LVEF with or without non sustained ventricular tachycardia. Ischemic heart 
disease was defined as a history of myocardial infarction (presence of an unstable coronary 
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lesion on angiography and/or the elevation of cardiac biomarker(s) above normal levels), 
or a history of significant coronary artery disease (an angiographically estimated diameter 
stenosis of at least 50% in at least one coronary artery and exercise induced myocardial 
ischemia/perfusion defect) that resulted in coronary revascularization.
Icd implantation
All defibrillator systems used were implanted transvenously without thoracotomy. The right 
ventricular lead was positioned in the right ventricular apex near the septum and adjust-
ments, if necessary, were made to achieve an optimal pacing threshold. During the implant 
procedure standard testing of sensing and pacing thresholds and defibrillation threshold 
testing was performed. Used systems were manufactured by Biotronik (Berlin, Germany), 
Medtronic (Minneapolis, MN, United States), Boston Scientific (Natick, MA, United States, 
formerly CPI, Guidant [St. Paul, MN, United States]) and St. Jude Medical/Ventritex (St. Paul, 
MN, United States).
In this primary prevention patient cohort, defibrillators were programmed as follows: a 
monitor zone was programmed in all patients to detect ventricular arrhythmias faster than 
150 bpm. No therapy was programmed in this zone. Ventricular arrhythmias faster than 188 
bpm were initially attempted to be terminated with two bursts of antitachycardiapacing 
(ATP) and, after continuation of the arrhythmia, with defibrillator shocks. In the case of a 
ventricular arrhythmia faster than 210 bpm, device shocks were the initial therapy. Further-
more, atrial arrhythmia detection was set to >170 bpm with supraventricular tachycardia 
(SVT) discriminators enabled. Settings were adapted, only when clinically indicated (i.e. 
hemodynamic well tolerated ventricular tachycardia at high rate; ventricular tachycardia in 
the monitor zone). The stimulation threshold was determined by automatic decrementation 
of the stimulus voltage at constant pulse duration of 0,5ms after implant.
follow-up and endpoints
All patients visited the clinic for follow-up assessments every 3 to 6 months. Patients were 
followed up to February 2009. At each patient visit, a trained device specialist or cardiolo-
gist performed device interrogation and determined sensing, pacing thresholds, and lead 
impedance.
The primary endpoint was ventricular arrhythmia triggering appropriate defibrillator 
therapy (antitachycardia pacing [ATP] or shock) or appropriate shock only. Secondary end-
point was all-cause death.
Icd evaluation
All printouts were checked for appropriate and inappropriate ICD therapy (ATP or shocks). 
Therapies were classified as appropriate when they occurred in response to ventricular tachy-
cardia (VT) or ventricular fibrillation (VF) and as inappropriate when triggered by sinus or SVT, 
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T-wave oversensing, or electrode dysfunction. Cutoff rate of the monitor or first therapy zone 
was noted.
statistical Analyses
Continuous data are expressed as mean (±standard deviation) or as median (25th/75th 
percentile); dichotomous data are presented as numbers and percentages. Differences at 
baseline were tested for statistical significance using a Chi-square test using Yate’s correction 
or student t-test for independent samples where appropriate. Event rates over time were 
analyzed by method of Kaplan-Meier with corresponding log-rank test for differences in 
distribution between the curves. Since follow-up was performed every three to six months, 
patients without data in the past six months were censored at the date of their last visit.
We used multivariable Cox regression analyses to assess the association between stimu-
lation threshold and ventricular arrhythmias independent of an increasing number of other 
risk factors including age, gender, cardiac resynchronization therapy, LVEF, history of atrial 
fibrillation/atrial flutter, use of amiodarone, use of beta-blocker, use of sotalol, and anterior-, 
lateral-, inferior- and posterior MI as potential confounders. Hazard Ratio (HR) is reported 
with the corresponding 95% confidence interval (CI). All tests were two-sided, a p-value 
of < 0.05 was considered statistically significant. Missing values of all the variables were 
seen only for the variable atrial fibrillation/atrial flutter, in less than 0.3% (n=2/689) of all 
patients. The regression models were done on the patients without missing values.
A receiver operating characteristic (ROC) curve analysis was used to measure the ability 
of the RV-threshold to discriminate between patients that received appropriate therapy and 
patients that did not.
resulTs
Patient population
A total of 1086 consecutive ICD recipients with a primary prevention indication were regis-
tered in the electronic database system. Fifty patients (5%) were excluded due to incomplete 
follow-up data, 332 patients (31%) due to non-ischemic heart disease and 15 patients (1%) 
due to non-documented baseline RV-threshold measurements. The remaining 689 patients 
were included in the present analysis and followed for a median 28 months (interquartile 
range (IQR) 16 to 46 months).
The majority of patients (87% male, 63 ± 11 years, LVEF 29 ± 11%) had a history of 
myocardial infarction (84%) or coronary revascularization procedure (PCI 28%, CABG 
43%) (Table 1). Median RV-threshold was 0.5V (IQR 0.5 to 0.8V) at 0.5ms pulse dura-
tion. ROC curve analysis of the RV-threshold suggested that a cutoff of 1V provided the 
best clinically useful dichotomous separation for assessment of the primary endpoint. A 
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RV stimulation-threshold ≥1V was observed in 166 (24%) patients. An equal distribution 
of lead types were used in both the RV threshold >1V group and the RV threshold <1V 
group (p=NS). There was not a significant difference between the groups in the use of any 
particular lead type (not shown).
Table 1. Baseline characteristics.
All patients
n = 689
RV threshold <1V
n = 523
RV threshold ≥1V
n = 166
p-value
Male sex 600 (87) 459 (88) 141 (85) 0.35
Age (years) 63 ± 11 63 ± 11 63 ± 11 0.81
Hypertension 318 (46) 239 (46) 79 (48) 0.72
Diabetes 176 (26) 130 (25) 46 (28) 0.40
Smoking 151 (22) 118 (23) 33 (20) 0.50
Prior myocardial infarction 578 (84) 436 (83) 142 (86) 0.55
 Anterior† 304 (53) 237 (54) 67 (47) 0.13
 Inferior† 161 (28) 112 (26) 49 (35) 0.043*
 Lateral† 76 (13) 54 (12) 22 (16) 0.32
 Posterior† 49 (9) 36 (8) 13 (9) 0.76
Prior PCI 192 (28) 145 (28) 47 (28) 0.92
Prior CABG 296 (43) 226 (43) 70 (42) 0.86
Hypercholesterolemia 463 (67) 364 (70) 99 (60) 0.051
Family History of CAD 300 (44) 220 (42) 80 (48) 0.21
AF/AFL flutter documented 170 (25) 123 (24) 47 (28) 0.26
QRS width 126 ± 34 125 ± 34 130 ± 34 0.10
Creatinine clearance (ml/min) 78 ± 35 78 ± 32 77 ± 43 0.70
Ejection Fraction 29 ± 11 29 ± 10 29 ± 13 0.90
Cardiac resynchronization therapy 335 (49) 263 (50) 72 (43) 0.13
Medication
 Beta-blocker 425 (62) 345 (66) 80 (48) <0.001*
 Sotalol 75 (11) 47 (9) 28 (17) 0.006*
 ACE-inhibitor/ATII-antagonist 580 (84) 443 (85) 137 (83) 0.54
 Diuretics 502 (73) 375 (72) 127 (77) 0.27
 Statin 560 (81) 426 (82) 134 (81) 0.82
 Aspirin 332 (48) 255 (49) 77 (46) 0.76
 Oral anticoagulation 400 (58) 304 (58) 96 (58) 1.00
 Amiodarone 110 (16) 70 (13) 40 (24) 0.002*
Values are expressed as n (%) or as mean ± standard deviation. * p <0.05
Hypercholesterolemia= Total cholesterol ≥190 mg/dl or previous pharmacological treatment.
Hypertension = Blood pressure ≥140/90 mm Hg or previous pharmacological treatment.
†Patients could fall into more than one infarction location category (i.e. anterolateral, inferoposterior 
infarction). AF: Atrial fibrillation; AFL: Atrial flutter.
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Baseline characteristics distributed according to RV-threshold are reported in table 1. 
With the exception of infarct localization (higher number of inferior wall infarctions in the 
>1 RV threshold group (p=0.04)) baseline characteristics were similar.
Cardiac resynchronization therapy was combined with the defibrillator device in approxi-
mately 50% of cases of either group (RV-threshold <1V: 50%, RV-threshold ≥1V: 43%; p 
= 0.13). Concerning the use of drugs: Patients with a higher threshold more often used 
sotalol and amiodarone than patients with a threshold < 1V. Patients with lower threshold 
more often used beta-blockers. The use of other drugs was similar in both groups.
device therapy
During follow up, a total of 1615 episodes of ventricular arrhythmia were appropriately 
terminated by the ICD in 24% (n=167) of patients either by ATP or by shock delivery. A total 
number of 278 shocks were delivered appropriately by the ICD in 13% (n=88) of patients. 
Furthermore, 68 patients (10%) experienced inappropriate shocks. Figure 1 shows the distri-
bution over time of first appropriate therapy and -shocks for the total patient cohort.
Appropriate therapy during follow-up occurred more often in patients with a RV-threshold 
≥1V (37%, 62 of 166 patients) when compared to patients with a RV-threshold <1V (20%, 
105 of 523 patients). Furthermore, the number of patients that experienced appropriate 
ICD shocks was more than three times higher in the group with a RV-threshold ≥1V (26%, 
43 of 166 patients) than in the group with a RV-threshold <1V (9%, 45 of 523 patients).
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figure 1. Kaplan-Meier Plot of Cumulative Incidence of first appropriate ICD therapy and appropriate 
shocks in the total study population.
App = appropriate; ICD = Implantable Cardioverter Defibrillator
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Figure 2 illustrates the time course of first appropriate therapy (panel A) and for first 
appropriate shocks (panel B) for patients with a RV-threshold <1V and a RV-threshold ≥1V. A 
significantly higher cumulative incidence of first ICD therapy and shocks was observed in the 
group with a RV-threshold ≥1V. Cumulative appropriate shock rate for patients with a RV-
threshold ≥1V was 16% (95%CI 10-22%) at 1 year, 24% (95%CI 17-31%) at 3 years and 
34% (95%CI 24-43%) at 5 years compared to 4% (95%CI 2-5%) at 1 year, 11% (95%CI 
7-14%) at 3 years and 17% (95%CI 12-23%) at 5 years for patients with a RV-threshold 
<1V (log-rank p<0.001).
Post-implant RV-threshold ≥1V was found to be an independent and significant predictor 
of first appropriate ICD therapy (adjusted HR model 3: 2.0, 95%CI 1.4-2.9) and appropri-
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figure 2.
A. Kaplan-Meier Plot of Cumulative Incidence of first appropriate ICD therapy.
B. Kaplan-Meier Plot of Cumulative Incidence of first appropriate ICD shocks.
RV = Right Ventricular; Thresh = threshold; other abbreviations as in Figure 1.
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ate shocks (adjusted HR model 3: 3.3, 95%CI 2.0-5.4) after correcting for other potential 
confounders as listed.
With higher measurements of the RV-threshold, the percentage of patients experiencing 
appropriate shocks increased. The area under the ROC curve for RV-threshold was sig-
nificantly greater than 0.5 (area under ROC curve 0.7; 95%CI 0.6-0.7; p<0.001). A high 
specificity was observed at a cut-off value around ≥1V (specificity 80% [95%CI 76-83%]) 
at the expense of sensitivity (49% [95%CI 38-60%]). The negative predictive value of the 
RV-threshold cut-off value of 1V was 91%.
Mortality
One-hundred and thirty-four (19%) patients died during the follow-up period. Total mortality 
in patients with a RV-threshold ≥1V (28%, 47 of 166 patients) was higher compared to the 
group of patients with a RV-threshold <1V (17%, 87 of 523).
Cumulative survival (%) for the two study groups is displayed in Figure 3. A trend exists 
toward decreased patient survival in the patient group with a RV-threshold ≥1V. Cumulative 
survival in this group is 90% (95%CI 86-95%) at 1 year, 78% (95%CI 72-85%) at 3 years 
and 70% (95%CI 61-78%) at 5 years, compared to 94% (95%CI 92-96%) at 1 year, 81% 
(95%CI 77-85%) at 3 years and 73% (95%CI 67-79%) at 5 years in the group with a RV-
threshold <1V. The log-rank test for this difference was not statistically significant (p=0.12).
However, post-implant RV-threshold ≥1V was found to be an independent and signifi-
cant predictor of mortality after correcting for potential confounders as listed in table 2. 
After adjustment the mortality rate was 60 percent higher among those with RV-threshold 
≥1V as compared to patients with RV-threshold <1V (adjusted HR model 3: 1.6, 95%CI 
1.1-2.5) (Table 2).
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figure 3. Kaplan-Meier Plot of Cumulative Incidence of Death.
Abbreviations as in Figure 2.
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dIscussIon
In this cohort of ICD treated patients with ischemic heart disease and a primary prevention 
indication for ICD treatment, a post-implant right ventricular stimulation threshold ≥1V was 
independently associated with (1) a higher occurrence of ventricular arrhythmias trigger-
ing appropriate therapy, (2) a 3-fold higher occurrence of ventricular arrhythmia triggering 
appropriate shocks and (3) a 60% higher risk of mortality compared to patients with a 
threshold <1V.
risk stratification for scd
LV function is an established indicator for an increased risk of SCD.6-8 Results of a series of 
randomized trials have resulted in a rise in the number of ICD implantations due to a great 
expansion in the indications for primary prevention ICD use.1;3-5 However, the relatively low 
percentage of ICD patients who receive appropriate therapy (35-40% of patients in MADIT 
II and SCD-Heft)1;10 suggested a considerable risk heterogeneity in the low LVEF-population. 
This has prompted a series of studies and secondary analyses from the major ICD trials in 
an attempt to identify factors that can be used to stratify patients with reduced LVEF into 
high- and low risk subgroups.14-22 Given the complexity and limitations of some of these 
proposed stratification strategies, the RV stimulation threshold is a relatively easy to use, 
straightforward prognostic and, more importantly, electric measure of arrhythmic risk. It may 
assist clinicians in identifying ICD treated patients at high risk of receiving appropriate ICD 
therapy and a higher risk of death, therefore facilitating better evaluation of the prognosis 
post-implant. The present study can not provide an answer as to the value of the stimula-
tion threshold as a pre-implant risk stratifier, it suggests only that the baseline stimulation 
threshold may enable some prognosis prediction post-implant, and may assist in guiding 
perhaps the medication regime or the frequency of outpatient visits especially for the group 
below the cutoff of 1V as the negative predictive value was 91%. Obviously such a cutoff 
Table 2. Multivariable Cox regression analyses.
RV threshold 
<1V (n=523)
RV threshold 
≥1V (n=166)
Unadjusted HR 
(95% CI)
Adjusted HR (95% CI)
Model 1 Model 2 Model 3
Appropriate 
therapy
105 (20) 62 (37) 1.8 (1.3-2.5) 2.0 (1.4-2.9)
p<0.001
2.0 (1.4-2.8)
p<0.001
2.0 (1.4-2.9)
p<0.001
Appropriate 
shocks
45 (9) 43 (26) 2.9 (1.9-4.4) 3.3 (2.0-5.3)
p<0.001
3.1(1.9-5.2)
p<0.001
3.3 (2.0-5.4)
p<0.001
All-cause 
mortality
87 (17) 47 (28) 1.3 (0.9-1.9) 1.7 (1.2-2.6)
p= 0.007
1.6 (1.1-2.4)
p= 0.028
1.6 (1.1-2.5)
p= 0.021
Values are expressed as n (%), or as HR = hazard ratio (95% CI = confidence interval).
Model 1 = adjusted for age, gender, cardiac resynchronization therapy, LVEF and inferior infarction;
Model 2 = additionally adjusted for beta-blocker-, sotalol- and amiodarone treatment.
Model 3 = additionally adjusted for anterior MI, lateral MI and posterior MI and history of AF/AFL.
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value should be treated just like any other “superficial” cutoff measure (like, for example 
a LVEF of 35% calculated by biplane echo). Common sense and personal and professional 
judgment is indispensable in solving such dilemmas.
In order to get to the stage of clinical usefulness, the pacing thresholds should be deter-
mined in a standardized prospective fashion utilizing MRI data in order to draw definite 
conclusions about the optimal cutoff, or perhaps range, with its associated arrhythmic risk 
groups.
Ischemic heart disease, poor excitability and arrhythmogenesis
Prior myocardial infarction leaves a residue of poorly excitable cardiac tissue. Findings from 
a canine study suggested that disruptions in cell-to-cell electrical continuity may contribute 
to slow conduction in the infarcted region.12 In later experiments a persistent reduction of 
the space constant existed in chronically infarcted canine myocardium 5-8 days after persis-
tent occlusion and reperfusion which is directly related to slow conduction velocity.13 The 
investigators hypothesized that these alterations were due to a depression in action potential 
depolarization, an increase in internal axial resistance (by modification of the low resistance 
gap junctions, therefore increasing anisotropy) and an increase in the axial resistance of the 
extracellular space (due to the fibrotic matrix in which surviving cells are distributed within 
the mottled infarcted myocardium). Furthermore, wavefront-obstacle interactions in a poorly 
excitable medium may reflect an arrhythmogenic process that permits formation of separate 
new wavelets which in vivo may lead to flutter, fibrillation, and sudden cardiac death.23
Arrhythmias leading to sudden cardiac death are often associated with the presence 
of inhomogeneities (obstacles) in cardiac tissue and reduced excitability of cardiac cells. 
Observations of fast arrhythmias in a medium of reduced excitability, combined with 
medium inhomogeneities provide a substrate for formation of multiple wavelets leading to 
high-frequency arrhythmias.11;24-26
device therapy and stimulation threshold
Stimulation thresholds vary immediately following implant due to lead-myocardium matura-
tion and chronically due to changes in underlying myocardium, ischemia, infarction, meta-
bolic state, or drug therapy.27-30 The present findings suggest that properties of the baseline 
RV stimulation threshold may be used clinically as an indicator of chronic changes caused by 
ischemic heart disease, increasing the risk of arrhythmic events requiring ICD therapy and the 
risk of mortality. A high RV stimulation threshold was used as a marker of the degree of poor 
myocardial excitability to indirectly indicate potentially arrhythmia-prone conditions. The 
association was found to be independent of infarction location despite the essentially local 
measurement position at the RV apex, which implies that the parameter reflects not only a 
localized effect but rather a sum of effects. In addition, when looking at a small sample of 
the first 15 patients who received appropriate ICD shocks (and of whom >1 measurement of 
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the RV threshold was available before the ICD therapy took place), we saw the RV threshold 
increasing several months before an appropriate shock in 11 patients (increase with as little 
as 0.2V or with a much as 3V), stay the same in 3 patients and decrease in 1 patient. After 
the ICD shock it remained the same in 14 patients and decreased in 1. According to this small 
sample of patients, one may cautiously suggest that there may also be a predictive value in 
serial measurement of the RV threshold regarding the imminent occurrence of a ventricular 
arrhythmia requiring appropriate ICD shock. These changes probably also reflect a state of 
progressing heart failure.
While the cumulative survival analysis was not able to demonstrate a significant difference 
in mortality incidence between the two study groups (Figure 3), post-implant RV-threshold 
≥1V was nevertheless found to be independently associated with a 60% increased hazard 
of mortality after adjusting for confounders as listed in table 2. Cardiac resynchronization 
therapy and LVEF were the most important variables influencing the association between 
RV-threshold and mortality, both to an equal extent. As the association of the RV-threshold 
with ventricular arrhythmia triggering appropriate shocks was strongest, the risk parameter 
may be most valuable for the estimation of fast, potentially life-threatening, arrhythmias.
Though the optimal cut-off value of the RV stimulation threshold for its best predictive 
value may vary slightly in post-MI patient subgroups with different baseline characteristics 
or for a different moment of baseline measurement, its ability to identify patient with a 
higher risk of arrhythmic events leading to appropriate ICD therapy and shocks will most 
likely not be affected. This is supported by results of the multivariate analyses that showed 
that the effect was independent of other predictors. Antiarrhythmic drugs such as beta-
blockers tend to increase the stimulation threshold, but paradoxically in the current study 
were used more frequently in the group with RV-threshold <1V, suggesting a limited clini-
cal effect. Amiodarone treatment was more prevalent in patients with RV-threshold ≥1V, 
but whether the type III antiarrhythmic drug has similar effects is as yet unclear. Virtually 
all antiarrhythmic drugs may influence the pacing threshold but usually become clinically 
important only at high serum concentrations.29
limitations
This is a single-center follow-up study based on data of routine clinical practice. Missing 
data in the enrolled population was seen in less than 1% of patients which limited potential 
over- or underestimation of findings. The single-center nature of this study was, in this case, 
an advantage in that it kept the variability between procedure protocol and operators at a 
minimum.
Guidelines for ICD eligibility might have changed over time, creating a more heteroge-
neous patient population than in the strict controlled conditions of a clinical trial. Potentially 
confounding effects of these heterogeneities were limited by using the multivariable Cox 
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analysis to assess the independent association between stimulation threshold and ventricu-
lar arrhythmias.
The electrophysiologists performing the procedure at our centre are trained to look for a 
RV threshold preferably below 1V, though the number and distribution of pacing sites is not 
pre-specified or standardized in the clinical protocol. The search for the optimal threshold 
was at the discretion of the operator. MRI data was not available of patients in this study 
to assess scar tissue. However, data was available on the culprit vessel, peak troponin levels 
and perfusion defects post-MI (assessed with gated SPECT) which informed us about loca-
tion and extensiveness of the myocardial damage. Other reasons led us to believe that the 
reported association between RV threshold and ICD therapy is valid, despite the study’s 
non-standardized nature.
First, although certainly far from the accuracy of MRI scar tissue data, simply the location 
of the MI as informed by the mentioned test modalities should have led to substantial 
confounding of the association between the pacing threshold and the ICD shock rate, 
certainly when taking into account the relatively large sample size and number of events. 
However, on the contrary, a very strong relationship was still observed. Considering that it 
concerned the “optimal achievable pacing threshold (site)” chosen by the operator at the 
time of implantation this finding suggests that the operator did already take the location of 
the infarction into account at placement of the lead and avoided it as much as was possible.
Second, despite variation in procedures, due to the law of “regression toward the mean” 
the eventual result of the threshold cutoff in a large sample size will probably approach 
the true mean. Patients included in this study were consecutive and non-selected, because 
the procedure was not done in a standardized trial setting. After reviewing the data of all 
patients and performing ROC analysis of all the measured thresholds a clear trend was 
visible with a RV threshold of 1V as the best statistical and clinical cutoff value. Although it 
is a relatively simple way to analyze the data, we believed it was best not to “over process” 
the data after documentation, in order to avoid introducing errors in the natural distribution 
of the values and simply report what we observed, as we did not have the benefit of a 
standardized controlled study protocol.
In summary, although lack of MRI scar tissue data is a certain limitation of the study, we 
still believe that the association we found is a true trend that really exists. However, in order 
to get to the stage of clinical usefulness, the best threshold cutoff should be determined in 
a standardized prospective fashion in the future utilizing MRI data in order to draw definite 
conclusions about the ideal cutoff, or perhaps range, and its associated risk group. Of 
note, clinical usefulness of the stimulation threshold before the implantation of the ICD still 
remains to be investigated.
Lastly, while appropriate ICD therapy was used as a primary endpoint throughout the 
current study, it should be noted that it is not a perfect surrogate for life-threatening ven-
tricular arrhythmia or SCD.
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conclusIon
In ICD treated patients with a primary prevention indication and ischemic heart disease the 
RV stimulation threshold at implantation has an independent prognostic value for the predic-
tion of potentially life-threatening ventricular arrhythmia and death.
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AbbrevIATIons
AT= atrial tachyarrhythmias
CHD= congenital heart disease
AFL= atrial flutter
IART= intra-atrial re-entrant tachycardia
FAT= focal atrial tachycardia
AF= atrial fibrillation
C
ha
pt
er
 1
1
168
AbsTrAcT
background
Catheter ablation has evolved as a possible curative treatment modality for atrial tachyar-
rhythmias (AT) in patients with congenital heart defects (CHD. However, data on long-term 
outcome is scarce. We examined characteristics of recurrent AT after ablation of post-
operative AT during long-term follow-up in CHD patients.
Methods and results
CHD patients (N=53, 27 male, 38±15 yrs) referred for catheter ablation of AT were studied 
during a follow-up period of 5±3 years.
After ablative therapy of the first AT (N=53, 27 atrial flutters (AFL), CL= 288±81 ms; 22 
intra-atrial re-entrant tachycardias, (IART), CL= 309±81 ms; 5 focal atrial tachycardias (FAT), 
CL= 380±147 ms, success rate: 65%), AT recurred (59% within the first year) in 29 patients, 
15 underwent repetitive ablative therapy. Mechanisms underlying recurrent AT was similar 
in 7 patients (IART: 2, AFL: 5). The location of arrhythmogenic substrates of recurrent AT 
(IART, FAT) was different for all but one patient. After 5±3 yrs, 5 patients died due to heart 
failure, 3 were lost to follow-up and the remaining patients had sinus rhythm (31), AT (5) or 
AF (14). Anti-arrhythmic drugs were used by 18 (57%) sinus rhythm patients.
conclusion
Successive post-operative AT in CHD patients developing over time may be caused by differ-
ent mechanisms, including focal and reentrant mechanisms. Recurrent AT originated from 
different locations suggesting that these new AT were not caused by arrhythmogenicity of 
previous ablative lesions. Long-term outcome is often complicated by development of AF. 
Despite frequent need for repeat ablative therapy, most patients are in sinus rhythm.
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InTroducTIon
Atrial tachyarrhythmias (AT) occurring late after cardiac surgery for congenital heart disease 
(CHD) or acquired heart disease are associated with hemodynamic deterioration, increased 
risk of thromboembolism and even cardiac death.1-5 Management of post-operative AT with 
anti-arrhythmic drugs is often not successful and accompanied by side effects.1,5-8 In recent 
years, catheter ablation has evolved as a feasible curative treatment modality for these AT.9-16 
As the arrhythmogenic substrate in patients with prior cardiac surgery is often complex 
detailed mapping prior to ablation is essential for successful ablative therapy.17,18
The first studies of ablative therapy of post-operative AT described ablation procedures 
using only fluoroscopy. During these procedures, multiple catheters were often required to 
comprehend the mechanism of the AT. Technological advancement over the years resulted 
in introduction of 3-dimensional electro-anatomical mapping techniques such as the 
CARTO™ system.19,20 By visualizing the electrical activation of the heart chamber mapped 
in a 3-dimensional reconstruction, these systems are able to facilitate ablative therapy. Ever 
since their implementation, numerous articles reported on the outcome of ablative therapy 
of post-operative AT.10,12,21-26 However, data of long-term outcome is scarce25,26 and there 
is a lack of information about characteristics of successive post-operative AT for individual 
patients.
The aim of this study was to evaluate long-term outcome after ablation of late post-
operative AT and to examine characteristics of recurrent AT in a large cohort of patients with 
predominantly complex congenital heart defects.
MeThods
study Population
The study population consisted of 53 consecutive patients with congenital heart disease and 
post-operative, drug refractory AT referred for ablation to our center between 2000 and 
2004. Data regarding congenital defects and surgical history were obtained from hospital 
records. The first visit to the out-patient clinic was 4 weeks after ablation. After this visit, 
patients were seen every 6 months. Evaluation prior to ablation and during the follow-up 
period included history, physical examination, ECG, Holter monitoring and echocardiographic 
examination.
Mapping Procedure
Mapping was performed using a 3-D electro-anatomical mapping system (CARTO™, 
Biosense-Webster, Diamond Bar, CA, USA). A detailed description of the underlying technol-
ogy of electro-anatomical mapping has been given previously.19,20 A 7F Navistar (4mm tip, 
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2 bipolar electrode pairs, inter-electrode distance 2 mm, Biosense-Webster, USA) was used 
for mapping and ablation. Bipolar electrograms were filtered at 10-400Hz. A bipolar atrial 
electrogram recorded by a 6F diagnostic catheter (Biosense-Webster) positioned in the RA 
served as a temporal reference. A sensor taped on the back served as a location reference.
If AT was not present at the onset of the procedure, it was induced using programmed 
electrical stimulation. 3-D bipolar activation and voltage maps were constructed during AT 
to 1) identify the underlying mechanism, and 2) select target sites for ablation. Stability 
parameters (variability in cycle length, local activation time and beat to beat difference of 
the catheter’s location) were used to exclude signals with low amplitudes due to poor con-
tact of the catheter’s tip with the endocardial wall. The local activation time was determined 
by automatically marking the maximum amplitude of each bipolar potential.
If necessary, markings were adjusted manually. The peak-to-peak amplitude of bipolar 
electrograms was used to construct colour coded voltage maps. In case of fractionated 
potentials, the peak-to-peak amplitude of the largest deflection was measured. Areas of 
scar were delineated using a cut-off value of 0.1 mV.18
classification of Atrial Tachycardia
Based on activation maps, three different types of AT were distinguished:
1) typical atrial flutter (AFL): a single (counter)-clockwise, cavo-tricuspid isthmus depen-
dent macro-reentrant circuit, 2) intra-atrial reentrant atrial tachycardia (IART): a macro-
reentrant tachycardia involving scar tissue, suture lines or prosthetic materials,
3) focal atrial tachycardia (FAT): electrical activation originating from a small, circum-
scribed region from where it expands to the remainder of the atria.
Ablation Procedure
After mapping, a radiofrequency catheter ablation procedure was performed. At each site, 
radiofrequency current was applied for 60 seconds. In case of non-cooled ablation, tip 
temperature was set at 70°C and the maximum output at 50W. During ablation using an 
irrigated-tip catheter (19% of the procedures), temperature was limited to 45-50°C and 
power to 40-45 W with saline flow of 20 ml/min. Each lesion was tagged on the electroana-
tomical map. Success was defined as (1) in AFL patients: establishment of a line of conduction 
block over the cavo-tricuspid isthmus, (2) in IART/FAT patients: termination during ablation.
statistical Analysis
Data were expressed as mean value ±SD or median (range). Statistical significance was 
defined as P<0.05. One-way ANOVA test was used to compare fluoroscopy time and 
procedure time required for ablation of different types of tachycardias. Survival free from 
arrhythmia recurrence was analyzed by method of Kaplan-Meier with corresponding log-
rank test for differences in distribution between the curves. The 2 groups were defined as 
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patients who underwent a successful ablation procedure and patients in whom ablation was 
not successful.
resulTs
characteristics of the study population
The study population consisted of 53 patients (27 male, median age 35 (6-80) yrs). Major 
common congenital heart defects included transposition of the great arteries (TGA: N=4), 
univentricular hearts (UVH: N=15), ventricular septal defect (VSD: N=2), coarctation of the 
aorta (CoA: N=2), atrial septal defect (ASD: N=11), tetralogy of Fallot (ToF: N=10) or valvular 
heart disease (VHD: N=9). Characteristics of the study population are given in Table 1.
Time to post-operative atrial tachyarrhythmias and first intervention
Figure 1 shows age at 1) the time of the first surgical procedure, 2) the onset of the AT and 
3) the first ablation procedure. Patients are grouped according to major common congenital 
defect; the groups are ranked according to the earliest averaged age at time of cardiac 
surgery. Age at time of the first surgical procedure ranged from 0 to 55 (median: 7) years. 
Median age at onset of AT was 31 (4-73) years; AT developed 18 (6 months to 44) years after 
the first surgical intervention. The first ablation procedure was performed at the median age 
of 38 (6-80) years. On average, median time between the onset of AT and the first ablation 
procedure was 4 years.
Table 1. Characteristics of the study population.
CHD
(number, gender)
Surgical Procedures
TGA (N=4, 3M) Mustard procedure
UVH (N=14, 7M)
Ebstein’s anomaly (N=1,M)
Fontan procedure (atrio-pulmonary conduit, N=11)
Mustard operation followed by Jatene procedure (N=1)
Conduit left ventricle –pulmonary artery (N=1)
Blalock shunt (N=1)
Glenn shunt and ASD closure (N=1)
VSD (N=2, 1M) surgical closure defect
CoA (N=2, 2F) resection stenotic part and interposition of a graft
ASD (N=11, 5M) surgical closure defect
ToF (N=10, 5M) total correction (N=9)
closure VSD and creation Blalock-Taussig shunt (N=1)
VHD (N=9, 5M) valve replacement (N=8)
surgical valvotomy (N=1)
CHD= congenital heart defect, N=number of patients, M=male, F=female UVH= univentricular hearts, 
TGA= transposition of the great arteries, VHD= valvular heart disease, CoA= coarctation of the aorta, 
ASD= atrial septal defect, VSD= ventricular septal defect, ToF= tetralogy of Fallot
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outcome first ablation procedure
In the entire study population, mapping revealed 27 AFL (cycle length= 288±81 ms), 22 
IART (cycle length= 309±81 ms) and 5 FAT (cycle length= 380±147 ms) at the first ablation 
procedure.
In one patient, 2 AT were eliminated during the same procedure. Successful ablative 
therapy was achieved in 65% (N=35) of all AT; 20% (N=11) of AT did not terminate and 
the other AT converted to either another AT (N=4, 7%) or AF (N=4, 7%) during ablation.
In case of AFL, termination during ablation and assessment of a bi-directional conduction 
block over the cavo-tricuspid isthmus was achieved in 67% (N=18). Despite entrainment 
demonstrating cavo-tricuspid isthmus dependent conduction, 18% (N=5) of the AFL did not 
terminate during ablation. Conversion from AFL to AF during ablation occurred in the other 
15% (N=4). In those patients, a bi-directional conduction block was assessed after electrical 
cardioversion to sinus rhythm.
Fifty-five percent of the IART terminated during ablation; conversion from IART to 
another regular AT or AF occurred in respectively 14% (N=3) and 5% (N=1). Target areas 
for ablation of IART were located between 1) areas of scar tissue (N=20), 2) scar tissue areas 
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figure 1. Age at the time of the first surgical procedure, onset of the AT and first ablation procedure 
for each patient separately. Patients are grouped according to major congenital/acquired heart disease 
and groups are ranked according to the earliest averaged age at time of cardiac surgery.
TGA = transposition great arteries, UVH = univentricular hearts, VSD = ventricular septal defects, CoA 
= coarctatioa aortae, ASD = atrial septal defect, ToF = tetralogy of Fallot, VHD=valvular heart disease.
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and the inferior caval vein (N=2). The critical path of the re-entrant circuit was located in the 
left atrium in only 3 patients. In 27% (N=6), AT did not terminate during ablation despite 
extensive mapping.
All FAT (N=5) were successfully eliminated by ablation at the site of earliest activation. 
The majority of the FAT also originated from the right atrium; 1 FAT emerged from the left 
side of the inter-atrial septum.
recurrent atrial tachyarrhythmias
Mean follow-up after the first ablation procedure was 5±3 (2.5-9) years. AT recurred in 
29 patients and 15 of them underwent therefore more than one ablation procedure. Time 
between ablative therapy and recurrences of AT are shown in Figure 2. Recurrences after the 
second ablation procedure occurred in seven patients. In one patient, 9 different AT were 
ablated during a follow-up period of 6-years (not shown). As demonstrated in Figure 2, most 
AT often re-appeared within the first year after ablative therapy.
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figure 2. Long-term time interval between ablative therapy and recurrences of AT. Twenty-nine 
patients experienced one or more recurrences.
C
ha
pt
er
 1
1
174
Mechanism and location of the arrhythmogenic substrate of recurrent 
atrial tachyarrhythmias
Figure 3 shows schematic representations of the atria demonstrating the location of the 
arrhythmogenic substrate of recurrent IART and/or FAT for patients undergoing repetitive 
ablative therapy (N=15); patients with recurrent AFL (N=5) are not shown. The mechanism 
underlying the AT is represented by a symbol and the number indicates the order of recur-
rences. The outcome of the ablation procedure is represented by the colour of the symbol 
(green: elimination of the AT, red: unsuccessful ablation procedure). In 7 patients with recur-
rent AT, the underlying mechanism of successive AT was similar, either IART (N=2) or AFL 
(N=5). Eight patients presented with successive AT caused by different mechanisms, includ-
ing IART+FAT (N=3), AFL+FAT (N=1), IART+AFL (N=2), AFL+FAT+AF (N=1) or IART+FAT+ AF 
(N=1). Interestingly, the re-entrant circuit of IART, or the origin of an FAT of consecutive AT 
was different for the majority of the patients. In one patient, the crucial pathway of the 
re-entrant circuit of 2 successive IART was located between the inferior caval vein and the 
atriotomy scar (first patient in the upper panel).
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figure 3. Schematic representations of the atria demonstrating the location of the arrhythmogenic 
substrate of recurrent AT for patients undergoing repetitive ablative therapy. The mechanism 
underlying the AT is represented by a symbol and the number indicates the order of recurrences. The 
outcome of the ablation procedure is represented by the colour of the symbol (green: elimination of 
the AT, red: unsuccessful ablation).
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long-term outcome
During the follow-up period, a total of 77 catheter ablation procedures were performed. 
In 4 patients, 2 AT were eliminated during the same procedure. Eighty-one distinct AT (29 
incessant) were mapped and treated with ablative therapy. In the entire study population, 
mapping revealed 34 AFL (CL= 372±99 ms), 32 IART (CL= 275±75 ms), 13 FAT (CL= 307±76 
ms) and 2 “focal” AF. Ablative therapy was succesful in 69% of all AT; 19% of AT did not 
terminate and the other AT converted to either another AT (5%) or AF (7%) during ablation. 
Fluoroscopy time during mapping and ablation of IART (55±26* minutes) was significantly 
longer than during AFL (42±27 minutes) or FAT (40±25 minutes) procedures, P =0.03. The 
 
 
figure 4.
Panel A: Flowchart describing the acute success, recurrences, additional ablation procedures and final 
outcome in the total patient population. Panel B: Kaplan Meier curve with survival free from arrhythmia 
for all patients (with and without acutely successful ablation). AF = atrial fibrillation, AFL = atrial flutter, 
AT = atrial tachycardia, LtoFU = lost to follow up, SR = sinus rhythm.
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procedure time required for ablative therapy of IART was also longer (300±100* minutes, 
compared to AFL: 229±76 minutes, FAT: 211±66 minutes, P=0.001).
The relation between the results of the ablation procedure and long-term outcome is 
demonstrated in Figure 4. During last follow-up visit of the 50 patients excluding 3 subjects 
lost for follow-up, they had either sinus rhythm (N=31, 59%), a regular AT (N=5, 9%) or 
AF (N=14, 26%). Five patients died due to progressive heart failure 34±28 months after the 
ablation procedure; rhythm prior to death was sinus rhythm (N=2) and AF (N=3).
Paroxysms of AT were recorded in 12 sinus rhythm patients who underwent a successful 
ablation procedure. Anti-arrhythmic drugs were used by 18 patients with sinus rhythm. 
Persistent AF developed during the follow-up period in 14 patients. Seven patients had AF 
despite a successful ablation; in the other 7 patients, AF resulted from progression of AT to 
AF. Eleven of the 19 patients with an unsuccessful ablative therapy had persistent AT at the 
onset of the ablation procedure. Surprisingly, 7 patients who had one or more unsuccess-
ful ablation procedures (no termination during ablation, conversion to AF or another AT) 
remained in sinus rhythm during the follow-up period.
dIscussIon
This study reports on characteristics of recurrent AT after ablative of late post-operative 
AT during long-term follow-up in a large cohort of patients with predominantly complex 
congenital heart defects.
The majority of the ablation procedures were guided by 3-dimensional electro-anatomical 
mapping techniques enabling accurate localization of the arrhythmogenic substrate. The 
key findings of our study are that though ablative therapy of post-operative AT is most 
often successful, a large number of patients presented with recurrent AT. However, repeated 
ablative therapy of recurrent AT was effective in maintaining sinus rhythm in most of the 
patients. As the arrhythmogenic substrate of patients who had multiple ablation procedures 
was located at different atrial sites it is most likely that recurrent AT are the result of diffuse 
electro-pathological alterations of atrial tissue and/or progressive atrial myopathy instead 
of arrhythmogenicity of prior ablative lesions. Despite recurrent AT in many patients, the 
majority of the study population was in sinus rhythm at the end of the follow-up period.
Atrial tachyarrhythmia mechanism
The mechanism underlying late post-operative AT in our study population was variable; often 
AFL and IART, less frequently FAT and rarely focal AF. In a large number of patients, different 
mechanisms gave rise to successive AT.
Consistent with other reports on the mechanism underlying post-operative AT in patients 
with congenital heart disease, IART and AFL were most often observed.8,27
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FAT were less frequently observed. We previously demonstrated that FAT arise mainly 
from areas where conduction is abnormal.28,29 The atria of patients with CHD contain areas 
of fibrotic tissue giving rise to local dissociation in conduction and hence favor develop-
ment of focal activity.30,31 Reports on focal AF in CHD patients are rare and the mechanism 
underlying this AT in our patient population has recently been described in detail.28,29
Ablative therapy
Most ablation procedures performed in this study population were guided by a 3-dimen-
sional electro-anatomical mapping system. Triedman et al. demonstrated the beneficial effect 
of an electro-anatomical mapping system over a conventional, fluoroscopy based mapping 
technique on the outcome of ablative therapy of post-operative AT. 32 However, compared to 
their ablation results, in our study 28% of the IART did not terminate during ablation despite 
the use of a 3-dimensional electro-anatomical mapping technique. This outcome emphasizes 
that ablation of IART remains very difficult despite facilitating mapping techniques.
Crucial pathways of the reentry circuit of most IART were located between areas of scar 
tissue, indicating necessity of accurate delineation of low voltage areas. 18 In patients who 
had multiple ablation procedures, target sites for ablation of successive AT were located 
at different atrial sites suggesting that new AT were not caused by arrhythmogenicity of 
previous ablative lesions. Most recurrences occurred in the first year after ablative therapy.
As the reentry circuit of post-operative AT in patients with CHD often consist of multiple 
re-entrant pathways a new reentry circuit may develop after ablation giving rise to early 
recurrences. Also, these new AT may simply be the result of diffuse electro-pathological 
alterations of the atrial tissue. Late recurrences also indicate progression of atrial myopathy.
After successful elimination of the AT, we did not induce other AT. It can be hypothesized 
that the incidence of redo-procedures can be reduced by additionally ablating other induc-
ible AT. However, low voltage areas and prosthetic materials are present throughout the 
atria and multiple reentry circuits may therefore be possible. Extensive ablation at different 
sites in the atria would be required to eliminate additional IART (with unknown clinical 
relevance). This might increase the chance of constructing incomplete lesions which may in 
turn be pro-arrhythmic.
Another interesting finding is that in some patients who had several ablation procedures 
mapping revealed different mechanism underlying the AT; e.g. an IART during the first abla-
tion procedure and a FAT in the next procedure. To our knowledge, the presence of different 
mechanisms underlying consecutive AT in patients with CHD has so far not been reported.
Surprisingly, despite some unsuccessful ablation procedures (no termination or conver-
sion to another AT or AF) patients converted to sinus rhythm after the ablation procedure 
and remained in sinus rhythm during the follow-up period.
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Atrial fibrillation
At the end of the follow-up period, 26% of the patients had AF. Kirsh et al. demonstrated 
that AF is not an uncommon AT in CHD patients.33 In some of our patients, AF resulted from 
progression of recurrent AT. Experimental mapping studies have demonstrated that a single 
macro-reentrant circuit may degenerate to AF if atrial tissue can not be activated at a high 
activation rate and fibrillatory conduction occurs consequently. 34 In line with these experi-
ments, we have previously reported on focal activity giving rise to fibrillatory conduction in 
two patients with CHD. However, AF developed in 7 patients despite successful elimination 
of the AT by ablative therapy suggesting that different mechanisms causing AF in this patient 
group may be involved. Further studies in larger populations are required in order to gain 
insight into the mechanism of AF in this patient group.
limitations
Holter monitoring was not consistently performed in every patient in order to determine the 
incidence of AT after ablative therapy. However, the majority of the CHD patients with an AT 
recurrence immediately visited the hospital because of symptoms. Data in this study are based 
on only 15/29 patients with recurrent AT who underwent more than one ablation procedure.
During the mapping procedure, crucial pathways of reentrant circuits were mainly selected 
by analyzing electro-anatomical activation maps. Entrainment techniques could not always 
be used as pacing in low voltage areas was often difficult and frequently resulted in conver-
sion to another AT. When one AT was successfully ablated, we did not try to induce other AT.
When one AT converted to another AT, we did not target this AT as well. Consequently, 
we do not know whether ablation of multiple AT during one ablation procedure could have 
prevented future recurrences. In addition, irrigated tip ablation was performed in only a 
minority of the patients and 8 mm tip catheters were not used. Hence, the applied mapping 
and ablation techniques may account for a number of recurrences observed in this study.
conclusIon
Focal and reentrant mechanisms underlie late post-operative AT in patients with CHD.
Successive AT developing over time may be caused by different mechanisms. The com-
plexity of the reentrant circuit is associated with the complexity of the CHD and correspond-
ing extensiveness of surgical procedures. In patients who had multiple ablation procedures, 
the AT originated from different atrial sites suggesting that these new AT were not caused 
by arrhythmogenicity of previous ablative lesions. Recurrent AT occurred frequently after 
successful ablation and occurred mainly in the first year after treatment. The long-term 
outcome is often complicated by development of AF. However, the majority of the patients 
were in sinus rhythm.
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Chapter 12
Long-term clinical outcome after 
radiofrequency ablation of cavotricuspid 
isthmus dependent atrial flutter and risks of 
atrial fibrillation occurrence.
Jael Z. Atary, Natasja M.S. de Groot MD, Jeroen Jansson, Marianne Bootsma, 
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AbsTrAcT 
 
 
 
 
 
 
 
objective
To assess long-term (median 40 months) outcome of cavotricuspid isthmus ablation in terms 
of atrial flutter (AFL) recurrence and particularly in terms of atrial fibrillation (AF) occurrence 
in a clinical population with electrocardiographically documented isthmus dependent AFL 
with or without a history of AF.
Methods
From 1995 to 2006 149 patients underwent radiofrequency ablation procedures for AFL. Of 
these patients, 87 patients had a known history of paroxysmal AF (87/149, 58%) and were 
assigned to group 1. The remaining patients were defined as group 2.
results
A total of 133/149 patients had an initially successful AFL ablation. In 85% (113/133) of 
procedures bidirectional isthmus block was achieved (others were defined as successful due 
to noninducibility). Patients in group 1 had a significantly higher cumulative incidence rate of 
AF occurrence than patients in group 2 (p=0.0007): The cumulative incidence of AF occur-
rence was 60% at 1 year (95%CI 48%-72%) and 81% at 5 years (95%CI 71%-92%). AF 
occurrence in group 2 at 1 year was 28% (95%CI 14%-43%) and at 5 years 57% (95%CI 
39%-75%). However, the large difference between groups 1 and 2 reflected primarily the 
much higher rate of AF occurrences in group 1 during the first 1.5 year post-ablation.
conclusion
Despite the efficacy of cavotricuspid isthmus RF ablation in the treatment of AFL, most 
patients cannot be considered completely cured, particularly with regard to AF occurrences. 
Patients with a preablation history of AF and high diastolic blood pressure were at signifi-
cantly higher risk and should be monitored more closely and treated more aggressively for 
hypertension. However, preablation AF did not lead to an increased long-term (>1.5 year) risk 
after AFL ablation. Patients in this subgroup therefore may expect the same long-term risk of 
AF as patients without pre-existing AF.
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InTroducTIon
Catheter ablation of the inferior vena cava–tricuspid isthmus is an established treatment 
modality for typical atrial flutter (AFL). Though ablative therapy of AFL has proven to be 
efficacious, long-term outcome of ablation may be complicated by the occurrence of atrial 
fibrillation (AF), either preexisting or developing de novo1-3. Studies investigating factors 
predictive of AF arising after ablation of AFL showed that there is a high risk of developing 
AF particularly in a subgroup of patients with a history of paroxysmal AF1-6. Despite the 
seemingly pessimistic outlook for this patient subgroup, several follow-up studies including 
patients with both AFL and AF, showed that ablation of the right atrial isthmus for typi-
cal AFL in combination with previously ineffective antiarrhythmic drug (AAD) therapy was 
found to result in longer arrhythmia-free intervals in a large proportion of patients7;8. It has 
therefore been suggested that patients with preexisting AF may benefit from isthmus abla-
tion of AFL in terms of less recurrences of AF and better effect of medication on previously 
therapy-resistant AF 7;8. The purpose of this retrospective study was to assess the long-term 
(median 40 months) outcome of cavotricuspid isthmus ablation in terms of AFL recurrence 
and particularly in terms of AF occurrence in a population of “real-practice” patients with 
electrocardiographically documented isthmus dependent AFL with or without a preablation 
history of AF.
MeThods
Patient population
Consecutive patients referred between June 1995 and Aug 2003 for ablative therapy of 
electrocardiographically documented isthmus dependent atrial flutter were included in the 
current retrospective study. Patients were divided into 2 groups: Group 1 were patients with 
isthmus dependent AFL and documented coexisting paroxysmal AF and group 2 consisted 
of patients with AFL who had no history of AF. Patients with congenital heart disease were 
excluded from this study.
electrophysiology study and ablation procedure
Linear ablation of the right atrial isthmus was guided by either fluoroscopy only or with 3-D 
electro-anatomical mapping techniques. In case of conventional mapping, the right atrial 
pattern of activation was studied with a 7F 20-electrode steerable catheter (Halo catheter, 
Cordis-Webster, Diamond Bar, California, USA) or a 8F 64-electrode collapsible Basket cath-
eter (Cardiac Pathways, Sunnyvale, California, USA).
Three-dimensional electro-anatomical mapping techniques used included the CARTO™ 
(Biosense-Webster, Diamond Bar, California, USA), the Real time position management 
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system (RPM, Cardiac Pathways, Sunnyvale, California, USA) or the Ensite system (Endo-
cardial Solutions Inc., St. Paul, Minnesota, USA). Detailed description of the underlying 
technology and use of these various electro-anatomical mapping techniques has been given 
previously by others.9-11
For induction of AFL, programmed electrical stimulation applying up to three extrastimuli 
or burstpacing at 2 times diastolic threshold (pulse width 2 ms) was performed with a 
constant current stimulator (Medtronic, Minneapolis, MN, USA). Ablation was performed 
with either a non-cooled or cooled 7F 4 mm Navi-star catheter (Biosense-Webster, Diamond 
Bar, California, USA), a 7F 4mm tip steerable cooled ablation catheter (Cardiac Pathways, 
Sunnyvale, California, USA) or a standard 7F 4 mm steerable ablation catheter.
At each site, radiofrequency current was applied for 60 seconds. In case of non-cooled 
ablation, tip temperature was set at 70°C and the maximum output at 50W. During abla-
tion using an irrigated-tip catheter, temperature was limited to 50°C and power to 45W 
with saline flow of 17 ml/hour (4 ml/min). Each lesion was tagged on the electro-anatomical 
right atrial map when using a 3-D electro-anatomical mapping system.
During the procedure, heparin was administered intravenously to maintain an anti-
clotting time of 2.5-3 times the control value for adequate anti-coagulation. If necessary, 
patients were intravenously sedated with midazolam and fentanyl. Acute procedural success 
was initially defined as termination of AFL during ablation and non-inducibility, and later 
in time as establishing bidirectional conduction block over the cavo-tricuspid isthmus.3;12
definitions
Some patients underwent more than one AFL ablation procedure. The first successful AFL 
ablation procedure is defined as the first of several AFL ablation procedures during which 
acute procedural success was achieved. The last successful AFL ablation procedure is defined 
as the last of several AFL ablation procedures during which acute procedural success was 
achieved.
AFL or AF episodes at follow-up were documented by either electrocardiographic or 
24-hour Holter recordings and by repeat electrophysiology study if repeat ablation was 
clinically indicated.
follow-up
Follow-up was conducted at the out patient clinic initially at 3 months post-ablation and 
subsequently continued at the arrhythmia clinic or at the patients’ referring physician at 6 
month intervals except when patients remained entirely free of symptoms. In the event of 
a recurrence, symptomatic or documented, patients were referred back to the arrhythmia 
clinic for re-analysis.
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statistical Analysis
Continuous data are expressed as mean (±standard deviation [SD]), or as median (interquartile 
range [IQR]), and dichotomous data are presented as numbers and percentages. Differences 
between categorical data were tested for statistical significance using a Pearson chi-square 
test using continuity correction where appropriate. Continuous normally distributed data 
were tested by student t-tests or in the case of a non-Gaussian distribution by a nonpara-
metric test for independent samples. One way analysis of variance (ANOVA) was performed 
when comparing normally distributed data between more than two independent groups. 
Normal distribution was tested using the Kolmogorov-Smirnov test. Survival was analyzed 
by method of Kaplan-Meier with corresponding log-rank test for differences in distribution 
between the curves. Univariate and multivariate Cox regression analysis was performed to 
determine a relation between potential risk factors at baseline and the occurrence of AF. All 
variables with an unadjusted p value of <0.10 entered the multivariate regression model. 
Adjusted Hazard Ratio (HR) is reported in the text with the corresponding 95% confidence 
interval (CI). All tests were two-sided, a p-value of <0.05 was considered significant.
resulTs
Patients
Between June 1995 and July 2006 149 patients underwent a total of 210 radiofrequency 
ablation procedures for isthmus dependent atrial flutter. Baseline characteristics are shown in 
table 1 for the total patient population and for group 1 and 2 separately. Of the total patient 
population, 87 patients had a known history of paroxysmal AF (87/149, 58%) and were 
therefore assigned to group 1.
Patients in group 2 were younger than patients in group 1 (61 ± 13 years vs. 66 ± 11 
years, p=0.015) and used more Class 1C antiarrhythmic drugs (20% vs. 5%, respectively, 
p=0.009). Eighty patients (80/149, 54%) had at least one kind of structural heart disease, 
the majority being valvular heart disease (n=63), which was in most cases mitral valve insuf-
ficiency (54/63, 86%). The incidence of structural heart disease was similar between the 
two patient groups as well as the cardiovascular risk profile.
Figure 1 illustrates the distribution of symptoms reported by patients in group 1 and 2. 
Overall, symptoms reported by patients were similar. Palpitations was the most frequently 
reported complaint (>70%) in both groups. Ten percent of all patients were asymptomatic 
at the time of enrolment. Significantly fewer patients in group 2 had complaints of dyspnea 
when compared to patients in group 1 (24% vs. 40%, p=0.041; Figure 1).
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Table 1. Baseline characteristics.
Total
(n=149)
Group 1
(n=87)
Group 2
(n=62)
p-value
Men 116 (78%) 72 (83%) 44 (71%) 0.09
Age (years ± SD) 64 ± 12 66 ± 11 61 ± 13 0.015*
Structural heart disease
 Dilating cardiomyopathy 16 (11%) 9 (10%) 7 (11%) 0.85
 Hypertrophic cardiomyopathy 6 (4%) 4 (5%) 2 (3%) 1.00
 Valvular heart disease 63 (42%) 41 (47%) 22 (36%) 0.16
 Coronary artery disease 16 (11%) 11 (13%) 5 (8%) 0.37
 Coronary bypass surgery 12 (8%) 9 (10%) 3 (5%) 0.36
 Congenital heart disease - - - -
Body Mass Index (± SD) 26.0 ± 3.9 26.1 ± 4.8 25.9 ± 3.0 0.80
Hypertension 37 (25%) 24 (28%) 13 (21%) 0.36
Diabetes 13 (9%) 7 (8%) 6 (10%) 0.73
Hypercholesterolemia 29 (20%) 21 (24%) 8 (13%) 0.09
Thyroid disease 13 (9%) 8 (9%) 5 (8%) 0.81
Antiarrhythmic drugs
 Class IA 1 (0.7%) 1 (1.6%) 0 0.86
 Class IB 1 (0.7%) 1 (1.6%) 0 0.86
 Class IC 20 (13%) 3 (5%) 17 (20%) 0.009*
 Class II 19 (13%) 14 (16%) 5 (8%) 0.15
 Class III 80 (54%) 49 (56%) 31 (50%) 0.45
 Class IV 21 (14%) 13 (15%) 8 (13%) 0.72
 Lanoxin 29 (20%) 18 (21%) 11 (18%) 0.65
Left atrial size (mm ± SD) 44.1 ± 0.8 45.5 ± 0.8 42.4 ± 0.7 0.055
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figure 1. Symptom characteristics.
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Procedure
Procedural characteristics are summarized in table 2. Of the 210 AFL ablation procedures 173 
(83%) were considered acutely successful, either by achieving termination of AFL with nonin-
ducibility (13%) or by the confirmation of a line of conduction block (87%). The proportion 
of patients with procedural success was not significantly different between the groups. In 
terms of patients, 133 of 149 patients (89%) underwent at least one ablation procedure that 
was considered acutely successful. Eleven patients required more than one ablation proce-
dure (11/133, 8%) to achieve this result. In the remaining patients, a bidirectional conduction 
block was not achieved despite extensive ablation.
Patients in group 2 had a shorter AFL cycle length than patients in group 1 (240 ± 45ms 
vs 259 ± 42ms, p=0.013) and acute success was more often defined by noninducibility 
than by bidirectional isthmus block when compared to patients in group 1 (19% vs 9%, 
p=0.042).
Table 2. Procedure characteristics.
Total
(n=149)
Group 1
(n=87)
Group 2
(n=62)
p-value
Procedures (n) 210 123 87
 Patients with >1 RFA of AFL (n) 47/149 (32%) 30/87 (35%) 17/62 (27%) 0.36
 Acute procedural success achieved 133/149 (89%) 80/87 (92%) 53/62 (86%) 0.21
 Acute success after 1st RFA 122/149 (82%) 74/87 (85%) 48/62 (77%) 0.23
Initial rhythm during study
 Sinus 110/210 (52%) 59/123 (48%) 51/87 (59%)
 AFL 71/210 (34%) 36/123 (29%) 35/87 (40%) <0.001*
 AF 29/210 (14%) 28/123 (23%) 1/87 (1%)
AFL cycle length (ms ± SD) 249 ± 44 259 ± 42 240 ± 45 0.013*
Acute success of RFA of AFL 173/210 (83%) 105/123 (85%) 68/87 (78%) 0.18
 Criteria of successful RFA
 Noninducibility 22/173 (13%) 9/105 (9%) 13/68 (19%)
 Bidirectional conduction block 151/173 (87%) 96/105 (91%) 55/68 (81%) 0.042*
Rhythm at procedure end
 Sinus rhythm 176/210 (84%) 105/123 (85%) 71/87 (82%)
 Conversion to AF 30/210 (14%) 17/123 (14%) 13/87 (15%) 0.37
 AFL 4/210 (2%) 1/123 (1%) 3/87 (3%)
Procedure time (min ± SD) 201 ± 72 199 ± 70 203 ± 75 0.82
Fluoroscopy time (min ± SD) 34 ± 19 34 ± 17 35 ± 21 0.97
RFA guiding technique
 Conventional 51/210 (24%) 27/123 (22%) 24/87 (28%)
 CARTO 134/210 (64%) 79/123 (64%) 55/87 (63%)
 Ensite 14/210 (7%) 9/123 (7%) 5/87 (6%)
 RPM 11/210 (5%) 8/123 (7%) 3/87 (3%) 0.62
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Ablation techniques
Ablation procedures were guided with conventional techniques (24%), or the CARTO™ 
(64%), the RPM (5%) or ENSITE (7%) system (Table 2). Overall, procedure time did not 
differ significantly between the 4 ablation techniques (overall mean procedure time: 201 ± 
72 minutes, one-way ANOVA test: p=0.52). Fluoroscopy time was for the most part similar 
between the different ablation techniques (overall mean fluoroscopy time: 34 ± 19 min), but 
a significant difference in fluoroscopy times was found between the 4 techniques due to the 
shorter fluoroscopy times in the subgroup guided with the CARTO™ system (32 ± 18min) 
when compared to the Ensite system (47 ± 22min, one-way ANOVA test: p=0.005). No 
significant differences were observed in procedure-, or fluoroscopy time between consecu-
tive ablation procedures.
follow-up: Afl recurrence rate
Figure 2 illustrates the estimated cumulative rate of freedom from AFL recurrence in patients 
with and without a history of AF from the moment of the last successful AFL ablation pro-
cedure (median follow-up: 34 months, IQR 2-62 months). As mentioned earlier, this was 
achieved in 133 patients (table 2). Of these patients, 43 (32%) underwent >1 AFL ablation 
procedure (26/80, 33% in group 1 and 17/53, 32% in group 2). As initial success was not yet 
based on bidirectional isthmus block in the earliest procedures performed in this study, the 
last successful AFL ablation procedure was chosen as starting point from which AFL recur-
rence rate was evaluated (Figure 2). In 89% (119/133) of these last procedures immediate 
success was defined by bidirectional isthmus block.
The cumulative incidence rate of AFL recurrence in patients of group 1 at 1 year was 
23% (95%CI 12%-33%) and at 4 years 34% (95%CI 22%-47%). For patients in group 2 
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figure 2. Recurrence of atrial flutter after the last successful AFL ablation procedure (32% of these 
patients underwent >1 AFL ablation procedure).
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the cumulative incidence of AFL recurrence was similar: At 1 year 20% (95%CI 7%–34%) 
and at 4 years 24% (95%CI 9.7%–38%).
follow-up: Af occurrence rate
Figure 3 demonstrates the estimated cumulative rate of freedom from AF in patients in 
groups 1 and 2 from the moment of the first successful AFL ablation procedure (n=133, 
median follow-up: 40 months, IQR 5-70 months). In 85% (113/133) of these early initially 
successful procedures bidirectional isthmus block was achieved (the rest was defined as suc-
cessful due to noninducibility of AFL). Not surprisingly, patients with a known history of AF 
(group 1) had a significantly higher cumulative incidence rate of AF occurrence than patients 
in group 2 (log-rank test: p=0.0007). The cumulative incidence rate of AF occurrence in 
group 2 at 1 year was 28% (95%CI 14%-43%) and at 5 years 57% (95%CI 39%-75%). For 
patients in group 1 the cumulative incidence of AF occurrence was 60% at 1 year (95%CI 
48%-72%) and 81% at 5 years (95%CI 71%-92%). However, figure 4 demonstrates that 
the large difference between groups 1 and 2 reflects primarily the much higher rate of AF 
occurrences in group 1 during the first 1.5 year post-ablation. This difference was highly 
significant (log-rank p=0.0006). After 1.5 year the cumulative incidence of first AF episodes 
in the group of patients with a history of AF was similar to the group of patients without a 
history of AF.
Multivariate Cox regression analysis (table 3) revealed that a known history of AF and 
a diastolic blood pressure ≥90 mmHg (measured at hospital admission for the ablation 
procedure) were independently associated with a 2-fold increased risk of AF occurrence at 
follow-up.
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figure 3. Occurrence of atrial fibrillation after initially successful ablation of typical AFL.
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long-term treatment course
Figure 4 shows prevalence of AAD treatment in patients who underwent a successful AFL 
ablation procedure (n=133). The percentage of patients on AAD therapy at baseline is shown 
next to the percentage of patients on AAD treatment by the end of follow-up (median 40 
months). There was no significant change in AAD use for patients in group 1 when compared 
to baseline AAD use: Fifteen percent (n=12/80) of patients in group 1 used no AAD at all at 
the end of follow-up versus 11% (9/80) at baseline (p=0.48)
Similarly, in group 2 the proportion of patients that did not require AAD treatment by the 
end of follow-up was comparable to the percentage of patients without AAD therapy at 
baseline (baseline: 26%, 14/53, versus follow-up: 36%, 19/53; p=0.29). However, there was 
a significant change in AAD treatment class. Significantly fewer patients in group 2 were 
on Class III AAD treatment at follow-up (baseline: 49%, 26/53, vs follow-up: 30%, 16/53; 
p=0.047). Of the 26 patients who were on Class III AAD’s at baseline, seven patients needed 
no AAD treatment by the end of follow-up, 3 patients were treated with only rate-control 
Table 3. Multivariable Cox Regression Analysis.
AF occurrence after successful AFL ablation
Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value
Age † 1.02 (1.00-1.04) 0.036* 1.01 (0.99-1.03) 0.456
Sex (male) 1.03 (0.59-1.80) 0.919
Preablation AF † 2.24 (1.33-3.77) 0.002* 2.17 (1.24-3.79) 0.006*
Syst. blood pressure ≥140 mmHg 0.98 (0.61-1.58) 0.932
Diast. blood pressure ≥90 mmHg 
†
2.02 (1.23-3.33) 0.006* 2.00 (1.21-3.31) 0.007*
Coronary artery disease 1.71 (0.69-4.26) 0.248
Diabetes Mellitus 0.55 (0.25-1.20) 0.134
Thyroid disease 0.77 (0.31-1.94) 0.579
Bidirectional isthmus block † 0.41 (0.17-1.03) 0.058 0.66 (0.24-1.86) 0.435
ACE-inh/AT2-antag. at discharge 0.75 (0.46-1.21) 0.237
Sotacor at discharge 0.91 (0.53-1.56) 0.743
Flecainide at discharge 0.68 (0.38-1.20) 0.184
Amiodarone at discharge 0.84 (0.45-1.58) 0.596
Verapamil at discharge 0.86 (0.43-1.74) 0.678
Statin at discharge 0.80 (0.45-1.41) 0.432
Recurrence of AFL 1.21 (0.72-2.04) 0.474
Left atrial diameter 1.02 (0.98-1.06) 0.340
AF at procedure end 0.60 (0.26-1.40) 0.240
RFA without use of 
3D-electroanatomical mapping †
2.08 (1.08-3.99) 0.028* 1.90 (0.92-3.96) 0.085
Only variables with an unadjusted p-value of <0.10 were included in multivariable analysis (indicated 
with †). Unadjusted and adjusted Hazard Ratio (HR) is reported with the corresponding 95% confi-
dence interval (CI). * p<0.05
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(beta-blockers) at follow-up and 3 patients were switched to a Class IC AAD. Slightly more 
patients in group 2 appeared to be on Class IC AAD therapy by the end of follow-up when 
compared to baseline (baseline: 6%, 3/53, vs follow-up: 17%, 9/53; p=0.066), but this was 
not statistically significant.
Ten patients (10/80, 13%) in group 1 underwent pulmonary vein isolation for AF dur-
ing follow-up. In group 2 only one patient (1/53, 2%, p=0.049) was treated for AF with 
pulmonary vein isolation during follow-up. His bundle ablation was performed in 11% of 
patients of group 1 (n=9/80) versus 6% of patients in group 2 (3/53, p=0.43).
dIscussIon
Key findings of this study are that: (1) The cumulative incidence of AF after successful AFL 
ablation procedures was high, with 57% during 5 year follow-up even in the patient group 
without preexisting AF (group 2), (2) that after 1.5 year post-AFL ablation patients with a 
history of AF had a similar AF occurrence rate compared to patients without a history of AF, 
and (2) a twofold and highly significant risk of AF occurrence was observed for patients with 
a diastolic blood pressure ≥90mmHg, independent of a pre-ablation history of AF.
Afl recurrence
Earlier studies of RF ablation of the cavotricuspid isthmus for typical AFL yielded disap-
pointing results with immediate procedural success rates as low as 78% and short-term 
recurrence rates as high as 41%.13 Since the introduction of complete bidirectional isthmus 
block as a procedural end-point, the success rate has risen to ≥90%.6;14-16 In accordance, 
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figure 4. Landmark incidence estimates for AF occurrence after successful AFL ablation.
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acute ablation success in this study was achieved in 89% (133/149) of patients, in >80% 
of patients by means of bidirectional conduction block as confirmation of success. With 
a 1-year recurrence rate of 22% (average of group 1 and 2) and a 4-year rate of 29% 
(average), recurrence of typical AFL was a relatively common problem in this series. In the 
early part of this series, conduction block in the isthmus was not tested as an endpoint after 
ablation and predominantly non-cooled catheter tips were used for ablation. It is possible 
that therefore analysis of recurrence is limited compared to other series where bidirectional 
block was used as endpoint and cooled catheter tips were used for isthmus ablation in all 
patients. Results are relatively comparable to other early observational studies with similar 
time period related experience, and procedural conditions.4;17
coexistence between Afl and Af
Atrial flutter and atrial fibrillation, which are both intra-atrial reentrant arrhythmias with dif-
fering complexity in their activation pattern and mechanisms, are frequently seen to cooexist 
in clinical practice. This was reflected in the present study by the fact that more than half of 
the unselected and consecutive patients referred for AFL ablation presented with a history of 
AF (87/149, 58%). Undoubtedly, the electrophysiological basis of the interrelation between 
AFL and AF needs further elucidation. The association generally reflects a similar arrhythmo-
genic substrate. One mechanism of AF occurrence is the electrical remodeling in the atrium 
induced by atrial flutter that predisposes to development of AF.18-20 Another mechanism 
may be that AF is the primary arrhythmia that precedes the onset of AFL because formation 
of a functional line of block between the vena cava during AF leads to the development 
of cavotricuspid isthmus dependent AFL.21 AF is then unmasked by elimination of the AFL 
substrate and continues to progress after AFL ablation.
Other theories include that AF development is part of the natural course of atrial flut-
ter in these patients, as atrial flutter is occasionally observed to spontaneously disorganize 
into atrial fibrillation in the electrophysiology laboratory. The right atrial flutter circuit is 
postulated to play a critical role in the initiation and maintenance of atrial fibrillation in 
some patients.22 These observations may explain the absence of recurrent atrial fibrillation 
in some patients with pre-ablation AF.
new-onset Af after Afl ablation
AF occurrence after RF ablation for AFL, either preexisting or de novo, is a phenomenon 
well documented in literature, with incidences ranging from 8%-82%.1;3;15;23;24. Though 
catheter ablation is an effective treatment for AFL and has become common, it is unclear if 
ablation is able to affect the risk for future AF development. Findings of a study by Halligan 
et al. all demonstrated that 56% of patients with AFL naturally developed new-onset AF 
after an average of 5 ± 6 years after the diagnosis of AFL in the absence of a preceding AFL 
ablation.25;26 This rate is very similar to the 5-year cumulative incidence rate of new-onset 
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AF found in the present study (57%, group 2). Ellis et al. reported a cumulative incidence of 
new-onset AF as high as 82% in patients with AFL after mean follow-up of 39 ± 11 months 
post-cavotricuspid isthmus ablation.24 These results suggest that the long term (≥5 years) risk 
of developing AF is already high for patients with “lone” AFL, and may not be affected by 
AFL ablation.
Af recurrence after Afl ablation
Should ablation be then undertaken in patients with AFL who also have AF? The answer to 
that question at present seems to be yes as there is ample evidence that ablation of AFL in 
patients who have both AFL and AF is associated with reduced incidence of subsequent atrial 
fibrillation by approximately 50%.1;2;16;27;28 It is suggested that, at least in a proportion of 
patients, reentry around a stable anatomical pathway such as the tricuspid annulus might 
serve as the underlying mechanism for maintaining AF.7
The present study found a high 5-year cumulative incidence of AF recurrence of 82% 
in the group with pre-existing paroxysmal AF (group 1). A recent observational study by 
Moubarak et al reported very similar results after AFL ablation, with an AF recurrence rate 
of 86% in patients with preexisting AF and a rate of new-onset AF of 62% after median 
follow-up of 7.8months in 135 patients who underwent successful isthmus-dependent AFL 
ablation.26
Is transisthmus ablation a definite cure for patients with AFL then, or can their follow 
up be characterized by the occurrence of other atrial arrhythmia, particularly in patients 
with a history of AF? Many studies have tried to answer these questions.1;4 The high and 
mostly unchanged number of patients receiving AADs at the end of follow-up in this study 
highlights the importance of the arrhythmic burden independent of the relapse of AFL. 
Despite the relatively pessimistic results of the current study for this subgroup of patients, 
further data analysis (figure 4) demonstrated a particularly pronounced difference in the 
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figure 5. Antiarrhythmic drug use at baseline and at the end of follow-up.
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incidence rate of AF occurrence between groups 1 and 2 in the first 1.5 year post-ablation, 
after which cumulative first events of AF occurrence appeared to happen at a similar rate 
between the groups. In addition, a limited percentage of patients (19%) with preablation 
AF (group 1) still had no (documented) recurrence of AF after 5 years of follow-up. It is 
possible that cavotricuspid isthmus ablation to some extent had a positive effect on the 
clinical course of AF in these patients. However, at the same time it is also possible that AF 
recurrence rates were underestimated because of asymptomatic episodes that may not have 
been documented. Nevertheless, in the 40% of patients of group 1 who were still free of 
AF 1.5 years after successful AFL ablation, the risk of AF recurrence was comparable to the 
risk of developing new-onset AF in the group without a history of AF (group 2) (Figure 4). 
These patients probably benefited from the ablation of isthmus-dependent AFL in terms of 
AF recurrences.
hypertension as additional treatment focus
Hypertension is frequently complicated by the development of AF though the mechanisms 
of this link are not completely understood. In a recent ovine study by Lau et al, investigators 
demonstrated that even short-duration hypertension (4-7weeks) may lead to significant 
atrial remodeling characterized by atrial enlargement/dysfunction, interstitial fibrosis, 
inflammation, slowed/heterogeneous conduction, increased ERP, and greater propensity for 
AF.29 Multivariate analysis in the present study revealed that a high diastolic blood pressure 
(≥90mmHg) predisposed patients to twice the risk of AF occurrence after AFL ablation, inde-
pendent of preexisting AF. Results shows that aggressive treatment of hypertension should 
be a prime focus of attention after successful AFL ablation, especially when considering the 
long-term risk of new-onset AF is >50% for patients with only AFL.
limitations
Our study population was classified into 2 groups on the basis of documentation of AFL 
alone or in combination with AF. The exact incidence and burden of arrhythmia episodes, 
(i.e. asymptomatic episodes, or in- or decrease of AF burden post-ablation), is not known and 
may have affected our classification and the evaluation of clinical improvement regarding 
arrhythmia burden. Elimination of flutter may have resulted in symptomatic improvement 
and facilitated better pharmacological control of atrial arrhythmia. Thus, the results should 
not be interpreted as lack of utility of transisthmic ablation in patients with coexisting AF and 
AFL; rather they show that transisthmic ablation cannot completely cure AF in this subgroup 
of patients.
Although every procedure involved a right atrial isthmus ablation, the ablation protocol 
and the criteria for procedural success have changed over the study period in keeping with 
advances in our knowledge. A complete bidirectional isthmus block at the conclusion of 
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a successful procedure was not obtained in all patients. This has obvious implications for 
analysis of arrhythmia recurrences.
Only 30% of the study population used no AAD at the end of follow-up. Thus, in these 
patients results should be interpreted as the consequence of the combination of RF ablation 
and AAD therapy rather than RF ablation alone.
conclusIon
Despite the efficacy of cavotricuspid isthmus RF ablation in the treatment of AFL, most 
patients cannot be considered completely cured, particularly with regard to AF occurrences. 
Patients with a preablation history of AF and high diastolic blood pressure were at signifi-
cantly higher risk and should be monitored more closely and treated more aggressively for 
hypertension. However, preablation AF did not lead to an increased long-term (>1.5 year) risk 
after AFL ablation, and patients in this subgroup therefore may expect the same long-term 
risk of AF as patients without pre-existing AF.
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Cardiovascular disease remains the leading cause of mortality in the western World, but 
significant improvements have been made in its treatment and prevention. This thesis shows 
that consistent implementation of a structured regional treatment and prevention program 
for acute myocardial infarction patients is feasible when health professionals of various dis-
ciplines collaborate (chapter 2). Guideline-recommended time-to-treatment intervals were 
achieved for the entire region of Hollands-Midden.
PCI in the setting of AMI significantly reduces mortality. The introduction of DES has sig-
nificantly improved one-year outcomes among patients undergoing elective PCI, primarily 
by reducing the need for repeat revascularization. Although DES are commonly used in AMI, 
there has been significant debate in the clinical community regarding their true efficacy 
and long-term safety. In chapter 3 results of the randomized MISSION!-intervention study 
demonstrates that safety of SES is comparable to BMS three years after the index event, in 
terms of death, stent thrombosis and nonfatal recurrent MI. The study also showed that the 
greatest efficacy of SES (compared to BMS) was achieved in the first year of follow-up after 
the AMI, by significantly reducing target vessel revascularizations. A similar need for target 
vessel revascularizations in SES and BMS treated patients was seen in the two subsequent 
years. It must be kept in mind though, that these results were achieved in the setting of the 
structured MISSION! AMI treatment protocol which ensured optimal treatment adherence 
and follow-up of patients.
In chapter 4 an effort was made to relate plaque characteristics at stent edges to clinical 
outcome at 9 months post PCI in 40 AMI patients by utilizing virtual histology intravascu-
lar ultrasound imaging (VH-IVUS). The technique allows for identification of four plaque 
components: fibrous, fibro-fatty, necrotic core and dense calcium. Plaque composition at 
9 months follow-up was believed to be different in SES treated patients when compared 
to BMS treated patients due to the potent antiproliferative effects of sirolimus. However, 
against expectations, the study did not demonstrate any significant changes in plaque com-
position at stent edges after 9 month follow-up in either SES or BMS treated patients. At 
the same time an effect of sirolimus on vascular lumen dimensions at the distal stent edge 
and neointima volume inside the stent was clearly present. Because of the relatively small 
patient sample size and perhaps too short follow-up, it is not possible to definitely conclude 
that no differences exists in plaque composition between SES and BMS at stent edges, but 
it may be possible that these changes are of smaller magnitude than anticipated. Also, the 
complexity of the VH-IVUS analysis technique in the setting of a follow-up study may have 
made it difficult to detect such small changes at the present time.
It is thought that routine thrombus aspiration prior to DES implantation in STEMI may 
improve clinical outcome after such procedures. Given the association between large throm-
bus burden in STEMI and late stent thrombosis, debulking thrombus burden could reduce 
the occurrence of residual thrombus and stent malapposition. In the study presented in 
chapter 5, a strategy of adjunctive thrombus aspiration before primary PCI in AMI patients 
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in combination with early (pre-hospital/in-ambulance) abciximab administration, was associ-
ated with a significant improvement in post-procedural ST segment resolution and with a 
lower mortality at one year follow-up.
In chapter 6 we evaluated the frequency and distribution of culprit lesions in patients 
presenting with ST-segment elevation myocardial infarction. This simple study demonstrated 
that the majority of occlusions occur in the proximal parts of the LAD and RCA with worse 
post-procedural LV-function in particular for LAD and LCX culprit lesions. The study shows 
that plaques in the proximal parts of the LAD and RCA are more prone to rupture. Knowl-
edge of the distribution of vulnerable plaques may help in the identification of patients at 
risk of coronary events.
chapter 7 aimed to provide more insight into the clinical profile, treatment delays, medi-
cation compliance and 12 month outcome of treatment in the elderly AMI patient popula-
tion (≥ 75 years). Results showed that older AMI patients had significantly less modifiable 
risk factors of coronary artery disease than younger patients and had a significantly higher 
in-hospital mortality rate despite similar post-procedural TIMI flow grades. Most importantly, 
the study showed that after surviving the first 3 months post AMI, elderly patients had a 
similar potential for favorable clinical outcomes at 12 months to their younger counterparts 
when they were treated with equal consistency and intensity
In recent years heart rate has been described as an increasingly important risk factor for 
reinfarction, revascularization and heart failure in patients with left ventricular dysfunction. 
The study presented in chapter 8 investigated clinical relevance of resting heart rate in post 
AMI patients who were treated with primary percutaneous intervention and a relatively 
preserved LV-function. During a mean follow-up of 20 months a baseline heart rate (first 
electrocardiogram at admission) of 72bpm or higher was associated with a significantly 
increased risk of the composite endpoint of all-cause mortality, nonfatal reinfarction, coro-
nary revascularization, and hospitalization for heart failure. In addition every 5bpm increase 
in baseline heart rate was associated with a further increase in risk for every one of those 
endpoints. Results of this study suggest that targeting heart rate in the currently growing 
population of post-AMI patients with preserved LV-function may also be of significant clini-
cal importance.
chapter 9 demonstrates that (1) left ventricular function can be preserved using an 
evidence-based protocol to manage AMI; (2), with preservation of left ventricular function, 
the proportion of post-MI patients fulfilling criteria for implantable cardioverter defibrillator 
(ICD) implantation is small; and (3), that relatively few of those patients who received ICDs 
receive appropriate ICD therapy delivery during follow-up. This last observation brings into 
question the current guidelines for the selection of patients for ICD implantation as primary 
prophylaxis against sudden cardiac death and should prompt a review of the evidence on 
which these guidelines are based.
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Findings of the study described in chapter 10 suggest that properties of the baseline 
stimulation threshold may be used clinically as an indicator of chronic changes caused by 
ischemic heart disease which increase the risk of arrhythmic events requiring ICD therapy 
and risk of mortality. A high right ventricular stimulation threshold was used as a marker of 
potentially arrhythmia-prone conditions. Although the simple uncontrolled measurement 
method in this retrospective observational study is by no means sufficient to suggest rou-
tine clinical use for assessment of arrhythmia risk or ICD eligibility at this time, the results 
indicate future potential in measuring and utilizing stimulation thresholds in a standardized 
prospective fashion, as clinical predictors for these patients.
chapter 11 aimed to provide more long-term (mean 5±3 years) data on the characteristics 
of recurrent atrial tachyarrhythmias (AT) after ablation of post-operative AT in 53 patients 
with congenital heart defects (CHD). A number of conclusions could be drawn from the find-
ings of this observational study: First, the data demonstrated that successive post-operative 
AT in CHD patients may be caused by different mechanisms, including focal and reentrant 
mechanisms. The complexity of the reentrant circuit was associated with the complexity of 
the underlying CHD and the extensiveness of the corresponding surgical procedure. Second, 
as recurrent AT originated from different locations, it seems unlikely that these new AT were 
caused by arrhythmogenicity of previous ablative lesions. Third, the long-term outcome was 
often complicated by development of atrial fibrillation. Finally, despite frequent need for 
repeat ablative therapy, most patients were in sinus rhythm by the end of follow-up.
The purpose of the observational study presented in chapter 12 was to provide more 
insight into long-term (median 40months) outcome of cavotricuspid isthmus ablation in 
terms of atrial flutter (AFL) recurrence and particularly in terms of atrial fibrillation (AF) 
occurrence in “real-practice” patients with electrocardiographically documented isthmus-
dependent AFL with or without a preablation history of AF. The study provided several inter-
esting findings. (1) The cumulative incidence of AF after successful AFL ablation procedures 
was high, with 57% during 5 year follow-up even in the patient group without preexisting 
AF (group 2), (2) that after 1.5 year post-AFL ablation patients with a history of AF had a 
similar AF occurrence rate compared to patients without a history of AF, and (2) a twofold 
and highly significant risk of AF occurrence was observed for patients with a diastolic blood 
pressure ≥90mmHg, independent of a pre-ablation history of AF.
conclusions
Standardized protocols like the multidisciplinary MISSION! program contribute to improved 
adherence to evidence-based medicine in routine clinical practice and to the uniform imple-
mentation of structured care for patients with AMI. It is clear that a good collaboration 
between general practitioner, ambulance services and hospital is essential in achieving well-
coordinated prevention, acute care and rehabilitation of (potential) AMI patients. Results 
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demonstrated in this thesis demonstrate the efficacy of a pre-hospital protocol in achieving 
predefined targets, stressing the importance of close collaboration with all partners. In a later 
stage of this thesis, it is additionally shown that by the rigorous adherence to this kind of AMI 
protocol, development of severe LV dysfunction post-MI can be prevented by focusing on 
minimal treatment delays, aggressive reperfusion therapy and the use of early and consistent 
optimal pharmacological therapy. This way, only a very small percentage of AMI patients 
eventually become candidates for primary prevention ICD implantation according to current 
guidelines which also helps contain the strain on financial resources.
Sirolimus-eluting stent implantation in acute ST-elevation myocardial infarction is associated 
with a significant benefit (compared to bare-metal stents) at 1 year follow-up in terms of 
target vessel revascularizations, but declines thereafter to some extent due to more similar 
target vessel revascularization rates during the 2 subsequent years. Rates of death and non-
fatal recurrent MI remain comparable.
There is a trend towards positive remodeling at the distal stent edges in SES patients and a 
significant inhibition of neointimal hyperplasia within the stented segment at follow-up as 
compared to BMS treated patients. The effect on the distal stent edge suggests a down-
stream effect of sirolimus elution, despite the fact that an effect on plaque composition is 
not visible with virtual histology IVUS at 9-months follow-up.
Among STEMI patients treated with primary PCI and receiving early (in-ambulance) abcix-
imab, it appears that the adjunctive use of manual thrombectomy significantly improves 
post-procedural ST-segment resolution, and may be associated with a lower clinical event 
rate. Therefore, although no benefit was observed regarding the enzymatic infarct size or 
LV function as assessed by Gated-SPECT, it appears that a selective strategy of thrombus 
aspiration still has an additive benefit, even with adjunctive early abciximab administration. 
This needs further confirmation in appropriately powered randomized trials.
Patients with ST-segment elevation AMI who are candidates for primary PCI are more likely 
to have a RCA or LAD culprit lesion that tends to be clustered in the proximal or mid vessel 
segments.
Older patients surviving the first 3 months post-MI have similar outcomes to younger 
patients in terms of cardiac function. Age was not a significant risk factor of 1-year mortality 
in survivors three months after MI. Therefore, though conservative treatment may be the 
adequate choice for some patients, many older patients have the potential to gain significant 
advantage from aggressive and invasive AMI treatment which suggests that age alone should 
not preclude intensive treatment after an MI.
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In patients after AMI treated with primary PCI and preserved left ventricular function, resting 
heart rate at admission is a strong independent risk factor for all-cause mortality, reinfarction, 
revascularization and hospitalization for heart failure. This emphasizes that achieving a lower 
heart rate should be a priority in the care for the currently growing population of post-AMI 
patients with preserved left ventricular function.
In a cohort of ICD treated patients with a primary prevention indication and ischemic heart 
disease the RV stimulation threshold at implantation has an independent prognostic value for 
the prediction of potentially life-threatening ventricular arrhythmia and death.
It may also have a predictive value when measured serially, but this requires further 
investigation in future studies.
Focal and reentrant mechanisms underlie late post-operative atrial tachycardia in patients 
with congenital heart disease (CHD). Successive atrial tachycardias developing over time may 
be caused by different mechanisms. The complexity of the reentrant circuit is associated with 
the complexity of the CHD and corresponding extensiveness of surgical procedures. In patients 
who had multiple ablation procedures, the atrial tachycardia originated from different atrial 
sites suggesting that these new atrial tachycardias were not caused by arrhythmogenicity 
of previous ablative lesions. Recurrent atrial tachycardia occurred frequently after successful 
ablation and occurred mainly in the first year after treatment. The long-term outcome is 
often complicated by development of atrial fibrillation. However, the majority of the patients 
are in sinus rhythm.
Despite the efficacy of cavotricuspid isthmus radiofrequency ablation in the treatment of 
atrial flutter, most patients cannot be considered completely cured, particularly with regard 
to atrial fibrillation (AF) occurrences. Patients with a preablation history of AF and high 
diastolic blood pressure are at significantly higher risk and should be monitored more closely 
and treated more aggressively for hypertension. However, preablation AF did not lead to 
an increased long-term (>1.5 year) risk after atrial flutter ablation. Patients in this subgroup 
therefore may expect the same long-term risk of AF as patients without pre-existing AF.
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